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“The universe is big. It’s vast and complicated and ridiculous. 
And sometimes, very rarely, impossible things just happen 
and we call them miracles” 
Dr. Who 
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1 Introduction 
1.1 Hepatitis C virus (HCV) infection 
Initially, Hepatitis C was described as a transfusion-associated hepatitis which was 
neither hepatitis A nor hepatitis B, thus was termed non-A non-B hepatitis (NANBH) 
(Feinstone et al. 1975). Almost 15 years later in 1989 the pathogen causing NANBH 
was isolated by Choo et al. (1989) and the identified positive stranded ribonucleic 
acid (RNA) virus was named hepatitis C virus (HCV). HCV can cause acute as well 
as chronic infection. After an incubation period of two weeks up to six months only 
approximately 20% of infected individuals exhibit usually mild symptoms like fever 
and nausea, while the vast majority of acute HCV infections remains asymptomatic. 
Chronic disease can cause severe liver disease including liver fibrosis, cirrhosis and 
hepatocellular carcinoma (HCC). Therefore, HCV is the major reason for liver 
transplantation in developed countries. To date, approximately 71 million people 
worldwide are chronically infected with HCV accounting for 1% of the population and 
the World Health Organization (WHO) estimates 1.75 million new HCV infections per 
year. HCV is still a major public health burden and each year approximately 400 000 
people die from liver cirrhosis and HCC caused by HCV infection. The worldwide 
distribution of HCV is uneven with the highest prevalence of 2.3% in the Eastern 
Mediterranean Region and the European Region (1.5%) while the lowest prevalence 
can be observed in the South-East Asian Region with 0.5% (WHO 2017).  
1.1.1 HCV structure 
HCV is a positive stranded enveloped RNA virus of the Flaviviridae family, which also 
comprises dengue, yellow fever and west Nile virus. Besides HCV only the 
GB-virus B (Adams et al. 2017), the nonprimate (NPHV) (Kapoor et al. 2011), rodent 
(RHV) (Kapoor et al. 2013) bat (Quan et al. 2013) and the bovine hepacivirus 
(Baechlein et al. 2015) are grouped into the Hepacivirus genus. HCV has a length of 
approximately 9.6 kilo bases (kb) and the genome is encoding for a single long open 
reading frame. The encoded polyprotein is proteolytically cleaved into three structural 
(core, E1, E2) and seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A 
and NS5B). Short untranslated regions (5´-UTR and 3´-UTR) which contain 
secondary RNA structures, needed for translation and replication of the genome, are 
flanking the approximately 3 000 amino acid long open reading frame. The 5´-UTR 
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contains an internal ribosome entry site responsible for the initiation of protein 
translation. Two functional modules are encoded by the HCV genome. While the 
assembly module comprises the two envelope proteins E1 and E2, the core protein, 
p7 as well as NS2, the other non-structural proteins are required for RNA replication 
and form the replication module (reviewed in Penin et al. 2004, and Bartenschlager 
et al. 2013) 
1.1.2 HCV genotypes 
HCV shows substantial genetic variability due to its high replication rate paired with a 
high error rate of the RNA-dependent RNA polymerase. The high error rate caused 
by the lack of proof reading function of the HCV RNA polymerase results in 10-3 base 
substitutions per site per year (Major et al. 1999). Together with the high turnover 
rate of approximately 1012 virions per day this leads to the generation of a highly 
heterogenous pool of viruses within an infected individual (Neumann et al. 1998). 
The HCV quasispecies represents the entirety of all viral variants in a single 
individual and the viral variants are phylogenetically closely related but show a 
sequence variability (Martell et al. 1992). Moreover, based on the genetic distances 
in phylogenetic trees HCV can be classified into different genotypes. Until now seven 
major HCV genotypes numbered from one to seven have been reported and multiple 
subtypes named alphabetically have been identified. HCV strains between genotypes 
differ at 30-35% (Okamoto et al. 1992, Simmonds et al. 2005) whereas subtypes vary 
at ˂15% of nucleotide sites (Smith et al. 2014). Worldwide genotypes 1 and 3 are the 
most common ones and calculations estimated that they account for respectively 
46% and 30% of HCV cases (Messina et al. 2015). The seven described genotypes 
show distinct geographical distribution with genotype 1 having the highest prevalence 
worldwide and being the most common genotype in Europe (50-70%) and North and 
South America (70%). Genotype 2 is the most common genotype in West Africa 
while genotype 4 is most prominent in Central and North Africa. In South and 
Southeast Asia genotype 3 and 6 are predominant. Accounting for less than 1% of 
the HCV cases genotype 5 mostly described in Southern and Eastern Sub-Saharan 
Africa, is responsible for the fewest infections besides genotype 7, which until now 
has only been reported in a few patients originating from the Democratic Republic of 
Congo (reviewed in Scheel et al. 2013, Messina et al. 2015, Murphy et al. 2015). 
These genotypes are not only associated with distinct geographical distribution but 
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also with different sensitivity to treatment, for instance, to interferon alpha (IFNα) 
therapy which was standard of care for a long time.  
1.1.3 HCV therapy 
Since some people are able to clear HCV spontaneously, HCV therapy is not always 
required during acute infection. In chronically HCV infected patients, the main goal of 
therapy is to cure the infection and therefore prevent HCV-related causes like HCC 
and liver cirrhosis. Successful treatment results in a sustained virological response 
(SVR) characterised by the absence of detectable HCV RNA after a defined period of 
time. The rate of SVR is strongly dependent on the treatment regimen and duration, 
the viral genotype and the stage of liver fibrosis. During the last few years, the launch 
of direct-acting antivirals (DAAs) changed HCV therapy dramatically. Before that, 
recombinant IFNα was the main component in HCV therapy regimens. Since then, 
therapy was stepwise improved by the combination of IFNα with ribavirin, the 
modification of INFα or the combination with protease inhibitors (reviewed in 
Pawlotsky et al. 2015). IFNα was administered as a HCV therapy for the first time in 
1986, when HCV was still known as NANBH (Hoofnagle et al. 1986). In addition to 
the severe side effects of IFNα therapy, SVR rates were extremely low 
(approximately 10%). However, combination treatment of IFNα with the nucleoside 
analogue ribavirin could increase overall SVR rates up to approximately 30%. 
Furthermore, modification of IFNα by the addition of polyethylene glycol (PEG) 
significantly increased the elimination half-life of IFNα and when administered in 
combination with ribavirin SVR rates over 40% were observed. Almost 10 years after 
the launch of PEGylated IFNα, PEGylated IFNα and ribavirin were combined with the 
first generation of DAAs. Treatment with the first-wave of protease inhibitors blocking 
the viral replication by targeting the active site of the NS3/4A protease resulted in 
SVR in approximately 70% of infected individuals (reviewed in Pawlotsky et al. 2015). 
Between 2011 and 2015 various DAAs were licensed and administered in different 
HCV therapy regimens, further improving SVR rates. Sofosbuvir, a nucleotide 
analogue inhibiting the NS5B polymerase, was the first DAA reaching a SVR rate of 
over 90% (Lawitz et al. 2013). In addition, the first pan genotypic drug Epclusa, a 
combination of sofosbuvir and the NS5A inhibitor valpatasvir, was launched and 
approved for genotypes one to six in 2016. SVR rates over 95% were achieved, thus 
nearly all HCV infected individuals are curable (Feld et al. 2015). Even though 
pan-genotypic therapies are nowadays licensed, most treatment options are still 
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genotype-specific, therefore, HCV genotyping before treatment onset is required. 
Although a variety of DAAs is available, a few patients still do not achieve SVR which 
has been linked to the occurrence of resistance associated substitutions (RAS). RAS 
affect for instance the SVR rate to treatment with NS5A inhibitors especially in 
treatment experienced and cirrhotic patients (Zeuzem et al. 2017). Therefore, HCV 
resistance testing can support treatment decisions under certain conditions. 
Identification of resistance associated mutations at baseline results in the selection of 
presumably efficient therapy options (Kalaghatgi et al. 2016). 
1.1.4 HCV transmission 
HCV is a bloodborne virus and transmitted through infected blood or blood products. 
Before the late 1980s and therefore prior to the availability of serological and 
molecular tests for HCV, the main risk factor for acquiring HCV, was the transfusion 
of blood products. Since then, blood products are screened for HCV-RNA and HCV 
transmission through this route is therefore rarely reported. Nowadays, injection drug 
use is the most common cause of HCV transmission in western industrialised 
countries (reviewed in Alter 1997, WHO 2017).  
1.1.5 HCV infection in people who inject drugs 
Due to the common practice of people who inject drugs (PWID) to share needles or 
other injection materials the HCV transmission rate in this group of individuals is 
particularly high. Globally intravenous drug use is a major public health issue and 
reports estimate 15.9 million people worldwide being PWID (Mathers et al. 2008). 
Worldwide an estimate of 10 million PWID have detectable antibodies against HCV. 
Cumulatively, China, the USA and Russia account for 44% of HCV-RNA positive 
PWID worldwide. Especially in high income countries, the estimated frequency of 
HCV transmissions caused by intravenous drug use is tremendously high (80%) 
(Nelson et al. 2011). This is also evident in Germany, as the majority (76.2%) of all 
newly reported HCV infections by the Robert Koch-Institut (RKI) in 2016, where the 
transmission route was accounted for, were caused by intravenous drug use (figure 
1.1) (Robert Koch-Institut 2016).  
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Figure 1.1: HCV transmission routes in Germany 
In Germany 4887 initial HCV infections were diagnosed in 2015. In 76.1% of HCV cases the 
transmission route was unaccounted for, while in 23.9% the transmission route was reported. From 
the 1170 newly infected individuals 76.2% acquired HCV due to intravenous drug use. The second 
most frequent transmission route with 8.1% was men having sex with men (MSM). The remaining 
15.7% of newly diagnosed HCV infections were either transmitted during dialysis, heterosexually 
transmitted from a HCV infected partner, acquired by transfusion of blood products before routine 
HCV testing was implemented or transferred perinatal (Robert Koch-Institut 2016). 
Prevalence of HCV infection measured as antibody positivity among PWID in Europe 
ranges from 21% in Finland up to 90.5% in Estonia (Nelson et al. 2011). The recently 
reported prevalence rate of HCV infection among PWID in Germany is 63% including 
44% of the total PWID having detectable HCV RNA. Depending on the geographic 
location reported HCV infection rates in Germany vary from 37% to 73% 
(Robert Koch-Institut Berlin 2016).  
HCV is efficiently transmitted by intravenous drug use since the infection rate in 
PWID during the first two years after onset is approximately 29%. With increasing 
duration of intravenous drug use the prevalence of HCV positive individuals is 
steadily rising, reaching 72% after 10 years of drug abuse (Robert Koch-Institut 
Berlin 2016).  
Neither spontaneous resolution of HCV infection nor treatment induced clearance 
protects from HCV reinfection, thus HCV infection does not confer immunity to 
subsequent infections. HCV reinfections are reported especially in high-risk 
populations like PWID, HCV-Human immunodeficiency virus (HIV) coinfected 
individuals and MSM (Lambers et al. 2011, Islam et al. 2017). In PWID reinfection 
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rates are also dependent on several factors such as age, gender and injection 
behaviour, like frequency of injections, sharing of injection materials and 
simultaneous multidrug use as well as imprisonment, or social factors such as 
residential stability, employment and social support (Grebely et al. 2012, Marco et al. 
2013, Islam et al. 2017). A reduction of reinfection risk is seen in PWID engaging in 
opioid substitution therapy and mental health counselling (Islam et al. 2017). 
Although previous infections do not confer immunity to HCV infection, there are 
indications for a trend towards lower HCV reinfections in individuals who 
spontaneously cleared the infection in comparison to successfully treated individuals 
(Ingiliz et al. 2017). Furthermore, spontaneous resolution of the primary HCV 
infection leads to a partial protection as the duration and the maximum level of 
viremia are lower during a secondary HCV infection compared to the initial infection. 
The higher clearance rate of secondary infections is accompanied by an increased 
occurrence of cross-reactive neutralising antibodies against HCV and a broadened 
cellular T cell immune response (Osburn et al. 2010). The high-risk behaviour of 
PWID does not only lead to high reinfection rates but, due to the frequent exposure 
to HCV, mixed infections can occur where multiple viral strain are detectable at the 
same time in a single individual (Pham et al. 2010, Grebely et al. 2012). 
An epidemiological study on PWID in Essen reported 45.2% being chronically HCV 
infected determined by presence of detectable HCV-RNA, whereas 27.9% resolve 
the infection consistent with absence of HCV-RNA and detectable HCV antibodies. 
The remaining 26.9% are anti-HCV negative as well as HCV-RNA negative 
(Robert Koch-Institut 2012). The described high-risk behaviour in PWID suggests 
that the anti-HCV negative group has likely been exposed to HCV but is able to clear 
infection prior to seroconversion.  
1.1.6 Interferons and HCV infection 
As IFNα administration was efficient in treatment of NANBH, the importance of 
interferons (IFNs) in HCV infection has been reported even before the term HCV was 
introduced (Hoofnagle et al. 1986). Three major classes of IFNs are described at the 
moment: type I, type II and type III IFNs. Type I IFNs comprise IFNα, IFNβ, IFNκ, 
IFNε and IFNω while type III IFNs include IFNλ1 to IFNλ4. Both groups are essential 
for the innate immune response and signal through the JAK-STAT pathway which 
results in the induction of interferon-stimulated genes (ISGs). These ISGs have 
antiviral and immunomodulatory roles. In HCV infection, viral RNA is sensed either in 
Introduction 
 
 7
the cytosol by retinoic acid inducible gene I (RIG-I) or the melanoma 
differentiation-associated protein 5 (MDA-5) or in the endosome through the Toll-like 
receptor 3 (TLR3). RIG-I mediated sensing, for instance, depends on the binding to a 
poly-(U/UC) region found in HCV in the 3´UTR. RNA sensing results in downstream 
signalling and the induction of type I as well as type III IFNs (Saito et al. 2008, Wang 
et al. 2009, Cao et al. 2015). 
Treatment of hepatocytes with IFNα leads to an increase in ISG expression and an 
inhibition of HCV replication (Castet et al. 2002). This upregulation of ISGs is also 
induced by treatment with PEGylated IFNα in patients achieving SVR whereas 
non-responders already show high expression of ISGs at baseline. In 
non-responders additional administration of IFNα does not result in a further increase 
of ISG expression because the IFN signalling pathway shows a reduced 
responsiveness to IFNs (Sarasin-Filipowicz et al. 2008). Moreover, a single 
nucleotide polymorphism (SNP) (rs12979860) upstream of the IFNλ3 locus is a 
strong predictor of achieving SVR to IFNα treatment. Furthermore, the C/C genotype 
of this SNP is an independent predictor for spontaneous clearance of HCV infection 
(Thomas et al. 2009, Tillmann et al. 2010, Fitzmaurice et al. 2015). The 
proinflammatory and antiviral cytokine IFNλ3 is upregulated in HCV infected liver and 
an increase in endogenous production of IFNλ by HCV infected hepatocytes has 
been reported (Marukian et al. 2011, Park et al. 2012). IFNλ3 is able to inhibit HCV 
virus replication by phosphorylating STAT1 and STAT2 leading to the activation of 
further signalling in the JAK-STAT pathway and transcription of ISGs in a similar 
manner like IFNα (Zhang et al. 2011). Furthermore, rs12979860 upstream of the 
IFNλ3 locus is in a high linkage disequilibrium with a dinucleotide variant that is the 
basis for IFNλ4. This dinucleotide variant, first described in HCV patients, 
(ss469415590) is a strong genetic predictor for HCV clearance as well (Prokunina-
Olsson et al. 2013). While the CC variant of the IFNλ3 SNP is beneficial during acute 
HCV infection (Thomas et al. 2009), the SNP is associated with increased risk of liver 
fibrosis in chronic HCV infection (Eslam et al. 2015). Recently, it was identified that 
zinc inhibits the binding of IFNλ3 to IFNL receptor 1, providing evidence that zinc can 
mediate anti-inflammatory effects in HCV infection and might be effective against 
IFNλ3 induced liver damage in chronic infection (Read et al. 2017). 
However, HCV has evolved mechanisms to evade the antiviral IFN system. The 
non-structural protein NS3/4A targets and cleaves the mitochondrial antiviral 
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signalling proteins that are important in the signalling of RIG-I and MDA5 and 
therefore prevents recognition and downstream signalling. Moreover, the NS3/4A 
protease blocks the TLR3 signalling by targeting TRIF which results in the inhibition 
of IFN production (reviewed in Morikawa et al. 2011, and Heim et al. 2014). 
1.1.7 The adaptive immune system in HCV infection 
Both the innate as well as the adaptive immune system is essential for eliminating 
HCV during acute infection. In contrast to the early induction of type I and III IFNs, 
virus specific T cell responses are detected in the liver weeks after infection (Thimme 
et al. 2002). Multiple studies show that virus specific CD4+ as well as CD8+ T cells 
are crucial for spontaneous resolution of HCV and that a lack of a strong T cell 
response results in virus persistence. In addition, HCV specific memory cells can 
persist after resolution and respond rapidly upon a second infection. A strong and 
sustained T cell response targeting a broad range of HCV epitopes is essential for 
HCV elimination during acute infection (Lechner et al. 2000, Thimme et al. 2001, 
Thimme et al. 2002). T cell depletion studies in chimpanzees demonstrated the 
importance of CD8+ as well as CD4+ T cells in the control of HCV infection (Grakoui 
et al. 2003, Shoukry et al. 2003). Thus, the help of CD4+ T cells is needed to 
maintain effective CD8+ T cell responses. As demonstrated in a chimpanzee model, 
animals that clear the infection have a strong cytotoxic T lymphocyte (CTL) response 
targeting several epitopes whereas animals that develop chronic infection display a 
weak CTL response during acute infection (Cooper et al. 1999). Viral clearance 
through HCV-specific CD8+ T cells is mainly attributed to their high capability to 
secrete antiviral IFNγ upon activation (Frese et al. 2002, Jo et al. 2009). In addition, 
HCV-specific CD8+ T cells efficiently secrete TNFα and are capable of directly killing 
virus infected cells via perforin or the Fas/Fas ligand (FasL) pathway (Ando et al. 
1997). Immunogenetic studies revealed associations between certain human 
leukocyte antigen (HLA) class I haplotypes presenting viral antigens to T cells and 
spontaneous resolution, indicating the importance of virus specific CD8+ T cell 
responses for infection outcome. HLA-B*27 and HLA-B*57 have been repeatedly 
associated with spontaneous immune control and a robust IFNγ response 
(McKiernan et al. 2004, Kim et al. 2011, Fitzmaurice et al. 2015).  
Failure of controlling HCV replication during acute infection is associated with 
exhaustion of T cells after initial priming and expansion. Exhaustion is driven through 
continuous stimulation of CD8+ T cells with viral antigens. CD8+ T cell exhaustion is 
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characterised by impaired antiviral functionality as well as increased expression of 
numerous inhibitory receptors such as PD1, Tim-3, CTLA-4 and 2B4 (reviewed in 
Timm et al. 2015). In comparison to the periphery, intrahepatic T cells display an 
even higher expression of exhaustion markers (Kroy et al. 2014). Furthermore, 
exhausted CD8+ T cells have a low proliferative potential (Kroy et al. 2014), an 
impaired ability to produce IFNγ and TNFα as well as a reduced cytotoxicity (Penna 
et al. 2007). Multiple studies addressed a possible reversion of the exhausted 
phenotype to restore HCV-specific CD8+ T cell function. Anti-PDL1 antibodies 
blocking the PD1/PDL1 interaction enhance HCV-specific CD8+ T cell function 
(Penna et al. 2007) however, to restore full antiviral functionality combined blockade 
of inhibitory receptors is required (Nakamoto et al. 2009).  
Evasion of immune recognition is a common phenomenon in HCV infection since the 
majority of individuals develop chronic infection. One mechanism of HCV to evade 
T cell recognition is by selection of mutations inside as well as in the flanking regions 
of the targeted epitope. Three different molecular viral escape mechanisms are 
described that lead either to the complete abolishment or reduced CD8+ T cell 
activation through the TCR peptide MHC class I complex. First, mutations within 
flanking regions of an HCV CD8 T cell epitope are able to alter the peptide 
processing in the proteasome by cleavage of the polypeptide inside the epitope 
sequence. However, correct proteasomal processing does not guarantee T cell 
response as mutations within the MHC class I binding sites can alter the binding 
affinity. Mutations within anchor residues result in unstable MHC class I/peptide 
complexes and regularly to an abolished presentation to the TCR through the loss of 
the epitope. Furthermore, mutations that occur inside the sequence that is 
recognised by the TCR can result in the reduction or the absence of a CD8 T cell 
response even though the epitope is properly cleaved and presented (reviewed in 
Holz et al. 2015). These viral escape mechanisms that perturb peptide binding to the 
MHC molecule and impair TCR recognition hinder the generation of a TCR-MHC 
class I complex which is able to activate CD8+ T cells to elicit a IFNγ response that is 
sufficient to control HCV infection. To fully escape T cell recognition by HLA-B*27, 
multiple substitutions within the immunodominant epitope are required, possibly 
explaining the protective effect of this allele in HCV infection outcome (Dazert et al. 
2009). Besides viral sequence mutations, a narrow TCR repertoire displaying a low 
diversity within the CDR3 region, is associated with immune escape in a chimpanzee 
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model, whereas the generation of a broadly cross-reactive TCR repertoire possibly 
prevents viral escape (Meyer-Olson et al. 2004). However, escape mutations can 
affect the viral fitness, thus reducing viral replication capacity (Neumann-Haefelin et 
al. 2008, Salloum et al. 2008, Dazert et al. 2009). As a result, the quasispecies 
generally comprises viral variants which balance viral replication and immune 
evasion (Uebelhoer et al. 2008). In the absence of immune pressure, reversion back 
to the prototype sequence occurs, which is advantageous for viral replication (Timm 
et al. 2004, Ray et al. 2005, Neumann-Haefelin et al. 2008).  
In comparison to T cells as part of the adaptive immune system, the innate immune 
system is the first line of defence which is induced directly after infection and Natural 
Killer (NK) cells are the major innate cell type for mediating antiviral effects during 
HCV infection. 
1.2 Natural Killer (NK) cells 
NK cells have been defined in 1975 as large granular lymphocytes with the ability to 
kill target cells without prior priming and without restriction to the MHC expression on 
the target cell. Kiessling et al. (1975) showed that mouse NK cells are capable of 
killing Moloney leukaemia cells in vitro. NK cells comprise approximately 15% of the 
lymphocyte population in the periphery and are traditionally defined by their cell 
surface phenotype, lacking the T cell linage marker CD3 but expressing CD56. 
Nowadays NK cells are not solely defined by the expression of CD56 but furthermore 
by CD16. Based on the cell surface density of CD56 and the expression of CD16, 
NK cells are divided into three subtypes: CD56dim, CD56bright and CD56negative. CD56dim 
NK cells account for the majority of NK cells (90%) defined by a low-density 
expression of CD56 and high surface expression of CD16. Whereas around 10% of 
NK cells in the periphery are CD56bright, the third subset of CD56negative CD16positive NK 
cells is very rare (reviewed in Cooper et al. 2001, and Caligiuri 2008). These NK cell 
subsets have been associated with different functional properties and distinct 
differentiation stages in NK cell development (figure 1.2). CD56dim NK cells have a 
higher cytotoxic activity than CD56bright NK cells, thus produce more cytolytic 
granules. Through their high cell surface expression of CD16, CD56dim NK cells are 
efficient in CD16 mediated antibody dependent cell cytotoxicity (ADCC) in contrast to 
CD56bright NK cells. On the other hand, CD56bright NK cells are the subset most 
efficient in production of cytokines like IFNγ, tumour necrosis factor alpha (TNFα) or 
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interleukin 10 (IL) whereas CD56dim NK cells have a slightly reduced capability to 
produce and release cytokines (reviewed in Cooper et al. 2001). 
NK cells arise from CD34+ hematopoietic progenitors in the bone marrow and 
differentiation into NK cells is mainly triggered by the transcription factors Tbet and 
Eomes. In the periphery NK cells differentiate from CD56bright via CD56dim to 
CD56negative NK cells accompanied by a decline in telomere length (Romagnani et al. 
2007). Furthermore, Björkström et al. (2010) described additional differentiation 
stages within the CD56dim NK cell population. CD56bright NK cells express high 
amounts of NKG2A whereas CD56dim NK cells continuously lose NKG2A while they 
steadily gain the expression of CD57 and killer cell immunoglobulin-like receptors 
(KIRs).  
 
 
 
Figure 1.2: NK cell differentiation 
NK cells differentiate from CD56bright to CD56dim to CD56negative NK cells. Differentiation is accompanied 
by the subsequent loss of CD56 and NKG2A and the acquisition of CD16 and killer cell 
immunoglobulin-like receptors (KIRs). NK cell subsets are associated with different functional 
properties. CD56bright NK cells produce a wide range of cytokines, whereas their ability to produce 
cytotoxic granules is restricted. In contrast, CD56dim NK cells are highly capable to release cytolytic 
granules and are efficient cytokine producers, although to a lower extent than CD56bright NK cells. 
CD56- NK cells display impaired functionality and proliferation potential. 
Early reports suggested mature NK cells to be terminally differentiated, incapable of 
self-renewal and short lived (Miller 1982, Zhang et al. 2007). However, in an adoptive 
transfer experiment into a lymphopenic environment NK cells underwent homeostatic 
proliferation, resulting in longevity of transferred NK cells residing in both lymphoid 
and non-lymphoid tissue for over six months. NK cells are capable of self-renewal at 
a slow turnover rate, thus display similarities with T cells. Moreover, NK cells retain 
their functional capacity and respond robustly to virus infections even months after 
transfer (Sun et al. 2011). Even though NK cells are considered members of the 
innate immunity, over the last years various features of NK cells have been described 
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that were initially assigned exclusively to adaptive immune cells. For instance, NK 
cells are educated during development (reviewed in Orr et al. 2010), NK cells 
undergo clonal expansion during infection and they are able to generate long lived 
memory NK cells as seen in cytomegalovirus (CMV) infection (Sun et al. 2009). 
1.2.1 NK cell education 
To gain the capacity to detect target cells with downregulated or low MHC class I 
surface expression, NK cells must undergo a process called education which is also 
referred to as licencing or tuning of NK cells. Whereas during T cell education an 
activation via the TCR is required, the NK cell education process is based on the 
engagement of MHC-class I specific inhibitory receptors leading to the maturation of 
a functional NK cell repertoire (reviewed in Höglund et al. 2010, and Orr et al. 2010). 
The extent of NK cell responsiveness is determined by the number of interactions of 
inhibitory receptors with self MHC class I molecules on haematopoietic or stromal 
cells during development in the bone marrow. In contrast to the negative selection 
process during T cell development, NK cells that are not able to engage MHC class I 
through inhibitory receptors are not driven into apoptosis but become anergic (Kim et 
al. 2005, Yu et al. 2007). Notably, the NK cell education process is not terminal and 
NK cells are capable of readjustment. Anergic NK cells placed in a different 
MHC-class I setting acquire functional competence, whereas educated NK cells 
become hyporesponsive in a MHC-class I molecules devoid environment. To 
maintain their responsiveness NK cells need the continuous engagement of their 
inhibitory receptors to MHC-class I molecules (Joncker et al. 2010). 
1.2.2 NK cell activation and effector mechanisms 
NK cells express various receptors including inhibitory, activating, adhesion and 
cytokine receptors enabling them to differentiate between healthy and target cells. In 
a healthy setting NK cells remain in a tolerant state. Healthy cells express 
MHC class I molecules that are engaged by inhibitory receptors on NK cells 
balancing activating and inhibiting signals. Loss or downregulation of MHC class I 
molecules, seen on tumour or virus infected cells, however, leads to an activation of 
NK cells due to missing self-recognition. Absence of MHC class I engagement results 
in cytokine production and release of cytotoxic granules of NK cells (reviewed in 
Ljunggren et al. 1990). Furthermore, activation of NK cells through activating 
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receptors such as NKG2D can be induced by upregulation of activating ligands like 
MICA as a result of cellular stress (figure 1.3) (Bauer et al. 1999).  
 
 
 
 
Figure 1.3: NK cell activation by tumour or virus infected cells 
NK cells remain in a tolerant state when the strength of the activating signal received through 
engagement of activating receptors is lower than the inhibitory signal through binding of inhibitory 
receptors to MHC-class I molecules. Virus infected and tumour cells either downregulate or loose the 
expression of MHC-class I molecules on the cell surface and therefore, NK cells lack the inhibitory 
signal. The activating signal is not dampened resulting in missing-self-induced cytokine production and 
release of cytotoxic granules by NK cells. Another mechanism to activate NK cells to produce 
cytokines and cytotoxic granules is stress-induced. Stressed cells upregulate activating ligands, thus 
the activation signal outweighs the inhibitory signal (reviewed in Vivier et al. 2012). 
As described, NK cells are able to recognise stressed cells triggering various effector 
mechanisms with the aim of eliminating the target cell. NK cell activation leads to the 
production of cytokines including IFNγ and TNFα. Moreover, target cells can be lysed 
by release of cytotoxic granules containing perforin or granzyme. Apoptosis of target 
cells can be induced via surface upregulation of FasL as well as tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) on NK cells and binding to Fas as 
well as TRAIL receptors on the target cell surface. Furthermore, NK cells mediate 
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cellular crosstalk by stimulating dendritic cell (DC) maturation and therefore 
enhancing priming of T cells. Stressed cells which are opsonised by antibodies 
trigger ADCC of NK cells. The activating receptor CD16, also called FcγRIII, can 
recognise those cell bound antibodies and through crosslinking leads to direct killing 
of opsonised cells by triggering the release of cytotoxic granules (figure 1.4) 
(reviewed in Parham 2009, and Cheent et al. 2011) 
 
 
 
 
Figure 1.4: NK cell effector mechanisms 
NK cells are able to release cytotoxic granules resulting in direct cytotoxic effects to target cells. 
Moreover, they can induce apoptosis via surface upregulation of Fas ligand (FasL) and tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL). Through the engagement with Fas and 
TRAIL receptors on the target cell surface, NK cells can directly kill tumour or virus infected cells. 
Furthermore, NK cells secrete IFNγ and TNFα which mediate a direct antiviral effect and induce 
adaptive immune responses (A) (reviewed in Cheent et al. 2011).The activating receptor CD16, also 
called FcγRIII, can generate ADCC. CD16 recognises cells which are opsonised by antibodies and 
directly kill them through the release of cytotoxic granules after crosslinking of CD16 with the 
antibodies (B) (reviewed in Parham 2009). 
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1.2.3 NK cell receptors 
NK cells express a variety of activating and inhibitory receptors on the cell surface 
mediating their activation and inhibition. These NK receptors engage MHC class I 
molecules, MHC class I–like molecules, and molecules unrelated to MHC on the 
target cell. In the human system, we can group most NK cell receptors into three 
receptor families: the killer cell immunoglobulin-like receptor (KIR) family, natural 
cytotoxicity receptors (NCRs) and the CD94/NKG2 receptor family (reviewed in 
Caligiuri 2008). 
1.2.4 Killer cell immunoglobulin-like receptors (KIRs) 
The first identified KIRs were inhibitory receptors leading to the initial naming as 
killer cell inhibitory receptors. Further studies determined that inhibitory as well as 
activating receptors belong to this receptor family therefore KIR was kept as the 
abbreviation for killer cell immunoglobulin-like receptors (Marsh et al. 2003). KIRs are 
able to bind to HLA class I molecules like HLA-A, -B, -C, –G and -F and to date 14 
expressed human KIR genes and two KIR pseudogenes have been described 
(Gonzalez-Galarza et al. 2015, Garcia-Beltran et al. 2016). KIRs are encoded on 
chromosome 19q13.4 in a compact cluster of genes that is part of the leucocyte 
receptor complex. Nomenclature of KIRs is mainly based on their protein structure 
with subdivisions according to the number of extracellular domains and the length of 
the cytoplasmic tail. The KIRs have either two (2D) or three (3D) extracellular 
immunoglobulin (Ig) domains and either a short (S) or a long (L) cytoplasmic tail 
(figure 1.5). Furthermore, there is a less frequently used naming according to the 
cluster of differentiation (CD) nomenclature system classifying KIR molecules as 
members of the CD158 series. The length of the cytoplasmic domain determines if 
KIRs signal through an immunoreceptor tyrosine-based inhibition motif (ITIM) or an 
immunoreceptor tyrosine-based activation motif (ITAM). KIRs expressing a long 
cytoplasmic domain transmit inhibitory signals through ITIMs located in their 
cytoplasmic domains (Carrington et al. 2003 pages 8-11) whereas, KIRs with a short 
cytoplasmic tail transmit activating signals through crosslinking of KIR with DAP12. 
DAP12 is an homodimeric adapter molecule which contains ITAMs in its cytoplasmic 
domain. Crosslinking of KIR and DAP12 leads to phosphorylation of DAP12 and 
therefore to downstream signalling through binding of ZAP-70 and Syk protein 
tyrosine kinases (Lanier et al. 1998).  
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Figure 1.5: KIR nomenclature 
The nomenclature of KIRs is based on the number of extracellular immunoglobulin (Ig)-like domains 
dividing them into KIR2D having two domains and KIR3D comprising three extracellular domains. 
Irrespective of the number of Ig domains KIRs either have a long or a short cytoplasmic tail appearing 
as (L) or (S) in the KIR nomenclature. While inhibitory KIRs have a long cytoplasmic tail and signal 
through a ITIM motif (red) activating KIRs have a short cytoplasmic tail and signal trough the 
association with an adapter protein DAP-12 containing an ITAM motif (green). 
For most KIR genes allelic variations have been described and their nomenclature is 
analogous to the one used for HLA alleles. An asterisk separates the gene name 
from the first three digits indicating the alleles that differ in the sequence of the 
encoded protein. Another four digits are used to discriminate alleles either having 
silent substitutions in the coding region or substitutions in an intron, promoter, or 
other noncoding regions of the sequence (Marsh et al. 2003). Based on the 
nomenclature KIR3DL1*001 for instance, is the first allele of the inhibitory KIR3DL1 
receptor with a long cytoplasmic tail and three extracellular Ig domains (Gonzalez-
Galarza et al. 2015).  
1.2.5 KIR3DL1 
KIR3DL1 shows a high allelic variability with 79 alleles described until now 
(Gonzalez-Galarza et al. 2015). According to the cell surface density, alleles can be 
grouped into alleles associated with intracellular retention and no cell surface 
expression (null) as well as alleles showing either low or high KIR3DL1 levels. In 
contrast to other pairs of inhibitory and activating receptors, KIR3DL1 and KIR3DS1 
are encoded in the same locus and segregate as alleles. The ligand for KIR3DL1 is a 
Bw4 motif comprised in a polymorphic region at amino acid positions 77–83 of HLA-A 
and HLA-B molecules. This region defines HLA alleles that are not capable to bind 
KIR3DL1 containing a so called Bw6 motif or alleles with a Bw4 motif able to interact 
with KIR3DL1. Amino acid positions 78 and 79 are conserved between the Bw4 and 
Bw6 motifs. The HLA class I residues that distinguish the Bw4 and Bw6 motif from 
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one another are amino acids 77, 80, 81, 82 and 83 as depicted in table 1.1 (Gumperz 
et al. 1997). 
Table 1.1: HLA class I residues determining Bw4 and Bw6 motifs 
 polymorphic position within HLA class I molecules 
epitope 77 80 81 82 83
 
 
Bw4 N/D/S I/T A/L L R 
Bw6 S/G N L R G 
A: alanine, R: arginine, D: aspartic acid, N: asparagine, G: glycine, I: isoleucine, L: leucin, S: serine, T: threonine  
 
The binding affinity of KIR3DL1 to the HLA molecule is determined by a dimorphic 
residue at position 80 of the Bw4 motif. HLA-Bw4 alleles with isoleucine (80I) are 
stronger ligands than alleles with threonine (80T). Furthermore, KIR3DL1 is 
described to bind not only to the Bw4 motif itself but also to the presented peptide. 
Particularly, positions 7 and 8 of the presented peptide are crucial for the interaction 
with KIR3DL1 (reviewed in Parham et al. 2012, and O'Connor et al. 2013). In contrast 
to KIR3DL1, binding assays could not identify a ligand for KIR3DS1 until 2016. 
Genetic as well as functional studies suggested that HLA-Bw4 80(I) is a potential 
ligand (Martin et al. 2002, Alter et al. 2007) but recent evidence demonstrated the 
binding of KIR3DS1 to HLA-F and therefore identifying the ligand for 
KIR3DS1(Garcia-Beltran et al. 2016).  
1.2.6 NK cells in HCV infection 
Since NK cells are highly enriched in the liver comprising up to 50% of the total 
lymphocyte population and the fact that HCV is a hepatotropic infection, many 
studies focused on the role of NK cells in HCV infection. Reports suggest NK cells to 
be activated in the acute phase of HCV infection but without apparent correlation with 
HCV clearance. This activation is characterised by an enhanced IFNγ production and 
a higher cytotoxicity compared to healthy individuals (Amadei et al. 2010, Pelletier et 
al. 2010). In addition, the expression of NK cell receptors is associated with HCV 
infection outcome. Alter et al. (2011) reported that low frequencies of NKp30+, 
NKp46+, CD161+, and NKG2D+ NK cells during acute infection correlate with 
spontaneous resolution of HCV infection. NK cells during acute infection are mostly 
associated with high functional competence, whereas impaired NK cell functionality 
has been described in chronic infection. IFNα leads to a functional polarisation of NK 
cells towards high cytotoxicity and impaired IFNγ production in chronic infections. 
Persistent exposure to endogenous IFNα modulates NK cell responsiveness to 
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become refractory correlating with the loss of efficacy of IFNα based antiviral 
therapies (Edlich et al. 2012). Highly activated NK cells in chronic infection with 
enhanced cytolytic activity and dysfunctional cytokine production correlate with the 
degree of liver inflammation (Oliviero et al. 2009). Moreover, NK cells in chronic HCV 
infection are associated with reduced NKp46 and NKp30 expression and a decrease 
in NCR mediated killing of target cells (Nattermann et al. 2006) even though 
contradicting reports suggest elevated NCR expression during chronic infection (De 
Maria et al. 2007, Ahlenstiel et al. 2010). Furthermore, NK cells can contribute to 
immune protection prior to seroconversion as described in studies of high-risk groups 
such as PWID or healthcare workers exposed to HCV due to needlestick injuries. 
Seronegative individuals display a higher proportion of effector CD56low mature NK 
cells associated with increased cytolytic activity. Moreover, expression of the 
activating receptor NKp30 protects against HCV infection in a high-risk cohort of 
PWID (Golden-Mason et al. 2010). In addition, healthcare workers that have been 
percutaneously exposed to HCV without seroconversion show increased NK cell 
responses like IFNγ production and cytotoxicity as well as enhanced expression of 
NKp44, NKp46 and NKG2A (Werner et al. 2013). Furthermore, the presence of 
KIR2DL3+ NKG2A- NK cells is associated with protection from seroconversion in HCV 
exposed individuals (Thöns et al. 2014). Collectively these data show that NK cells 
contribute to an anti-HCV negative state in HCV exposed individuals therefore 
providing protection from HCV infection prior to seroconversion.  
1.2.7 KIRs and infection 
Genetic association studies have associated certain KIR/KIR-ligand combinations 
with viral infection outcome. Patients harbouring the genetic combination of KIR2DL3 
with two HLA-C group1 (C1) alleles are more likely to spontaneously clear the 
infection than heterozygous C1/C2 or homozygous C2/C2 individuals (Khakoo et al. 
2004). Moreover, the same genetic combination has been correlated with protection 
from HCV infection prior to seroconversion in a PWID cohort. Furthermore, 
individuals with this genetic constellation are more likely to achieve SVR if 
undergoing treatment (Knapp et al. 2010). In addition, the genetic constellation of 
KIR3DL1 with Bw4 is associated with increased SVR in genotype 1b infected 
patients treated with PEGylated IFNα and ribavirin in combination with or without 
telaprevir (Umemura et al. 2014). 
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1.3 Natural Killer T (NKT) cells  
Clearance of HCV infection has been associated with the activation of the innate 
immune system as well as the subsequent activation of the adaptive immune system. 
20 years ago, a new cell subset has been identified forming a link between both. 
Natural Killer T cells (NKT cells) were first described in the mid-1990s as a subset of 
T cells in mice that share some characteristics with NK cells, specifically the 
expression of the NK cell marker NK1.1. The characterisation of NKT cells as a T cell 
subset was based on the expression of a TCR (Lantz et al. 1994, Makino et al. 
1995). To date NKT cells are grouped as an intermediate between the innate and the 
adaptive immune system since they share characteristics of T cells as well as NK 
cells (reviewed in Taniguchi et al. 2003). NKT cells can be subdivided into two 
groups; Type I NKT cells, also termed invariant NKT (iNKT) cells and Type II NKT 
cells also referred to as non-invariant NKT cells. iNKT cells are defined by a highly 
conserved semi-invariant TCR. In mice, the TCR is encoded by Vα14 and Jα18 
paired with a set of Vß chains like Vß8.2, Vß7 and Vß2 (Lantz et al. 1994). In 
contrast, the human TCR receptor comprises a Vα24Jα18 chain exclusively 
combined with Vß11 (Dellabona et al. 1994). Non-invariant NKT cells in mice as well 
as in humans express a more diverse TCR repertoire (Behar et al. 1999). In 
comparison to conventional T cells that recognise antigens presented by MHC 
molecules, NKT cells recognise antigens presented by the non-classical MHC class I 
like molecule CD1d. CD1d is essential for the presentation of glycolipids to NKT 
cells. The first identified glycolipid ligand for iNKT cells was α-Galactosylceramide 
(αGalCer), an exogenous lipid isolated from the marine sponge Agalas mauritianus 
(Kawano et al. 1997). Although invariant as well as non-invariant NKT cells are CD1d 
restricted, non-invariant NKT cells do not recognise α-linked glycolipids presented 
through CD1d, thus are not αGalCer responsive. Besides this prototypic antigen for 
iNKT cells, various other glycolipid antigens have been described for iNKT cells. 
These include bacterial lipids like mycobacterial phosphatidylinositol mannoside or 
endogenous glycolipids such as the lysosomal glycosphingolipid 
isoglobotrihexosylceramide (iGb3) (Fischer et al. 2004). The endogenous iGb3 is 
recognised by mice as well as human iNKT cells and is implicated in mediating iNKT 
cell development. Moreover, iGb3 expression in the peripheral tissue is involved in 
controlling iNKT cell responses for instance to infections (Zhou et al. 2004).  
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Initially, NKT cells were defined by the expression of NK1.1 in mice and CD161 in 
humans. However, CD161 negative NKT cells have been reported in the periphery 
suggesting that the detection and definition of NKT cells requires adaptation (Pellicci 
et al. 2002). Since αGalCer has been identified as a strong antigen presented by 
CD1d, multimers were designed to identify αGalCer-CD1d restricted iNKT cells. 
These multimers of αGalCer loaded CD1d are highly sensitive and specific for 
identifying invariant Vα14+ NKT cells in mice. CD1d restricted non-invariant NKT 
cells, however, do not recognise and respond to αGalCer presentation, thus are not 
detected with this method. Therefore, αGalCer loaded CD1d multimers have been 
proposed as an effective tool to study CD1d restricted iNKT cells in mice (Matsuda et 
al. 2000). 
1.3.1 NKT cell differentiation  
NKT cells develop in the thymus similar to T cells. The highest frequency of NKT 
cells can be detected early in the fetal age and the numbers decrease continuously 
with age. Human NKT cells are able to leave the thymus at an undifferentiated stage 
to further differentiate in the periphery (Sandberg et al. 2004). Like classical T cells, 
NKT cells undergo a positive selection process. Therefore, immature double positive 
cortical thymocytes (CD4+CD8+) present CD1d the selecting ligand for NKT cell 
development. This positive selection is crucial to ensure, that the TCR of NKT cells 
can interact with CD1d (Bendelac 1995). As previously described, NKT cells are 
often defined by CD161 and the maturation process of NKT cells is associated with 
an increase of CD161 expression. However, most NKT cells leave the thymus at an 
immature CD161- state and continue their maturation process in the periphery. 
Therefore, CD161- cells represent precursors of more mature NKT cells in the 
periphery (Pellicci et al. 2002). In the thymus, the majority of NKT cells are CD4+ 
whereas in the periphery NKT cells can acquire the expression of CD8, thus based 
on their expression of CD4 and CD8 four different NKT cell subsets can be defined in 
the periphery (Baev et al. 2004, Montoya et al. 2007). Nevertheless, there is only a 
limited correlation between NKT cell frequencies in the thymus and in the peripheral 
blood (Berzins et al. 2005). The main transcription factor for the development of 
nonconventional T cells, including NKT cells is the promyelocytic leukaemia zinc 
finger protein (PLZF). PLZF leads to the development of fully functional NKT cells 
which are capable of secreting cytokines like IFNγ and IL4 as well as being able to 
release cytotoxic granules (Kovalovsky et al. 2008). In addition, histone 
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deacetylase 3 has recently been identified as being essential for NKT cell 
development and NKT cell differentiation into functional NKT cells (Thapa et al. 
2017). 
1.3.2 CD1d restricted activation of invariant NKT (iNKT) cells 
The TCR of NKT cells from mice and humans recognises the antigen presenting 
molecule CD1d. Even though mice CD1 and human CD1d only exhibit a sequence 
similarity of approximately 60% in the antigen binding region, the interaction of the 
invariant TCR with CD1 is highly conserved between both species. The hydrophobic 
antigen binding groove enables CD1d to present lipid antigens, more specifically 
glycolipids in most cases. Mouse as well as human CD1d can present the iNKT 
prototype antigen αGalCer leading to a rapid activation of iNKT cells (Brossay et al. 
1998). CD1d is able to present self-ligands as well as foreign lipid antigens that can 
activate iNKT cells. The binding affinity of endogenous lipids like iGb3 is low in 
comparison to αGalCer. However, the induction of a weak TCR signal by low affinity 
antigens can be sufficient to induce iNKT cell activation if a second signal by 
inflammatory cytokines like IL12 is provided. Such a strong cytokine signal can for 
instance, be represented by IL12 that is produced in response to microbial products 
by antigen presenting cells like DCs. This way of signalling is proposed to be the 
main mechanism of iNKT cell activation in microbial and viral infections (Brigl et al. 
2003) (figure 1.6). 
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Figure 1.6: Activation of iNKT cells 
iNKT cell activation is dependent on two signalling mechanisms: a TCR signal, provided by the 
engagement with a glycolipid-CD1d complex and a cytokine driven signal. iNKT cells can be activated 
through a TCR signal provided by the presentation of a strong foreign antigen as αGalCer that is 
largely independent of further cytokine stimuli (A). In contrast, a weak TCR signal by binding to low 
affinity microbial or self-lipids as iGb3, requires a strong cytokine signal. Activation can be mediated by 
the release of pro-inflammatory cytokines like IL12 from antigen presenting cells (B). 
1.3.3 CD1d the ligand for NKT cells 
The human CD1 family comprises five CD1 genes (CD1a, b, c, d, and e) located on 
chromosome 1, whereas mice only express the equivalent to CD1d. CD1 proteins 
are mainly expressed on cells that are involved in antigen presentation, such as the 
majority of thymocytes, DCs, macrophages, monocytes or B cells (reviewed in 
Porcelli et al. 1999). High CD1d expression was detected on hepatocytes whereas 
MHC class I expression in the liver was poor. These data indicate that CD1d 
restricted cells such as iNKT cells are important regulators of immune responses in 
the liver (Agrati et al. 2005) 
1.3.4 iNKT cell effector mechanisms 
iNKT cells are cytokine producing effector cells that also mediate direct cytolysis by 
release of cytotoxic granules. The main priming mechanism for the cytolytic activity of 
the CD4- iNKT cell subset, is the exposure to cytokines like IL2 and IL12. Moreover, 
this subset primarily secretes T helper (TH) 1 cytokines such as IL2, IFNγ and TNFα. 
CD4+ CD1d restricted iNKT cells, however, are mainly characterised by their 
production of TH2 cytokines like IL4, even though they are able to produce TH1 
cytokines as well. In addition, they can mediate cytolysis by releasing cytotoxic 
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granules containing perforin, in comparison to CD4- iNKT cells, however, this 
cytolytic ability is not mediated by cytokines (Gumperz et al. 2002).  
 
Figure 1.7: iNKT cell crosstalk with the innate and adaptive immune system 
iNKT cells can regulate and activate various cells of the innate and adaptive immune system. NKT cell 
activation can lead to DC maturation and increased antibody production of B cells. Furthermore, NK 
cells can be induced by iNKT cells to produce IFNγ. Treg proliferation is enhanced by IL2 secretion of 
NKT cells and naïve T cells are indirectly regulated through cross presentation by DCs.  
IFNγ produced by iNKT cells can directly activate NK cells. Activated NK cells are 
driven to produce IFNγ and therefore, enhance the induction of IFNγ production 
further, suggesting a prompt activation of the innate immune system by iNKT cells 
(Carnaud et al. 1999). NKT cells have the capability to recognise myeloid DCs early 
during the immune response through their CD1d specific TCR. NKT cells induce 
maturation of DCs and activate them to produce IL12. For this activation induced 
IL12 production, a second signal besides the TCR signal is needed and provided by 
CD40L engagement (Vincent et al. 2002). Thus, by NKT cell mediated maturation of 
DCs, the adaptive immunity is modulated by the increased potential of mature DCs to 
efficiently stimulate the proliferation of naïve T cells. Furthermore, iNKT cells can 
provide signals for B cell activation by interaction with CD40 on the B cell surface. 
iNKT cells are therefore able to improve antibody titers and B cell memory responses 
(Galli et al. 2007). In addition, IL2 produced by NKT cells can induce the 
development of regulatory T cells (Treg), whereas these in turn inhibit NKT cell 
proliferation, cytokine release and the production of cytotoxic granules (figure 1.7) 
(reviewed in La Cava et al. 2006). 
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1.3.5 iNKT cells in disease 
In different disease settings iNKT cells mediate promoting or inhibitory effects. CD1d 
restricted iNKT cells, especially their production of IL4, is associated with protection 
from type I diabetes. In type I diabetic patients a strong bias towards TH1 cytokines 
like IFNγ and a loss in the capability of iNKT cells to secrete IL4 has been described 
(Wilson et al. 1998). Moreover, iNKT cells can be beneficial in microbial and fungal 
infections. Activation of iNKT cells confers protection from Mycobacterium 
tuberculosis and IFNγ production by activated iNKT cells leads to local resistance to 
the fungi Cryptococcus neoformans (Kawakami et al. 2001, Chackerian et al. 2002). 
In a mouse model iNKT cell activation has been shown to inhibit Hepatitis B virus 
(HBV) replication (Kakimi et al. 2000) postulating, that activated intrahepatic iNKT 
cells are important during natural infection and contribute to viral clearance. 
Clearance of HBV deoxyribonucleic acid (DNA) in the blood as well as in the liver is 
correlated with an early increase in IFNγ levels and is not mediated by the adaptive 
immune system (Guidotti et al. 1999). Therefore, IFNγ production can be either 
attributed to NK or iNKT cells or perhaps an interplay of both. 
1.3.6 iNKT cells in HCV infection 
Several studies have determined iNKT cell frequencies in the periphery as well as in 
the liver of HCV infected individuals. However, reports are highly inconsistent. Some 
reports suggest no difference in frequencies whereas, others state that decreased 
frequencies are associated with chronic infection and increased frequencies with a 
seronegative state. Healthcare workers that have been exposed to HCV infection 
without seroconversion show increased frequencies of CD1d multimer+ iNKT cells six 
weeks after exposure accompanied by an increase in NKG2D expression on iNKT 
cells (Werner et al. 2013). Inoue et al. (2006) and van der Vliet et al. (2005) do not 
observe any differences in frequency of Vα24+ Vβ11+ iNKT cells in the periphery 
between chronically HCV infected patients and healthy individuals. Whereas, 
significantly lower frequencies of Vα24+ Vβ11+ iNKT cells in HCV-RNA positive 
individuals in comparison to patients that resolved the infection and healthy controls 
have been described by Lucas et al. (2003). Furthermore, Vα24+ iNKT cells are 
depleted in the liver of individuals with cirrhotic chronic HCV infection (Deignan et al. 
2002). 
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1.4 DNA methylation 
NK cells can confer early immune control or prevention of HCV infection by their 
cytolytic activity resulting in killing of virus infected hepatocytes or priming of the 
adaptive T cell immunity (Golden-Mason et al. 2010, Pelletier et al. 2010). NK cell 
differentiation, essential for the development of responsive NK cells as well as their 
effector functions, for instance, the capacity to produce IFNγ is epigenetically 
regulated. Epigenetic modifications include posttranslational histone modifications, 
modifications of the DNA and chromatin modulating processes that are crucial for the 
regulation of various cellular processes comprising the expression of genes and 
microRNA, X-chromosome inactivation or cellular differentiation. Modifications like 
methylation, acetylation, phosphorylation, ubiquitination, SUMOylation, 
ADP-ribosylation, deimination and proline isomerisation can alter the gene activity 
without affecting the underlying DNA sequence (reviewed in Kouzarides 2007). DNA 
methylation is the most intensely studied modification and the occurrence of 
hypomethylation was first described in 1983 in human cancer. Feinberg et al. (1983) 
showed that cancer cells harbour unmethylated CpG clusters whereas CpG sites 
within normal tissues are methylated.  
DNA methylation occurs at cytosine residues that are located in CpG dinucleotides. 
The process of the addition of a methyl group transferred from S-adenosylmethionine 
to the fifth carbon of the cytosine forming a five-methyl-cytosine (5mC) is catalysed 
by a DNA methyltransferase. These CpG sites cluster in regions called CpG islands 
commonly present in gene promoters or in gene regulatory regions but being rare 
within genes. DNA methylation is associated with decreased or inhibited gene 
expression due to interference of the 5mC with the binding of transcription factors 
therefore, preventing the formation of transcription factor complexes required for 
optimal transcription (Watt et al. 1988). Moreover, gene transcription can be 
repressed by the binding of methyl-CpG binding domain proteins to 5mC, thus 
blocking transcription factor binding. In contrast, hypomethylation of CpG islands 
leads to gene activation and transcription (reviewed in Portela et al. 2010). For 
mapping DNA methylation patterns, bisulfite genome sequencing is a reliable method 
for the detection of methylated cytosine. Upon treatment of the DNA with bisulfite, 
cytosines are deaminated and therefore converted into uracil. However, methylated 
cytosine is not influenced by this treatment and therefore remains unchanged. This 
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allows discrimination after amplification by polymerase chain reaction (PCR) and 
subsequent sequencing of the region of interest (Frommer et al. 1992).  
1.4.1 DNA methylation of NK cells  
In early NK cell maturation stages KIR genes are epigenetically silenced. During the 
NK cell differentiation process KIRs become transcribed through opening of 
chromatin structures and demethylation of the promoter region. Furthermore, 
KIR3DL1 promoter methylation determines the allele-specific expression on the NK 
cell surface. The promoter of KIR3DL1- NK cells is highly methylated, whereas 
KIR3DL1+ NK cells display a completely unmethylated promoter (Chan et al. 2003). 
However, only a few studies focused on the functional impact of DNA methylation on 
NK cells. Long term activation of NK cells is associated with a methylation profile 
similar to activated lymphocytes especially T cells. Hypomethylation and therefore 
activation has been described in the loci of TNFA family members and the TH2 
cytokine IL13. Activated NK cells display high demethylation, whereas naïve NK cells 
are mostly methylated suggesting the NK cell methylome might display plasticity 
which can be remodelled during activation (Wiencke et al. 2016). 
1.4.2 DNA methylation and IFNγ competence of immune cells  
The functional capacity of immune cells to express IFNγ is correlated with the DNA 
methylation status. Hypomethylation within the IFNG promoter is associated with 
high IFNγ capacity. Complete methylation of CpG sites within the IFNG gene and 
within a transcriptional activator element preceding the IFNG gene is seen in naïve 
CD4+ T cells and neonatal T cells that are associated with low IFNγ competence, 
whereas CD8+ T cells and effector CD4+ T cells with high IFNγ competence show 
hypomethylation in the IFNG locus. The differentiation process of naïve CD4 T cells 
to TH1 cells that is accompanied by epigenetic alterations within the IFNG locus is 
needed to gain the capability to efficiently produce IFNγ (Melvin et al. 1995). Distal 
cis-regulatory elements in proximity to the IFNG gene are described to be associated 
with initiation of IFNG transcription through recruitment of transcription factors 
(Balasubramani et al. 2010). Therefore, methylation of distal regions impacts IFNγ 
production by immune cells. Similar to T cells changing their epigenetic profile during 
differentiation from naïve to TH1, NK cells undergo epigenetic changes of the IFNG 
promoter during their differentiation process. The maturation process from CD56bright 
NK cells to CD56dim NK cells is associated with demethylation of the IFNG promoter 
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and a proposed acquisition of a higher IFNγ competence (Luetke-Eversloh et al. 
2014).  
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1.5 Aims of the study 
The most important risk factor in western industrialised countries to acquire HCV 
infection is intravenous drug use. The high infection rates among PWID are caused 
by their common practice of sharing needles and other injection materials. For this 
reason, we utilise a PWID cohort to study HCV infection and comparatively analyse 
PWID developing chronic infection, spontaneously resolving HCV infection and PWID 
remaining anti-HCV seronegative. The aim is to provide novel insight into innate and 
adaptive mechanisms of the immune system leading to spontaneous immune control 
or the protection against HCV infection prior to seroconversion. Since the role of 
iNKT cells for the outcome of HCV infection is poorly defined and contradicting 
reports regarding described frequencies in chronic HCV infected individuals exist, the 
aim is to comparatively analyse frequencies and function of iNKT cells in HCV-RNA 
positive and anti-HCV positive PWID with resolved HCV infection. iNKT cells are still 
poorly covered by scientific reports in HCV infection, however, there is growing 
evidence for the importance of NK cells for HCV infection outcome. Different genetic 
association studies revealed that distinct KIR/KIR ligand constellations are 
associated with differential outcome in infections. Therefore, the aim is to analyse the 
impact of different KIR/KIR-ligand genotypes on the outcome of HCV infection in 
PWID. Moreover, KIR/KIR ligand constellations might influence NK cell phenotype 
and function which will be addressed in this study. Epigenetic modifications can alter 
gene expression and therefore influence cytokine competence of various immune 
cells including NK cells. Since IFNγ production of NK cells is a crucial effector 
mechanism for the outcome of HCV infection and DNA methylation in the IFNG 
region impacts IFNγ production the aim is to analyse if NK cells with different 
KIR/KIR ligand constellations are differentially regulated by epigenetic modifications.  
1. The role of iNKT cells in HCV infection 
a. Is there a distinct iNKT cell phenotype associated with HCV infection 
outcome? 
b. Do iNKT cells differ in their functionality depending on the HCV status? 
2. Association of KIR/KIR-ligand constellations on HCV infection outcome in our PWID 
cohort 
a. Do genetically determined KIR/KIR ligand constellations that correlate with 
infection outcome influence the phenotype and function of NK cells?  
3. Epigenetic regulation of the IFNγ competence 
a. Is the IFNγ production of NK cells with different KIR/KIR ligand combinations 
associated with distinct methylation patterns in the IFNG locus?
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2 Materials 
2.1 Chemicals and reagents 
α-Galactosylceramide (αGalCer) Funakoshi 
Anti-Mouse Ig, κ/Negative Control Compensation 
Particles Set (BD CompBeads)  Becton Dickinson (BD) 
BD FACS™Clean BD 
BD FACS™Flow BD 
BD FACS™ Shutdown Solution BD 
BD FACS™Rinse BD 
Biozym LE Agarose Biozym 
Brefeldin A (BFA) Sigma 
Cellclean® CL50 Sysmex 
Cellpack® Sysmex 
CellTrics® filter 50 µm Sysmex 
Cytometer Setup & Tracking Beads Kit (CST beads) BD 
Biocoll Separating Solution Biochrome 
dimethyl sulfoxide (DMSO) ≥99.8% Roth 
DNA ladder 100 bp 0.5 mg/mL peQlab 
DNA loading Dye 6x Thermo Scientific 
dNTP mix 10 mM each Invitrogen 
Dulbecco's Phosphate-Buffered Saline, 1X (PBS) Gibco 
Ethanol absolute Merck 
Ethidium bromide solution 0.025% 250 µg/mL Roth 
GeneRuler 1kb DNA ladder 0.5 µg/µl Thermo Scientific 
IC Fixation Buffer  eBioscience (eBio) 
Interferon alpha A, alpha2a, human Pbl assay science 
Interleukin-28B/ Interferon λ3, human Pbl assay science 
IL12 Human Reprokine 
IL15 Human Reprokine 
IL18 Human Reprokine 
Ionomycin Calbiochem 
Nuclease-Free water Ambion 
PCR Buffer 10x 15 mM MgCl2 Qiagen 
Permiabilization Buffer (10x) eBio 
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Platinum® Taq DNA polymerase Invitrogen 
PMA Sigma 
2-Propanol VWR 
Stromatolyser®-WH Sysmex 
SYBR® Green PCR Master Mix Applied biosystems 
Tris-Borate-EDTA buffer Sigma 
2.2 Cell culture media and additives 
Fetal bovine serum (FBS) superior Biochrome 
Interleukin2 (IL2) human  Roche 
HEPES Buffer Solution (1M) Gibco 
Penicillin/ Streptomycin (100x) PenStrep Gibco 
RPMI Medium 1640 1x + GlutaMAXTM Gibco 
2.3 Composition of cell culture media 
Prior to supplementation of Fetal bovine serum (FBS) superior to the medium it was 
heated for 30 min at 56°C to inactivate the complement system. 
R10 RPMI Medium 1640 
 10% FBS 
 10 mM HEPES 
 100 IU/mL penicillin 
 100 µg/mL streptomycin 
 
Freezing medium FBS 
 10% DMSO 
2.4 Cell line 
The K562 cell line is a human erythroleukemic cell line that is highly undifferentiated. 
It was established by Lozzio et al. (1975) from a pleural effusion of a 53-year-old 
woman with a chronic myelogenous leukaemia. In NK cell assays K562 cells are 
highly sensitive targets for killing as they are HLA devoid. 
2.5 Commercial kits 
EZ DNA Methylation-DirectTM Kit Zymo Research 
LIVE/DEAD® Fixable Blue Dead Cells Stain Kit Life technologies 
QIAamp® DNA Blood Mini Kit Qiagen 
QIAquick® PCR purification Kit Qiagen 
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2.6 Antibodies for flow cytometry 
All conjugated antibodies were stored at 4°C and were mouse anti-human if not 
stated otherwise. Table 2.1 indicates the amount of antibody that is needed to stain 
1x106 cells. 
Table 2.1: Antibodies for flow cytometry 
specificity fluorochrome clone isotype µl/10
6
 
cells company 
αGalCer loaded 
CD1d dextramer 
allophycocyanin 
(APC) 
n.a. n.a. 5 immudex 
CD1d peridinin chlorophyll 
(PerCP)-eFluor™710 
51.1 IgG2b 5 eBio 
CD3 APC-eFluor® 780 OKT3 IgG2a 2 eBio 
CD3 eFluor® 450 OKT3 IgG2a 2 eBio 
CD3 PerCP-Cy5.5 OKT3 IgG2a 1 eBio 
CD4 APC-eFluor® 780 RPA-T4 IgG1 2 eBio 
CD4 phycoerythrin 
(PE) 
RPA-T4 IgG1 1 eBio 
CD8a APC RPA-T8 IgG1 1 eBio 
CD8a eFluor® 450 RPA-T8 IgG1 0.2 eBio 
CD14 PE-Cy7 61D3 IgG1 1 eBio 
CD14 PerCP-Cy5.5 61D3 IgG1 2 eBio 
CD14 APC-eFluor® 780 61D3 IgG1 2 eBio 
CD16 APC-eFluor® 780 eBioCB16 IgG1 1 eBio 
CD16 PE B73.1 IgG1 1 eBio 
CD19 APC-eFluor® 780 HIB19 IgG1 1 eBio 
CD19 PerCP-Cy5.5 SJ25C1 IgG1 2 eBio 
CD38 PerCP-eFluor™ 710 HB7 IgG1 1 eBio 
CD45RA PE-Cy7 HI100 IgG2b 0.5 eBio 
CD45RO Fluorescein 
isothiocyanate 
(FITC) 
UCHL1 IgG2a 2 eBio 
CD56 Brilliant Violet (BV) 
421™ 
HCD56 IgG1 2 Biolegend 
CD56 FITC MEM188 IgG2a 5 eBio 
CD56 PerCP-eFluor™ 710 CMSSB IgG1 0.5 eBio 
CD57 FITC TB01 IgM 0.5 eBio 
CD107a PE-Cy7 H4A3 IgG1 2 BD 
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specificity fluorochrome clone isotype µl/10
6
 
cells company 
CD127 PE-Cy7 HIL-7R-M21 IgG1 5 BD 
CD158b2/KIR2DL3 FITC 180701 IgG2A 5 R&D 
CD158e1/KIR3DL1 APC DX9 IgG1 2 Biolegend 
CD159a/ NKG2A PE-Cy7 Z199 IgG2b 5 Beckman 
Coulter (BEC) 
CD159c/ NKG2C PE 134591  IgG1 5 R&D 
CD161 PE-Cy7 HP-3G10 IgG1 5 eBio 
CD197/CCR7 PE 3D12 Rat/ IgG2a 5 eBio 
CD272/BTLA PE MIH26 IgG2a 2 Biolegend 
CD278/PD1 BV421™ EH12.2H7 IgG1 2 Biolegend 
CD314/NKG2D PerCP-eFluor™ 710 1D11 IgG1 1 eBio 
Fixable Viability Dye eFluor™ 506 n.a. n.a. 0.1 eBio 
IFNγ FITC 4S.B3 IgG1 1 eBio 
IL2 PerCP-eFluor™ 710 MQ1-17H12 Rat/ IgG2a 2 eBio 
TNFα PE MAb11 IgG1 1 eBio 
Vα24 FITC C15 IgG1 5 BEC 
Vβ11 PE C21 IgG2a 5 BEC 
n.a.: not applicable 
 
2.7 Oligonucleotides 
All primers were ordered from Eurofins. Lyophilised primers were reconstituted in 
nuclease-free water at a concentration of 10 pmol/µl and stored at -20°C. Table 2.2 
depicts all primers used for the DNA methylation analysis and the estimated PCR 
product size. 
Table 2.2: Primer sequences 
Primer name region Primer sequence 5´ - 3` product size 
IFNγ forward IFNγ 
promoter 
TTGAATGGTGTGAAGTAAAAGTG (23 bp) 
543 bp IFNγ reverse CAACCACAAACAARTACTATTAAAAA (26 bp) 
CNS1 forward CNS1 
region 
AGAAAAGGGGGGATTTA (17 bp) 
247 bp CNS1 reverse TAACACTCACAACCAAATTATC (22 bp) 
 
2.8 Patients 
Blood samples from healthy individuals were collected from the centre for blood 
donation from the University Hospital Düsseldorf with approval of the local ethics 
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committee. Due to an anonymisation process after the collection no donor 
information concerning age and gender was available. 
Whole blood samples from treatment-naïve patients with a history of intravenous 
drug use were collected from the ward for inpatient detoxification treatment of drug 
addicts or the clinic for opioid maintenance treatment at the Department for Addiction 
Medicine and Addictive Behaviour of the LVR-Hospital Essen, Hospital of the 
University of Duisburg-Essen. Written informed consent was obtained from all 
patients included in this study. The study was approved by the ethics committee of 
the Medical Faculty of the University of Duisburg-Essen. Samples were tested for 
anti-HCV antibodies by a chemiluminescent microparticle immunoassay from Abbott. 
Presence of HCV-RNA was determined by Abott RealTime HCV PCR assay with a 
detection limit of 12 IU/mL. PWID were grouped according to their anti-HCV and 
HCV-RNA status into three groups: 1. anti-HCV seropositive with detectable 
HCV-RNA (HCV-RNA positive), 2. anti-HCV seropositive without detectable 
HCV-RNA (HCV-RNA negative) and 3. Anti-HCV seronegative PWID without 
detectable HCV-RNA (anti-HCV negative). 
In addition, blood samples of anti-HCV positive PWID from North America were 
collected at the infectious diseases or hepatology clinics at Massachusetts General 
Hospital in Boston with local ethics committee approval. Data from these patients 
were kindly provided by Georg M. Lauer and Arthur Y. Kim. 
2.9 Consumables and equipment 
Allegra® X-15R Centrifuge BEC 
Cell culture flask 25 cm2, 75 cm2 Corning 
Cell culture flask 175 cm2 Thermo Scientific 
Cell culture plate (48 well) Greiner 
Cell culture plate (24 well, 96 well) Corning 
Cell scraper  TPP 
Cellstar® tubes 15 mL, 50 mL(Falcon) Greiner 
Centrifuge 5415 D Eppendorf 
Centrifuge 5810R Eppendorf 
Combitips advanced® 5 mL, 10 mL Eppendorf 
Cryo tubes, 2.0 mL Greiner Bio-One 
FACS Canto II BD 
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Filter tips 10 µl, 10/20 µl, 20 µl, 200 µl, 1 000 µl Starlab 
Freezer (-20°C) Bosch 
Agagel mini/maxi gel electrophoresis chamber Biometra 
Ice machine AF100 Scotsman 
Incubator 37°C BBD 6220 Heraeus 
Laminar flow Herasafe Thermo Scientific 
Leucosep™ tubes 50 mL Greiner 
Liquid nitrogen tank Biosafe® MD Cryotherm 
Liquid nitrogen tank HEco Series 800-190 MVE 
Mastercycler nexus GSX1 Eppendorf 
Megafuge 40R Thermo Scientific 
MicroAmp® Optical 8-cap strip Applied Biosystems 
Microwave Küppersbusch 
Microscope Primovert Zeiss 
Microscope TS100 eclipse Nikon 
MoFloXDP BEC 
Mr. Frosty™ Cryo 1°C freezing Container Nalgene 
Multipette® plus Eppendorf 
Multichannel 8 research 300 µl Eppendorf 
Multichannel 12 research plus 30-300 µl Eppendorf 
NanoDrop 2000 Thermo scientific 
Sprout Minicentrifuge, PCR tube centrifuge Biozym 
Syringe filters 0.8 μm Whatman 
Syringe Omnifix® 20 ml Braun 
PCR Tube Strips 0.2 mL Eppendorf 
Pipettes research tips (10 µl, 20 µl, 100 µl, 200 µl, 1 000 µl) Eppendorf 
pipetus® Hirschmann 
Polystyrene Round-Bottom FACS tubes 5 mL BD 
7500 Real time PCR System Applied Biosystems 
Reagent reservoir 50 mL Corning 
Refrigerator  Bosch 
Safe-Lock tube 2 mL eppendorf 
Safe Seal tube 1.5 mL sarstedt 
Scale JL602-G Mettler Toledo 
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Scale ScoutPro Ohaus 
Stripette® 2 mL, 5 mL, 10 mL, 25 mL costar 
Thermomixer comfort Eppendorf 
Thermocycler T3000 Biometra 
Thermocycler Professional TRIO Biometra 
ThermoStat plus eppendorf 
Tissue culture plate (6 well, 12 well)  TPP 
Tissue culture plate 96 well-U VWR 
96 well U bottom tissue culture plate BD 
Ultra-Low temperature freezer (-80°C) U725-G Innova® New Brunswick 
UV-System  Intas 
Vortexer VV3 VWR 
Vortexer L46 Labinco 
Water bath Köttermann 
XP-300 cell counter Sysmex 
2.10 Software and webpages 
Allele Frequency Net Database http://www.allelefrequencies.net 
FlowJo 10.0.7 Tree Star Inc. 
Geneious 7.1.9 Biomatters Ltd. 
Graph Pad Prism 5.04 GraphPad Software, Inc. 
Microsoft Office 2010 Microsoft Corporation 
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3 Methods 
3.1 Standard cell culture methods 
3.1.1 Thawing of cells 
Frozen cells (PBMCs or K562) were taken out of the liquid nitrogen and quickly 
thawed in a 37°C water bath. The cells were transferred into 15 mL tubes containing 
9 mL of prewarmed PBS. Afterwards the cells were centrifuged at 754 x g for 7 min. 
The supernatant was discarded and the pellet resuspended in 10 mL of PBS. 
Following another washing step, the cells were counted with the XP-300 cell counter 
and resuspended in the appropriate amount of media or PBS depending on the 
assay. Cells were either transferred into cell culture flasks or plates for further culture 
whereas cells for ex vivo fluorescence-activated cell sorting (FACS) analysis were 
transferred into 96 well U bottom tissue culture plates or polystyrene round-bottom 
FACS tubes for subsequent staining. 
3.1.2 Freezing of cells 
Cells were centrifuged at 754 x g for 7 min and the pellet was washed once with 
PBS. Afterwards the cell pellet was resuspended in 500 µl of FBS and transferred 
into a 2 mL cryo vial containing 500 µl FBS with 20% dimethyl sulfoxide (DMSO), 
thus cells were frozen in a final concentration of 10% DMSO in FBS. Cells were 
frozen slowly at a rate of approximately 1°C per minute in a Mr. Frosty™ freezing 
container, containing 2-Propanol and placed at -80°C to ensure optimal cell viability. 
Thereafter cells were transferred into the liquid nitrogen tank.  
3.1.3 Splitting of cells 
Cells were maintained in culture at 37°C, 5% CO2 and 95% humidified atmosphere. 
Cells lines were regularly checked for their confluence and passaged appropriately. 
Therefore, suspension cells were resuspended thoroughly and transferred into a new 
flask containing fresh media. Cell debris was removed whenever necessary by 
centrifugation at 149 x g for 7 min. Moreover, cells lines were regularly checked for 
mycoplasma contaminations (described in 3.4.5) to ensure that all experiments were 
performed with mycoplasma free cells. 
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3.2 Isolation of peripheral blood mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were isolated from 
EDTA-anticoagulated whole blood from PWID or buffy coats from healthy individuals 
via Ficoll density centrifugation (Boyum 1968). The isolation of mononuclear cells is 
based on different migration properties of peripheral cells during centrifugation. 
Centrifugation leads to the formation of several layers containing different cell types. 
While the bottom layer contains by Biocoll aggregated erythrocytes the intermediate 
layer contains mostly granulocytes. The mononuclear cell layer is visible as a small 
white ring in between the ficoll and the plasma layer. The interphase above the filter 
contains cells which are not dense enough to pass the Biocoll layer and consists of 
platelets, monocytes and lymphocytes.  
To obtain plasma, for instance, for the analysis of the CMV serostatus anticoagulated 
blood was centrifuged for 15 min at 1455 x g. Plasma was stored at -80°C until 
further analysis. For the isolation of PBMCs, blood was diluted 1:2 with PBS to 
ensure an optimal separation. 35 mL of blood-PBS were pipetted slowly into a 50 mL 
Leucosep™ tube containing 15 mL of Biocoll Separating Solution beneath the filter. 
After a 10 min centrifugation at 1126 x g the interphase, containing the PBMCs was 
transferred into a 50 mL tube and centrifuged at 754 x g for 7 min. To ensure removal 
of residual Biocoll and platelets, cells were washed twice in a total volume of 50 mL 
with PBS. Prior to the second washing step 200 µl cell suspension were transferred 
in a 1.5 mL tube and frozen at -20°C for subsequent DNA isolation (described in 
3.4.1). Furthermore, the cell number was determined with the XP-300 cell counter 
and the cell pellet was resuspended in freezing medium. Cell aliquots were 
transferred into a Mr. Frosty™ freezing container and placed in a -80°C freezer. After 
at least 80 min cryo vials were placed in the liquid nitrogen. 
3.3 Cultivation of PBMCs 
PBMCs were cultured in RPMI 1640 medium supplemented with 10% FBS, 
1% Pen/Strep (10 000 IU/mL Penicillin, 10 000 µg/mL Streptomycin) and 1% HEPES 
Buffer (1 M) at 37°C, 5% CO2 and 95% humidity. 
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3.4 Standard molecular biological techniques 
3.4.1 Isolation of DNA from PBMCs 
Genomic DNA was extracted from frozen PBMCs (aliquoted during 3.2) using the 
QIAamp® DNA Blood Mini Kit. Isolation was performed according to the 
manufacturer’s instructions. In short, PBMCs were thawed and 20 µl of QIAGEN 
protease was added to the cell suspension. Following the addition of 200 µl of 
AL buffer the mixture was homogenised by pulse-vortexing for 15 s. For efficient 
lysis, the mixture was incubated for 10 min at 56°C. After the incubation, 200 µl of 
ethanol were added and the sample was transferred to a QIAamp Mini Spin Column. 
Following a centrifugation for 1 min at 5939 x g the flow through was discarded and 
500 µl of washing buffer AW1 were added. Following another centrifugation, the spin 
column was transferred into a new 2 mL collection tube and washed with 500 µl of 
buffer AW2 at 15682 x g for 3 min. Thus, the DNA bound to the QIAamp membrane, 
was washed twice with two different washing buffers which resulted in improved 
purity of subsequently eluted DNA and ensured removal of contaminants. In order to 
remove all remaining AW2 buffer, the column was placed in a new collection tube 
and centrifuged again for 1 min at 15682 x g. To elute the purified DNA the spin 
column was placed into a 1.5 mL tube. Subsequently 50 µl of nuclease-free water 
were added and after a 1 min incubation the DNA was eluted by centrifugation for 
1 min at 5939 x g. To increase DNA yields the elution step was repeated. Therefore, 
the purified DNA was eluted in a final volume of 100 µl. The DNA concentration was 
determined afterwards via measurement with the NanoDrop 2000. 
3.4.2 HLA typing 
DNA from patients and healthy individuals was isolated as described in 3.4.1. HLA 
class I typing at four-digit resolution-level (HLA-A, HLA-B and HLA-C) was performed 
by the use of sequence-specific oligonucleotides (LABType methodology) provided 
by One Lambda Inc. (Canoga Park, CA), at the Institute for Transfusion Medicine, 
University Hospital Essen. 
3.4.3 KIR typing 
DNA from patients was isolated from PBMCs using Qiagen spin columns (3.4.1) and 
KIR genotyping was performed as previously described (Thöns et al. 2014). In short, 
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by use of sequence-specific oligonucleotides KIR typing was performed on a 
Luminex™ flow analyser platform at the Institute for Transfusion Medicine University 
Hospital Essen. Consistency of genotypes was verified through comparison with all 
published KIR haplotypes on Allele Frequency Net (Gonzalez-Galarza et al. 2015). 
DNA based KIR3DL1 allele subtyping was performed as described by Boudreau et 
al. (2014) with adjusted cycling conditions at the Institute for Transplantation 
Diagnostics and Cell Therapeutics, University Hospital Düsseldorf. KIR3DL1 
subgroups were determined according to the subtyping in null, low or high. 
3.4.4 Measurement of CMV IgG antibodies 
CMV serostatus was determined in the routine diagnostic lab of our institute via a 
quantitative detection of CMV specific IgG antibodies, based on a chemiluminescent 
immunoassay method. Therefore, plasma was tested with the LIAISON® CMV IgG II 
assay and analysed on a LIAISON® XL. 
3.4.5 Detection of mycoplasma in cell cultures 
Cell cultures were regularly checked for mycoplasma contamination. Therefore, cell 
culture supernatants of 3-day old cultures were analysed via an inhouse 
Real-time-Sybr-Green PCR. 
3.5 Flow cytometric analysis 
Performance checks via measurement of CS&T beads were regularly performed to 
ensure an optimal flow cytometer setup of the BD FACS Canto II. Through the 
measurement of single stained cells or BD CompBeads a compensation for each 
individual panel was calculated. BD CompBeads were utilised for panels that 
included rare cell populations or dimly expressed cell surface antigens whereas cells 
were used for panels that comprised only highly expressed antigens. 
3.6 Flow cytometric identification of iNKT cells 
In order to determine iNKT cells through flow cytometry, 3x106 PBMCs were stained 
with antibodies against the invariant T cell receptor and a commercially available 
fluorescently labelled CD1d dextramer loaded with αGalCer. Therefore, PBMCs were 
thawed and transferred to polystyrene round-bottom FACS tubes. Cells were stained 
for 20 min with the APC labelled CD1d dextramer at room temperature (RT) in a total 
volume of 100 µl in PBS. After incubation cells were washed with 2 mL of PBS and 
centrifuged for 5 min at 524 x g. The supernatant was removed by decantation. 
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Afterwards cells were stained with 100 µl of fixable viability dye eFluor506 for 15 min 
at 4°C to distinguish between viable and dead cells in the subsequent analysis. 
Following another washing step, the cells were stained with fluorochrome-conjugated 
antibodies against the invariant TCR chains Vα24 (FITC) and Vβ11 (PE). 
Furthermore, the cell surface antigens CD3 (eFluor450) and CD19 (APC-eFluor 780) 
were stained for 15 min at 4°C. After cell surface staining, cells were washed and live 
cells were fixated at 4°C for 15 min by the addition of 100 µl of cold IC fixation buffer. 
Treatment with IC fixation buffer results in the fixation of cells through cross-linking of 
proteins. Fixated cells were washed with PBS and acquired on a BD FACS Canto II. 
During analysis with FlowJo 10.0.7 CD3+ iNKT cells were defined after the exclusion 
of CD19+ cells due to unspecific binding of the CD1d dextramer to B cells.  
3.7 Phenotypical characterisation of iNKT by flow cytometry 
To determine possible differences in the phenotype of iNKT cells from HCV-RNA 
positive and HCV-RNA negative individuals, PBMCs were quickly thawed and the 
iNKT cell frequency was determined through αGalCer loaded CD1d dextramer 
staining. Therefore, 2x106 PBMCs were transferred into polystyrene round-bottom 
FACS tubes and stained for 20 min with the CD1d dextramer (APC) at RT in a total 
volume of 100 µl in PBS. Afterwards the cells were washed with 2 mL of PBS and 
centrifuged at 524 x g for 5 min. Following the staining of dead cells with fixable 
viability dye eFluor506 prediluted in 100 µl of PBS, for 15 min at 4°C, cells were 
washed again with 2 mL of PBS. PBMCs were stained for the cell surface antigen 
CD19 (APC-eFluor 780) for 15 min at 4°C. After washing with PBS and fixation with 
100 µl of IC fixation buffer for 15 min at 4°C, cells were acquired on a BD FACS 
Canto II. For phenotypic ex vivo analysis of iNKT cells, 3x106-5x106 PBMCs were 
stained in two separate steps with the αGalCer loaded CD1d dextramer (APC) and 
the viability dye as previously indicated. Subsequently PBMCs were stained for 
various cell surface antigens with additional fluorochrome-conjugated antibodies. All 
panels included CD19 (APC-eFluor 780) as a marker to exclude CD19+ B cells. A 
master mix containing all antibodies of interest was prepared for each individual 
panel and staining was performed in a total volume of 100 µl. PBMCs were stained 
for CD38 (PerCP-eFluor 710), CD127 (PE-Cy7), CD161 (PE-Cy7), CD57 (FITC), 
NKG2A (PE-Cy7), NKG2D (PerCP-eFluor 710), KIR2DL3 (FITC), PD1 (BV421) and 
BTLA (PE). After an incubation time of 15 min at 4°C cells were washed with PBS 
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and fixed with 100 µl of IC fixation buffer. Prior to flow cytometric measurement on 
the BD FACS Canto II cells were washed once again with PBS. 
3.8 Expansion of iNKT cells with αGalCer 
PBMCs were thawed and resuspended at a concentration of 2x106 cells/mL in R10. 
The medium was supplemented with 25 IU/mL of recombinant IL2. Afterwards 
PBMCs were stimulated with the exogenous glycolipid αGalCer (1 µg/mL) and 
incubated at 37°C in a humidified atmosphere containing 5% CO2. After 5-7 days half 
of the total volume R10 containing 25 IU/mL recombinant IL2 was added to the 
culture. To determine the expansion potential of iNKT cells and possible changes in 
the activation status 1x106 cells were stained after 10 days of expansion with the 
αGalCer loaded CD1d dextramer (APC) and antibodies against the cell surface 
antigens CD38 (PerCP-eFluor 710) and CD127 (PE-Cy7) after 10 days of expansion 
as stated in 3.7. To evaluate possible changes to the initial situation, ex vivo staining 
was performed as well.  
3.9 Analysis of iNKT cell function via intracellular cytokine staining 
iNKT cell function was analysed ex vivo and after in vitro expansion. On day 10 after 
stimulation with αGalCer 5x105-1x106 cells were transferred into polystyrene 
round-bottom FACS tubes whereas ex vivo analysis was performed with 2x106 
PBMCs. Cells were washed twice with R10 medium at 524 x g for 5 min and then 
stimulated with 1 µg/mL Ionomycin and 10 ng/mL Phorbol myristate acetate (PMA) 
for 5 hours in the presence of Brefeldin A (BFA) (100 ng/mL). For determining the 
degranulation ability an antibody against CD107a (PE-Cy7) was directly added to the 
culture. As a negative control, one well remains unstimulated without the addition of 
PMA and Ionomycin. During the 5 hour incubation period BFA disrupts the structure 
and function of the Golgi apparatus and therefore prevents the transport of vesicles 
from the endoplasmic reticulum to the cell surface. Intracellular vesicles are retained 
in the cell allowing a detection of produced IFNγ and IL2 during the incubation time. 
Afterwards PBMCs were washed with 2 mL of PBS and pelleted at 524 x g for 5 min. 
Following another washing step with 2 mL PBS cells were stained with a APC 
labelled αGalCer loaded CD1d dextramer for 20 min at RT in the dark. Following a 
washing step, cell viability was determined through staining with a fixable viability dye 
eFluor506 for 15 min at 4°C in a total volume of 100 µl to exclude dead cells. Cells 
were washed with 2 mL of PBS at 5 min at 542 x g. Afterwards PBMCs were stained 
Methods 
 
 42 
with antibodies against the surface antigens CD4 (PE), CD8 (eFluor450) and CD19 
(APC-eFluor 780) in a total volume of 100 µl for 15 min at 4°C. Cells were washed 
once with PBS and PBMCs were fixed for 15 min at 4°C with 100 µl of IC fixation 
buffer. Cells were permeabilised by two washing steps with 1x Permeabilization 
Buffer. Through permeabilisation small holes were created in the cell membrane that 
allow intracellular staining of cytokines. The cells were stained for intracellular IFNγ 
(FITC) and IL2 (PerCP-eFluor 710) in 100 µl of 1x Permeabilization Buffer for 20 min 
at 4°C. Following another washing step with PBS the cells were resuspended in 
100 µl PBS. Cells were acquired on a FACS Canto II and analysis was performed 
using FlowJo 10.0.7. The percentage of IFNγ+, IL2+, CD107a+ iNKT cells was 
determined by subtracting the background cytokine production from the stimulated 
samples.  
3.10 In vitro activation of iNKT cells  
PBMCs from healthy individuals were stimulated either with IFNα or IFNλ3 or a 
combination of IL12, IL15 and IL18 to address the possible influence of these 
cytokines on the activation status of iNKT cells. The differences between the medium 
control without the addition of cytokines and the stimulated samples were 
determined. Changes in the activation status of iNKT cells was assessed through the 
measurement of the activation marker CD38 by flow cytometry. Therefore, PBMCs 
were quickly thawed and adjusted to a concentration of 2x106 cells/mL in R10. After 
stimulation with IFNα (100 IU/mL) or IFNλ3 (1 000 IU/mL) or IL12/15/18 (10 ng/mL, 
100 ng/mL, 50 ng/mL) or IL12 (10ng/mL) or IL15 (100 ng/mL) or IL18 (100 ng/mL) 
over a period of 24h, 1x106 cells were transferred into polystyrene round-bottom 
FACS tubes. Cells were washed twice with PBS to remove all stimulants. Following 
the αGalCer loaded dextramer staining (APC labelled), cells were stained with the 
fixable viability dye eFluor506 and subsequently with antibodies against the cell 
surface antigens CD19 (APC-eFluor 780) and CD38 (PerCP-eFluor 710). Prior to cell 
acquisition with the BD FACS Canto II cells were fixed. 
 
3.11 CD1d expressing peripheral cells 
To determine which cells in the periphery express CD1d on the cell surface, PBMCs 
from healthy individuals were analysed. Cell viability was evaluated by staining of 
dead cells via the fixable viability dye eFluor506. Following incubation, cells were 
washed and stained with antibodies against cell surface markers attributed to T cells, 
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B cells, NK cells and monocytes. While T cells, B cells and NK cells reside in the 
lymphocyte gate, monocytes display a different morphology and could be 
distinguished from the other cell types by analysing the forward and sideward scatter 
(FSC/SSC) plot. Cells were stained with antibodies targeting the cell surface antigens 
CD3 (eFluor 450), CD4 (PE) and CD8 (APC) to identify T cells and their subsets. 
Furthermore, NK cells were defined as CD3-/CD14-/CD19- and staining positive for 
CD56 (FITC) while B cells were identified as CD19+ (APC-eFluor 780). In addition to 
determining monocytes by FSC and SSC they were identified after a 15 min 
incubation at 4°C with an antibody against CD14 (PE-Cy7). Following fixation and 
cell acquisition on a BD FACS Canto II cell surface staining for CD1d 
(PerCP-eFluor 710) was analysed for all cell types. 
Furthermore, PBMCs from 13 HCV-RNA positive and 13 HCV-RNA negative PWID 
were analysed for their CD1d expression on monocytes and B cells. Therefore, 
5x105 cells were stained with the fixable viability dye eFluor506 to exclude dead 
cells. Subsequently cells were stained with antibodies against the cell surface 
antigens CD1d (PerCP-eFluor 710), CD14 (PE-Cy7) and CD16 (APC-eFluor 780) to 
define CD1d expressing monocytes. Whereas CD1d expressing B cells were 
determined after the addition of antibodies targeting CD19 (APC-eFluor 780) and 
CD1d (PerCP-eFluor 710) and subsequent incubation for 15 min at 4°C. Following 
cell fixation by IC fixation buffer cells were analysed by flow cytometry. 
3.12 Influence of IFNα treatment on CD1d expression 
PBMCs from healthy individuals were thawed and adjusted to a concentration of 
2x106 cells per mL in R10. Cells were treated with IFNα (100 IU/mL) or IFNλ3 
(1 000 IU/mL) or IL12/15/18 (10 ng/mL, 100 ng/mL, 50 ng/mL) over 24 h. As 
monocytes adhere to plastic cell surfaces, detachment prior to cell staining was 
performed. To avoid enzymatical digestion methods based for instance on trypsin 
that influences the cell viability, monocytes were detached by exposure to a cold 
environment. Following a centrifugation for 5 min at 754 x g the R10 was carefully 
removed. Ice cold PBS was added to the cells and the plate was placed at 4°C for 
15 min to allow detachment. After incubation at 4°C, the remaining attached cells 
were detached by repeatedly pipetting up and down the PBS or cautious cell 
scraping. The level of detachment was visually analysed via an inverse microscope. 
1x106 stimulated cells as well as control cells, that were placed for 24 hours in R10 
medium without further addition of stimulants, were transferred into polystyrene 
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round-bottom FACS tubes. Viable cells were determined through staining with the 
fixable viability dye eFluor506. Subsequently cells were washed with PBS and 
pelleted at 524 x g for 5 min. After discarding the supernatant, the cells were 
incubated with antibodies against CD14 (PE-Cy7), CD16 (APC-eFluor 780) and 
CD1d (PerCP-eFluor 710) for 15 min at 4°C. After an additional washing step cells 
were fixed and monocytes were analysed for their surface expression of CD1d by 
measurement on the BD FACS Canto II. 
3.13 Monocyte depletion experiment 
To investigate the role of monocytes, as a cell type expressing CD1d, in the 
expansion and activation of iNKT cells, PBMCs from 15 healthy individuals were 
expanded over a period of 10 days in the presence or absence of monocytes. 
Monocytes have the ability to adhere to plastic surfaces and this ability was used to 
deplete monocytes from the PBMC culture. PBMCs were adjusted to a concentration 
of 2x106 cells per mL in R10. Cells were plated into two separate tissue culture 
plates, 5x106 cells were transferred into a 12 well plate whereas 2x106 cells were 
transferred into a 24 well plate. After 3 hours of incubation at 37°C monocytes were 
attached to the surface of the tissue culture plate. Non-adherent cells were carefully 
collected from the 12 well plate without scratching the adherent layer whereas the 
second plate remained untouched. Non-adherent cells were counted using a XP-300 
cell counter and 2x106 cells were transferred into a 24 well plate in a total volume of 
1 mL R10. Subsequently untouched PBMCs as well as cells after monocyte depletion 
were stimulated with IL2 (25 IU/mL) and αGalCer (1 µg/mL). After 5 days of culture 
500 µl R10 supplemented with IL2 (25 IU/mL) were added into each well. Frequency 
of iNKT cells as well as their expression of CD38 was analysed by flow cytometry 
directly after thawing and after 10 days of culture. For ex vivo analysis 2x106 cells 
were used for staining while measurement of in vitro expanded cells were performed 
with 1x106 cells. Cell viability (fixable viability dye eFluor506) and the expression of 
the cell surface antigens CD3 (eFluor 450), CD38 (PerCP-eFluor 710), CD19 
(APC-eFluor 780) was determined on iNKT cells after staining with the αGalCer 
loaded CD1d dextramer (APC). Staining was performed as previously described in 
3.7. Following cell fixation, cells were acquired on a BD FACS Canto II.  
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3.14 Isolation and analysis of intrahepatic lymphocytes 
Liver tissue was obtained from patients undergoing liver resection at the University 
Hospital Essen. A perfusion of the resected liver piece was performed at the 
Department of Gastroenterology and Hepatology at the University Hospital Essen. 
Ruth Bröring kindly provided the liver perfusate comprising intrahepatic 
lymphocytes (IHL). The perfusate was transferred into 50 mL tubes and centrifuged 
at 524 x g for 7 min. After the supernatant was carefully decantated, the cell pellets 
were resuspended and combined. PBS was added up to a final volume of 35 mL. For 
IHL isolation 15 mL Bicoll were added into a 50 mL tube and the cell suspension was 
slowly layered over the Biocoll solution. Following a 20 min centrifugation at 1341 x g 
without brakes the mononuclear cell ring was transferred into a new tube. 
Subsequently cells were washed with PBS to remove residual Biocoll and pelleted at 
524 x g for 7 min. Cells were resuspended in PBS and the cell number was 
determined. After another washing step cells were frozen in freezing media as 
described in 3.1.2. For determining intrahepatic iNKT cell frequencies, IHL were 
stained with the αGalCer loaded CD1d dextramer (APC) as previously described in 
chapter 3.7. 
3.15 Flow cytometric analysis of KIR3DL1+ NK cells 
KIR3DL1+ NK from 90 PWIDs either being HCV-RNA positive, HCV-RNA negative or 
anti-HCV negative and 120 healthy individuals were analysed for their IFNγ and 
TNFα secretion as well as CD107a expression. PBMCs were thawed and rested in 
R10 overnight at a concentration of 2x106/mL. In addition, K562 were splitted 1:2 
one-day prior to the stimulation assay to ensure optimal viability of the target cells. 
5x105 PBMCs were incubated with K562 at an effector target ratio of 1:10. As K562 
are HLA devoid, engagement of inhibitory receptors on NK cells is abrogated, NK 
cells are activated and produce cytokines and cytotoxic granules. For the functional 
analysis of NK cells, PBMCs were washed once with R10 and 5x105 PBMCs were 
transferred into a 96 well U bottom tissue culture plate. In parallel K562 cells, the 
NK cell targets, were counted and washed once with R10. After K562 cells were 
transferred, BFA (10 ng/mL) and a CD107a specific antibody (PE-Cy7) was added to 
the culture. Stimulation of NK cells with K562 cells was performed in a total volume of 
250 µl of R10. For each analysed sample one well remained unstimulated, thus 
PBMCs were cultured in the presence of BFA without the addition of K562. After 
incubation at 37°C, 5% CO2 and 95% humidity cells were pelleted during a 5 min 
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centrifugation at 524 x g and washed twice with PBS to remove all residual FBS, 
since proteins in the buffer reduce brightness of the viability staining. Staining for 
15 min at 4°C with fixable viability dye eFluor506 allowed the exclusion of dead cells 
during subsequent analysis. Following another washing step PBMCs were stained 
with PerCP-Cy5.5 labelled antibodies against CD3, CD14 and CD19 to exclude 
T cells, monocytes and B cells. PBMCs were further stained with antibodies against 
the cell surface antigens CD16 (APC-eFluor 780), CD56 (BV-421) and KIR3DL1 
(APC) to identify KIR3DL1 expressing NK cells. A master mix was prepared 
comprising all antibodies against cell surface antigens. Each sample was stained in a 
total volume of 100 µl of antibodies pre-diluted in PBS. Following an incubation at 
4°C for 15 min, PBS was added and cells were centrifuged at 524 x g for 5 min. 
Afterwards cells were fixed through the addition of 100 µl IC fixation buffer for 15 min 
at 4°C. Subsequently cells were washed twice with 1x permeabilisation buffer and 
stained with antibodies against IFNγ (FITC) and TNFα (PE), previously intracellularly 
retained through the addition of BFA to the cell culture. Intracellular cytokine staining 
was performed in a total volume of 100 µl 1x permeabilisation buffer. Following 
incubation for 20 min at 4°C cells were washed with PBS and measured with a BD 
FACS Canto II. Subsequently results were analysed using FlowJo 10.0.7. and NK 
cell effector functions were calculated after the subtraction of the negative control. 
3.16 Flow cytometric analysis of KIR3DL1+ T cells 
To determine the frequency of KIR3DL1 expressing T cells through flow cytometry, 
PBMCs from 15 healthy individuals were thawed and 5x105 PBMCs were transferred 
into a 96 well U bottom tissue culture plate. To exclude dead cells, a viability staining 
with fixable viability dye eFluor506 was performed. Subsequently cells were stained 
by antibodies against the cell surface antigens CD3 (PerCP-Cy5.5), 
CD4 (APC-eFluor 780), CD8 (eFluor450) and KIR3DL1 (APC). Following the 15 min 
incubation at 4°C, cells were washed and fixed by IC fixation buffer. Prior to the cell 
acquisition cells were washed once and the cell pellet was resuspended in PBS. 
3.17 Flow cytometric analysis of NKG2C+ NK cells 
PBMCs from ten healthy individuals, that were included in the methylation analysis, 
were thawed and the NKG2C expression on NK cells was determined. 1x106 PBMCs 
were transferred into polystyrene round-bottom FACS tubes and stained for viable 
cells by the addition of fixable viability dye eFluor506. After an incubation for 15 min 
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at 4°C, cells were washed with 2 mL of PBS. Following a centrifugation for 5 min at 
524 x g cells were stained with antibodies against the cell surface antigens CD3, 
CD14, CD19 (all PerCP-Cy5.5), CD16 (APC-eFluor 780), CD56 (BV-421), KIR3DL1 
(APC) and NKG2C (PE). 
3.18 CpG methylation analysis 
To determine possible epigenetic imprinting leading to differences in IFNγ production, 
the methylation pattern of the IFNG region including the IFNG promoter and the 
conserved noncoding sequence (CNS)1 region localised 4.2 kb upstream from the 
transcriptional start site of IFNG was analysed. CD4+ T cells, TH1 cells and NK cells 
from healthy individuals were analysed for their DNA methylation pattern in the two 
selected regions. 
3.19 Cell sort of naïve CD4+ T cells, TH1 cells and NK cells for methylation 
analysis 
The percentage of methylated CpGs of CD4+ T cells, TH1 cells and NK cells was 
determined following FACS sorting of these cell populations. Therefore, frozen 
PBMCs from healthy individuals were thawed quickly in a 37°C water bath. The cells 
were transferred into 15 mL tubes containing 9 mL of prewarmed sterile filtered PBS. 
Afterwards the cells were centrifuged at 233 x g for 10 min. The supernatant was 
discarded and the pellet was resuspended in 10 mL of sterile PBS. Following another 
washing step, cells were counted and 1x107 cells were further used for staining. Cells 
were stained for 15 min at RT either with antibodies against the cell surface antigens 
CD3 (APC-eFluor 780) and CD56 (PerCP-eFluor 710) to define NK cells as CD3-
CD56+ or with CD3 (PerCP-Cy5.5), CD4 (APC-eFluor 780), CD45RA (PE-Cy7), 
CD45RO (FITC), CCR7 (PE) to investigate naïve CD4 T cells and TH1 cells. While 
both subsets express the T cell markers CD3 and CD4 they could be divided by their 
expression of CCR7, CD45RO as well as CD45RA into CCR7+ CD45RO- CD45RA+ 
naïve CD4+ T cells and CCR7- CD45RO+ CD45RA- TH1 cells. Subsequently cells 
were washed twice with sterile PBS and filtered prior to FACS based cell sorting 
using CellTrics® filters with a diameter of 50 µm. Cells were sorted through a BEC 
MoFlo XDP at the Core Flow Cytometry Facility of the University Hospital Düsseldorf.  
3.20 Cell sort of KIR3DL1- and KIR3DL1+ NK cells for methylation analysis 
To determine the methylation pattern of KIR3DL1 negative and positive NK cells, 
frozen PBMCs were thawed as described in 3.19. PBMCs from ten healthy 
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individuals were stained in 500 µl sterile PBS for 15 min at RT using 
0.5 µl/1x106 cells of live/dead fixable blue dead stain to distinguish viable from dead 
cells. Afterwards PBMCs were washed with 2 mL of sterile PBS and pelleted at 
233 x g for 10 min. PBMCs were stained for surface antigens CD16 (PE), CD56 
(PerCP-eFluor 710), KIR3DL1 (APC) and CD3/CD14/CD19 (all APC-eFluor 780) for 
15 min at 4°C. The concentration of CD56 was adjusted to the detection with MoFlo 
XDP as the intensity of PerCP-eFluor 710 was dimmer on this cytometer, thus 2 µl 
instead of 0.5 µl were used per 1x106 cells, which allowed reliable detection of 
NK cells. Thereafter, cells were washed twice with 2 mL of sterile PBS and filtered 
before detection to avoid cell aggregates. Viable, single, lymphocytes which were 
CD3- CD14- CD19- and CD56dim NK cells were positively selected and further 
subdivided by their expression of KIR3DL1 into KIR3DL1- and KIR3DL1+. Sorting 
was performed by a BEC MoFlo XDP. 
3.21 Bisulfite treatment of DNA 
Sorted global NK cells, naïve CD4+ T cells, TH1 cells as well as KIR3DL1- and 
KIR3DL1+ CD56dim NK cells were pelleted and dissolved in 12 µl of nuclease-free 
water. Ex vivo FACS sorted cells were treated with proteinase K and bisulfite 
converted by using the EZ DNA Methylation-Direct™ Kit according to the 
manufactures instruction. Through bisulfite treatment unmethylated cytosines were 
converted into uracil and could be detected as thymidin during sequencing while 
methylated cytosines were not affected by the treatment and remain as cytosine in 
the sequence (principle of bisulfite sequencing is depicted in figure 3.1). Sorted cells 
were digested with proteinase K. Therefore, 12 µl sample were mixed in a PCR tube 
with 13 µl digestion buffer (2x) and 1 µl proteinase K and incubated for 20 min at 
50°C. Followed by a 5 min centrifugation at 9279 x g, 20 µl of the supernatant were 
used for the subsequent bisulfite conversion. The supernatant was mixed with 130 µl 
of CT Conversion Reagent and placed into the thermocycler. During 8 min at 98°C 
the proteinase K was inactivated and the DNA is thermally denaturated. During an 
incubation at 64°C for 3.5 hours the single stranded DNA was converted. Afterwards 
the sample could be stored up to 20 hours at 4°C. Following incubation 600 µl of 
M-binding buffer were added into a Zymo-Spin™ IC Column and the sample was 
mixed carefully with the buffer through inverting. While the converted single stranded 
DNA was bound to the membrane, centrifugation for 30 seconds at 15682 x g 
removed sodium bisulfite from the sample. After discarding the flow through the DNA 
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was washed with 100 µl of M-Wash Buffer to ensure complete removal of residual 
sodium bisulfite. The last step of the conversion process was the desulfonation into 
uracil by the addition of 200 µl of M-Desulphonation Buffer to the membrane bound 
DNA. The incubation period of 20 min at RT was followed by a centrifugation for 
30 seconds at 15682 x g. Converted DNA was washed twice with 200 µl of M-Wash 
buffer before elution of the DNA by the direct addition of 10 µl M-Elution Buffer onto 
the membrane and subsequent centrifugation for 30 seconds at 15682 x g. Bisulfite 
converted DNA was stored at -80°C until further usage.  
 
 
Figure 3.1: Principle of bisulfite sequencing 
Bisulfite sequencing is a reliable method to distinguish methylated from unmethylated cytosines in 
CpGs of the region of interest. Unmethylated cytosines in a single stranded DNA are converted by 
bisulfite treatment into uracil and are detectable as thymine in the subsequent PCR amplification and 
sequencing (positions 8,11,12,14,18). However, methylated cytosines are not converted and remain 
as cytosine in the sequence (position 22). Therefore, through sequencing methylated CpGs can be 
distinguished from unmethylated CpGs and by calculating the ratio between cytosine and thymine the 
percentage of methylation can be determined. Furthermore, evaluation of cytosines outside the CpG 
sites can give insight into the efficacy of the bisulfite conversion, as they should be completely 
converted into thymine. The exemplary Sanger sequencing shown here provides proof of a complete 
conversion process and a high methylation of the analysed CpG. For quantitative instead of qualitative 
results from Sanger sequencing next generation sequencing was used to determine the frequency of 
methylation at each individual CpG site.  
3.22 PCR amplification of bisulfite converted DNA 
1 µl of bisulfite converted DNA was amplified using Platinum Taq DNA Polymerase 
and the composition of the PCR master mix is shown in table 3.3. The PCR reaction 
was performed in a total volume of 25 µl as the amplification protocol states (table 
3.1 and table 3.2). Primer combinations used for the PCR are shown in table 2.2. 
Successful amplification of the bisulfite converted DNA was verified by gel 
electrophoresis. Therefore, 5 µl of PCR product were mixed with 1 µl of DNA loading 
dye (6x) and applied to a 1.5% agarose gel that comprised 5 drops of 0.025% 
ethidium bromide solution. The gel electrophoresis was performed in 
1x Tris-Borate-EDTA buffer for 60 min at 120 V, 400 milliampere. The 247 bp (CNS1) 
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or 543 bp (IFNG promoter) sized PCR products were evaluated in comparison to the 
100 bp and 1 kb base pair DNA ladder. 
Table 3.1: PCR amplification protocol for the CNS1 region 
step temperature duration cycles 
initial denaturation 94°C 2 min 1 
denaturation 94°C 0.5 min  
annealing 52°C 0.5 min 45 
elongation 72°C 1 min  
final elongation 72°C 10.0 min 1 
  
Table 3.2: PCR amplification protocol for the IFNG promoter 
  
 
 
  
 
 
Table 3.3: PCR Master mix 
component volume  
Nuclease-free water 19.9 µl 
10 x Taq PCR Buffer (containing 15 mM MgCL2) 2.5 µl 
dNTP mix, 10 mM each 0.5 µl 
Forward-primer 10 pmol/µl 0.5 µl 
Reverse-primer 10 pmol/µl 0.5 µl 
Platinum Taq DNA Polymerase 0.1 µl 
Bisulfite treated DNA template 1 µl 
3.23 PCR purification 
After successful PCR amplification was confirmed, the PCR product was purified 
before sending it to Sanger sequencing. To remove impurities from the PCR product 
like primers, unused nucleotides and salts a PCR purification of amplified CNS1 and 
IFNG products was performed according to the Qiagen PCR purification kit protocol. 
In short, 200 µl PB binding buffer and 20 µl PCR product was added into the spin 
column. Nucleic acids are able to bind to the silica membrane of the spin column. 
Therefore, all other ingredients could be discarded after a centrifugation for 
30 seconds at 15682 x g. The DNA was washed with 750 µl PE buffer and the 
flow-through was discarded after 30 seconds of centrifugation at 15682 x g. An 
step temperature duration cycles 
initial denaturation 94°C 2 min 1 
denaturation 94°C 0.5 min 
45 annealing 50°C 0.5 min 
elongation 72°C 1 min 
final elongation 72°C 10.0 min 1 
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additional centrifugation for 1 min was performed to remove residual ethanol 
comprised in the binding buffer. Afterwards the column was placed in a second 
1.5 mL microcentrifuge tube and 30 µl EB buffer were added directly to the silica 
membrane. Followed by a 1 min incubation at RT the DNA was eluted through a 
centrifugation for 1 min at 15682 x g. The concentration of the purified DNA was 
measured with a Nano Drop at 260 nm since bisulfite converted DNA is A, U and T 
rich, the absorption resembles the absorption of RNA.  
3.24 Sanger Sequencing  
To confirm sufficient bisulfite conversion efficacy the purified DNA product was 
analysed by Sanger sequencing. Therefore, 50 ng of purified DNA in a total volume 
of 15 µl nuclease-free water was mixed with 2 µl (10 pmol/µl) of the specific primer 
for each of the analysed regions separately. The IFNG promoter region and the 
CNS1 region were both sequenced with the forward as well as the reverse primer. 
The sequencing was performed by Eurofins and analysed with Geneious 7.1.9.  
3.25 DNA methylation analysis of the IFNG locus by Next generation 
sequencing 
After confirmation of efficient bisulfite conversion, PCR sequencing of six CpG sites 
of the CNS1 region localised 4.2 kb upstream from the transcriptional start site of 
IFNG and five CpG sites in the IFNG promoter was performed by next generation 
sequencing (NGS). Therefore, the IFNG and CNS1 PCR products were sequenced, 
performed by Seq-IT GmbH & Co. KG in Kaiserslautern. Raw data were provided 
from forward and reverse reads. Data were evaluated through Geneious 7.1.9. The 
mean methylation was calculated from every single CpG site from all available reads. 
Per sample and region between 166 503 and 237 445 reads were used for 
calculation. 
3.26 Statistical analysis 
Data were examined for normal distribution and followed by an equivalent outlier test. 
For the comparison of two groups either a parametric or nonparametric t test was 
performed. For the calculation of statistical significance between groups displaying 
paired observations either the Wilcoxon matched pairs test or the paired t test was 
used depending on the distribution of the data. Three or more groups were compared 
by one-way analysis of variance (ANOVA) or a Kruskal-Wallis test. Linear regression 
analysis was performed to determine the correlation of two parameters. 
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P-values ≤0.05 were considered to be statistically significant. Statistical analyses 
were performed using GraphPad Prism 5.04 software (GraphPad Software, San 
Diego California USA). 
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4 Results 
4.1 iNKT cells in HCV infection 
Initially, iNKT cells have been studied intensively in mice utilising either antibodies 
against the T cell receptor chains Vα14 and Vβ8.2, Vß7 and Vß2 or αGalCer loaded 
CD1d dextramers. Since iNKT cells recognise αGalCer presented by the MHC 
class I like molecule CD1d, dextramers of αGalCer loaded CD1d can be used for the 
analysis of iNKT cells. Therefore, human PBMCs were stained for iNKT cells utilising 
a commercially available fluorescently labelled αGalCer loaded CD1d dextramer. By 
flow cytometric analyses iNKT cells were identified after exclusion of dead cells and 
doublets. CD1d dextramer+ NKT cells were congruent with the described human 
invariant T cell receptor chains expressed by iNKT cells as they solely express Vα24 
in combination with Vβ11 (figure 4.1). Further analysis of iNKT cells in this study 
were focused on invariant CD1d restricted cells that were detectable via a αGalCer 
loaded CD1d dextramer. 
 
 
Figure 4.1: Identification of human iNKT cells 
To determine iNKT cells using flow cytometry, lymphocytes were identified and dead cells, doublets as 
well as CD19+ B cells were excluded. iNKT cells were identified as CD1d dextramer+ cells and 
subsequently analysed for the expression of the T cell receptor chains Vα24 and Vβ11. 
In contrast to iNKT cells, identification of non-invariant NKT cells, that are 
characterised by a diverse TCR repertoire, with existing methodology is challenging. 
Non-invariant NKT cells are commonly defined by their CD1d-restriction and the 
absence of the invariant TCR chains, as a unique surface marker to distinguish them 
from iNKT cells is still lacking (reviewed in Rhost et al. 2012). Therefore, the analysis 
of non-invariant NKT cell was not included in this study. 
Results 
 
 54 
4.1.1 Frequency of iNKT cells in HCV-RNA positive and HCV-RNA negative 
PWID 
The role of iNKT cells for the outcome of HCV infection is poorly defined and 
decreased iNKT cell frequencies have been reported in chronically HCV infected 
patients, however, contradicting reports exist. Therefore, iNKT cell frequencies in 
HCV infection were re-evaluated in a high-risk cohort of PWID. Since injection drug 
use represents the most important risk factor for HCV infection in industrialised 
countries as Germany, we utilised this cohort to comparatively study PWID 
developing chronic infection and individuals that spontaneously resolve HCV 
infection. In this study, a total of 61 individuals with a history of injection drug use 
were analysed including 28 HCV-RNA positive and 33 anti-HCV positive PWID with 
resolved HCV infection (HCV-RNA negative). Significantly reduced NKT cell 
frequencies have been observed early in HIV infection (Fernandez et al. 2014). 
Therefore, no HCV-HIV coinfected individuals were included to focus on HCV 
mediated effects. Patient characteristics of individuals included in the analysis of 
iNKT cells are summarised in table 4.1. 
Table 4.1: Patient characteristics of PWID included in the iNKT cell study  
complete cohort HCV-RNA positive HCV-RNA negative 
n 28 33 
mean age in years (range) 35 (22-55) 39 (22-53) 
male (%) 23 (82.1%) 30 (90.1%) 
HCV genotype 1 (%) 12(42.9%) n.d. 
HCV genotype 3 (%) 12(42.9%) n.d. 
other HCV genotypes or unknown 
(%) 4 (14.3%) n.d. 
median viral load in IU/mL (range) 582900 (615-34 010 000) n.d. 
anti-HIV positive (%) 0 (0%) 0 (0%) 
n.d. not determined 
iNKT cell frequencies in PWID ranged from undetectable to 0.23% and no significant 
difference in frequency could be observed between PWID with resolved HCV 
infection and HCV-RNA positive individuals. The median frequency was slightly 
higher in the HCV-RNA positive group with 0.032% compared to 0.017% in the 
HCV-RNA negative group (figure 4.2 A). Furthermore, a weak nonsignificant 
correlation between age and iNKT cell frequencies was observed in our cohort 
(p=0.083, r2=0.050, figure 4.2 B). In addition, iNKT cell frequencies were not 
associated with the gender of patients, even though this analysis was limited due to 
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the small percentage of female PWID in this cohort. Moreover, no association of 
iNKT cell frequencies and viral load in HCV-RNA positive individuals could be 
determined (data not shown). 
HCV-RNA pos HCV-RNA neg
0.00001
0.0001
0.001
0.01
0.1
1 0.4512
%
 
iN
KT
 
ce
lls
20 30 40 50 60
0.00
0.02
0.04
0.06
0.08
0.10
0.20 p = 0.083
R2= 0.050
age in years
%
 
iN
KT
 
ce
lls
A B
 
Figure 4.2: iNKT cell frequencies in HCV-RNA positive and HCV-RNA negative PWID 
iNKT cell frequencies were determined via a CD1d dextramer staining of PBMCs from 28 HCV-RNA 
positive and 33 HCV-RNA negative individuals. Displayed is the percentage of iNKT cells from single, 
viable lymphocytes after the exclusion of CD19+ B cells. To apply a logarithmic scale the limit of 
detection was defined as 0.0001% for individuals with no measurable iNKT cells frequencies. The 
dotted line at 0.01% represents the cut off for PWID that were included in further analysis. The p-value 
was calculated by nonparametric Mann Whitney test and the median is depicted (A). Moreover, the 
frequency of iNKT cell was correlated with the age of each analysed PWID independent of their HCV 
status. Linear regression was performed and the p-value as well as the R2 is indicated (B). 
Since iNKT cell were not measurable in all analysed individuals only individuals with 
previously detectable iNKT cells above the defined cut off of 0.01% were further 
included in phenotypical as well as functional analysis. 
4.1.2 Phenotype of iNKT cells in HCV-RNA positive and HCV-RNA negative 
PWID 
In HCV infection, various NK cell phenotypes have been repeatedly associated with 
HCV infection outcome. Moreover, differences in expression of differentiation or 
exhaustion markers on T cells have been linked to HCV infection outcome. Since 
elaborate phenotypical analyses of iNKT cells that share both characteristics of NK 
and T cells in HCV infection are lacking we aimed to comparatively analyse the 
phenotype of iNKT cells from HCV-RNA positive and HCV-RNA negative PWID. 
iNKT cells were defined as CD1d dextramer positive lymphocytes and were analysed 
for their expression of markers commonly associated with the NK cell linage like 
CD161, receptors of the CD94/NKG2 family and KIR2DL3 exemplifying the receptors 
of the KIR family. Furthermore, CD161 has been initially described as a NKT defining 
cell marker. In addition, to addressing the expression of the exhaustion marker PD1, 
that has been linked to T cell exhaustion in HCV infection, the expression of several 
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differentiation as well as activation markers such as CD57, CD127 and CD38 were 
analysed on iNKT cells (figure 4.4). By flow cytometric analysis lymphocytes were 
identified and subsequently dead cells as well as doublets were excluded. Following 
an exclusion of CD19+ B cells due to unspecific staining of B cells by the dextramer, 
iNKT cells were defined. The gating strategy for iNKT cells and selected surface 
antigens CD38, PD1 and NKG2A, is shown in figure 4.3. 
 
 
 
Figure 4.3: Representative gating strategy for iNKT cells in PWID  
Representative gating strategy of the analysis of iNKT cells from chronically HCV infected PWID and 
PWID with spontaneously resolved HCV is depicted. Cryopreserved PBMC were thawed and iNKT 
cells were defined through CD1d dextramer staining as CD19-, live, single lymphocytes. Subsequently 
the frequency of iNKT cells expressing NKG2A, NKG2D, KIR2DL3, CD38, CD127, CD57, PD1 and 
BTLA on iNKT cells were determined. An Exemplary gating for CD38, NKG2A and PD1 is shown. 
As previously reported, high frequencies of CD161+ cells in the iNKT cell population 
could be confirmed with a median frequency of 85% (Lee et al. 2002). Expression of 
the NK cell receptors NKG2A, NKG2D and KIR2DL3 on iNKT cells, previously 
described to be differentially regulated on NK cells in HCV infection, did not 
significantly differ between groups. Interestingly, out of the nine tested receptors the 
activation marker CD38 was significantly higher expressed on iNKT cells of 
HCV-RNA positive PWID (mean: 24.5%) compared to HCV-RNA negative PWID 
(mean: 8.9%; p=0.0008). Despite this activated phenotype in PWID with chronic HCV 
infection, iNKT cells expressed high levels of CD127 and predominantly lacked 
CD57, irrespective of the infection status. Moreover, no difference in expression of 
the exhaustion markers PD1 and BTLA could be observed between groups. 
Results 
 
 57 
PD1
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.5316
%
 
PD
1+
 
iN
KT
 
ce
lls
BTLA
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.5316
%
 
B
TL
A
+
 
iN
KT
 
ce
lls
CD127
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.7196
CD
12
7+
 
iN
KT
 
ce
lls
CD38
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.0008
CD
38
+
 
iN
KT
 
ce
lls
NKG2A
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.2883
%
 
N
KG
2A
+
 
iN
KT
 
ce
lls
NKG2D
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.3840
%
 
N
KG
2D
+
 
iN
KT
 
ce
lls
CD57
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.9578
CD
57
+
 
iN
KT
 
ce
lls
CD161
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.5035
CD
16
1+
 
iN
KT
 
ce
lls
KIR2DL3
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 1.0000
KI
R
2D
L3
+
 
iN
KT
 
ce
lls
 
Figure 4.4: Phenotypical comparison of iNKT cells from HCV-RNA positive and 
HCV-RNA negative PWID 
Expression of the NK cell markers CD161, NKG2A, NKG2D and KIR2DL3 (lower panel) as well as the 
differentiation markers CD127, CD57 (middle panel) and markers associated with exhaustion and 
activation like CD38, PD-1 and BTLA (top panel) were analysed by flow cytometry on iNKT cells. In 
total 13 HCV-RNA positive and 13 HCV-RNA negative PWID were analysed for their iNKT cell 
phenotype. Samples size between panels varies due to limitation in the availability of patient samples. 
If no or extremely low expression was observed as this was the case for CD57 and KIR2DL3 or if 
analysis was performed as proof of principle which holds true for CD161, data acquisition was 
discontinued, accounting for further differences in sample size. P-values were calculated by 
nonparametric Mann Whitney test and the median is depicted. 
To determine if this activated phenotype is solely seen on iNKT cells, CD38 
expression was analysed on CD1d dextramer negative lymphocytes. No difference in 
CD38 frequency could be observed between HCV-RNA positive and negative PWID 
on non iNKT lymphocytes (appendix figure 6.1). This indicates that solely iNKT cells 
in chronic HCV infection are in a pre-activated state. 
Four different human iNKT cell subsets have been previously described in the 
periphery, which are defined by the expression of the cell surface antigens CD4 and 
CD8. To address a possible change in iNKT cell subset distribution during HCV 
infection CD4+/CD8– (CD4+), CD4–/CD8+ (CD8+), double negative (DN) and double 
positive (DP) iNKT cells were determined in HCV-RNA positive and HCV-RNA 
negative PWID. However, the observed frequency of each subset was similar to 
previously described proportions in healthy individuals. Moreover, iNKT cell subset 
distribution did not significantly differ between HCV-RNA positive and HCV-RNA 
negative PWID (figure 4.5). 
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Figure 4.5: iNKT cell subset distribution in HCV-RNA positive and HCV-RNA negative 
PWID 
iNKT cell subset distribution was analysed in 14 HCV-RNA positive and 10 HCV-RNA negative PWID. 
Frequency of CD4+/CD8– (CD4+), CD4–/CD8+ (CD8+), double negative (DN) and double positive (DP) 
iNKT cells was determined. Statistical analysis revealed no associations and the mean ± standard 
error of mean (SEM) is depicted. 
4.1.3 Functional analysis of iNKT cells in HCV-RNA positive and HCV-RNA 
negative PWID 
Since iNKT cells of chronically HCV infected individuals displayed an activated 
phenotype, further analysis is needed to investigate if this translates into different 
functional properties of iNKT cells from HCV-RNA positive and HCV-RNA negative 
PWID. The proliferation potential of iNKT cells was determined by treatment of 
PBMCs with αGalCer, an exogenous ligand for iNKT cells. Robust iNKT cell 
expansion was induced after 10 days of culture in both groups. Independent of HCV 
infection status, iNKT cell frequencies were significantly increased after in vitro 
stimulation compared to iNKT cell frequencies ex vivo (****p≤0.0001, figure 4.6 A). 
The expansion potential of iNKT cells was calculated as fold change of iNKT cell 
frequencies determined ex vivo and after in vitro expansion. A slight tendency 
towards an increased expansion capacity of iNKT cells from HCV-RNA positive 
individuals could be observed in comparison to HCV-RNA negative PWID (p=0.1662, 
figure 4.6 B). Expansion of iNKT cells in both HCV-RNA negative PWID and PWID 
spontaneously resolving HCV infection was significantly associated with upregulation 
of the activation marker CD38 and downregulation of CD127 (figure 4.6 D+E). 
Downregulation of CD127 has been associated with T cell activation in HIV infection 
(Benito et al. 2008). Therefore, the determined iNKT cell phenotype of CD38high 
CD127low indicates that iNKT cells become highly activated during expansion with 
αGalCer irrespective of infection outcome.  
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Figure 4.6: Proliferation potential of iNKT cells from HCV-RNA positive and HCV-RNA 
negative PWID 
PBMCs from 13 HCV-RNA positive and 13 HCV-RNA negative PWID were analysed for their 
proliferation potential. Frequencies of iNKT cells were determined ex vivo and after 10 days of in vitro 
expansion with IL2 and αGalCer (A). Fold change of CD1d dextramer+ iNKT cells between day 0 and 
day 10 was calculated (B). Furthermore, the frequency of CD38+ iNKT cells and CD127+ iNKT cells 
was determined after expansion (C+D). For statistical analysis Wilcoxon’s matched-pairs signed rank 
test was used (****p≤0.0001; A). For comparison of differences in iNKT fold change the p-value was 
calculated by nonparametric Mann Whitney test (B). One-way ANOVA was used for the statistical 
comparison of four groups (C and D **p≤0.01, ***p≤0.001). 
As the distinct activated phenotype observed in chronic HCV infection had only 
marginal impact on the proliferation capacity of iNKT cells, functional characteristics 
of iNKT cells of patients with chronic and resolved HCV infection were further 
addressed. iNKT cells are characterised by their ability to rapidly produce cytokines 
such as IFNγ or IL2 and the release of cytotoxic granules upon activation. Expression 
of CD107a, a marker for degranulation and cytotoxicity, as well as the production of 
IFNγ and IL2 of iNKT cells was analysed in 14 HCV-RNA positive PWID and 13 
HCV-RNA negative PWID with resolved HCV infection in response to stimulation with 
PMA and Ionomycin. The function of iNKT cells was examined either ex vivo or after 
10 days of in vitro expansion (figure 4.7). Ex vivo functional analysis revealed a high 
IFNγ production potential of iNKT cells while the degranulation ability was low and 
only detectable in approximately half of the analysed patient samples. However, 
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independent of HCV status, iNKT cells produced similar levels of IFNγ, IL2 and 
CD107a. Interestingly, the potential of iNKT cells to produce IL2 as well as their 
degranulation ability determined by CD107a expression was significantly improved 
by stimulation of PBMCs with αGalCer over 10 days. Even though no significant 
difference in iNKT functionality regarding production of IFNγ, IL2 and expression of 
CD107 could be observed, there was a slight tendency towards increased IFNγ 
production in HCV-RNA positive individuals after in vitro expansion. 
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.6606
%
 
IF
N
γ+
 
iN
KT
 
ce
lls
HCV-RNA pos HCV-RNA neg
0
20
40
60
80
100 0.1667
%
 
IF
N γ
+
 
iN
KT
 
ce
lls
HCV-RNA pos HCV-RNA neg
0
20
40
60
80 0.3641
%
 
IL
2+
 
iN
KT
 
ce
lls
HCV-RNA pos HCV-RNA neg
0
20
40
60
80 0.7159
%
 
IL
2+
 
iN
KT
 
ce
lls
HCV-RNA pos HCV-RNA neg
0
10
20
30
40 0.9758
%
 
CD
10
7a
+
 
iN
KT
 
ce
lls
HCV-RNA pos HCV-RNA neg
0
10
20
30
40 0.9420
%
 
CD
10
7a
+
 
iN
KT
 
ce
lls
ex vivo after in vitro expansion
IFNγ
IL2
CD107a
 
Figure 4.7: Cytokine profile of iNKT cells from HCV-RNA positive and HCV-RNA 
negative PWID 
The frequency of IFNγ+, IL2+ and CD107a+ iNKT cells in 14 PWID with chronic or 13 with resolved 
HCV infection was measured via intracellular cytokine staining and flow cytometric analysis. Samples 
were either stimulated with PMA (10 ng/mL)/Ionomycin (1 µg/mL) for 5 hours in the presence of 
BFA (100 ng/mL) ex vivo (C) or their functionality was addressed after 10 days of expansion with 
αGalCer. Samples with less than 10 detectable iNKT cells were excluded from the ex vivo analysis. 
P-values were calculated using a nonparametric Mann Whitney test and the median is depicted. 
4.1.4 Combination of interleukins induces CD38 expression on iNKT cells in 
vitro 
ISGs induced by type I or type III IFNs as IFNα or IFNλ3 are upregulated in HCV 
infected liver and increased endogenous production of IFNλ by HCV infected cells 
has been reported (Marukian et al. 2011, Park et al. 2012). Although IFNs mediate 
antiviral effects, chronic HCV infection has been associated with increased IFNα 
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levels. Continuous induction of ISGs seen in chronic infection lead to decreased 
responsiveness to PEGylated IFNα based therapies (Sarasin-Filipowicz et al. 2008). 
Therefore, it was addressed if IFNα or IFNλ have a direct influence on iNKT cells. 
Moreover, potential effects of a combination of IL12, IL15 and IL18, previously 
reported to activate NK cells, were assessed. PBMCs from healthy individuals were 
stimulated over a period of 24 hours and the frequency of CD38 as a marker for 
activation was determined on iNKT cells by flow cytometry. While no difference in 
activation of iNKT cells could be observed in response to IFNα or IFNλ3 stimulation 
(figure 4.8 A+B), treatment with a combination of IL12, -15 and -18 led to a significant 
increase in CD38+ iNKT cells (p=0.0030, figure 4.8 C). Moreover, an additive effect of 
IL12 and IL15 could be observed (figure 4.8 D). In contrast to NK cells, IL18 had no 
effect on iNKT cell activation and the observed increase was solely mediated by IL12 
and IL15. However, this IL12, IL15 mediated activation was not unexpected since 
NKT cells harbour various NK cell properties. 
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Figure 4.8: Influence of IFNα, IFNλ3 and IL12, -15 and -18 on iNKT cell activation 
PBMCs from healthy individuals were stimulated over 24 hours with or without 100 IU IFNα/mL (A) 
and the expression of CD38 on iNKT cells was determined by flow cytometry. Furthermore, PBMCs 
were stimulated for 24 hours in media supplemented with IFNλ3 (1 000 IU/mL) (B), IL12 (10ng/mL), 
IL15 (100 ng/mL) or IL18 (100 ng/mL) alone or in combination (10 ng/mL, 100 ng/mL, 50 ng/mL) 
(C+D). Activation of iNKT cells was determined by the measurement of the frequency of CD38+ iNKT 
cells. Significance was calculated by paired t-test and comparison of more than two groups was done 
using One-way ANOVA **p≤0.01. 
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4.1.5 Expression of the iNKT cell ligand CD1d is independent of HCV infection 
outcome 
In HIV infection CD1d is downregulated by the Nef protein and this downregulation is 
associated with reduced iNKT cell activation (Chen et al. 2006). Since we observed 
an increase in iNKT cell activation displayed by CD38 expression we hypothesised 
that in chronically HCV infected patients CD1d might be upregulated in comparison 
to patients with resolved infection. To identify cells, capable of presenting glycolipids 
to iNKT cells in the periphery, PBMCs from five healthy individuals were analysed by 
flow cytometry for their cell surface expression of CD1d. In line with previous reports, 
suggesting that CD1d is most prominently expressed on antigen presenting cells 
(Roark et al. 1998), monocytes showed the highest CD1d expression of all analysed 
cells in the periphery. Moreover, CD1d expression could be detected in B cells while 
T and NK cells lacked CD1d on the cell surface (figure 4.9 A). Since B cells and 
monocytes displayed detectable CD1d on their surface, both cell types were 
subsequently studied in HCV infected individuals. For that purpose, CD1d expressing 
monocytes and B cells from 13 PWID with chronic HCV infection and 13 PWID with 
resolved infection were identified by flow cytometry. However, the analysis between 
HCV-RNA positive and HCV-RNA negative individuals revealed no significant 
differences in the expression of CD1d neither on monocytes nor on B cells (figure 
4.9 B+C).  
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Figure 4.9: Expression of CD1d on peripheral cells  
CD1d expression on CD3+ T cells, CD56+ NK cells, CD19+ B cells and CD14+ monocytes from 
five healthy individuals was determined. As monocytes have a different cell morphology they were first 
identified through the FSC/SSC scatter plot as a population distinct from lymphocytes because of their 
increased size. Afterwards populations were defined by their expression of cell surface markers 
specific to the cell type (A). One-way ANOVA **p≤0.01 ****p≤0.0001 was used to analyse statistical 
significance. Since monocytes displayed the highest CD1d mean fluorescence intensity (MFI) in the 
periphery, PBMCs from 13 chronically HCV infected PWID and 13 PWID with spontaneously resolved 
HCV infection were analysed for CD1d MFI (B). Moreover, CD1d MFI on B cells was examined 
between groups. Unpaired t-test was performed to determine significance and the median is depicted. 
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4.1.6 IFNα mediates upregulation of the iNKT cell ligand CD1d in vitro 
While no direct effect of IFNα and IFNλ stimulation on iNKT cell activation could be 
detected, IFNs might mediate other effects and thus indirectly contribute to iNKT cell 
activation. Classical MHC class I expression in the hepatic compartment is low 
compared to other tissues, whereas hepatocytes express high levels of CD1d (Agrati 
et al. 2005). Since IFNs are upregulated in HCV infected liver we hypothesised that 
they might contribute to differences in CD1d expression. Therefore, the influence of 
IFNα, IFNλ or the combination of IL12, -15 and -18 on CD1d expression was 
determined. Expression analysis was focused on monocytes as they displayed the 
highest CD1d expression in the periphery. No influence on CD1d expression could 
be detected after 24 hours of stimulation with IFNλ or the combination of IL12, -15 
and -18 (figure 4.10 C+D). Interestingly, it could be demonstrated that CD1d is 
significantly increased on monocytes upon IFNα treatment (p=0.0120 figure 4.10 B), 
suggesting that high IFNα levels in the liver might mediate upregulation of CD1d on 
hepatocytes and subsequently lead to the activation of iNKT cells in the liver. 
 
Figure 4.10: Influence of IFNα, IFNλ3 and IL12, -15 and - 18 on CD1d expressing 
monocytes 
PBMCs from healthy individuals were stimulated for 24 hours in media supplemented with either 
100 IU IFNα/mL or IFNλ3 (1 000 IU/mL) or IL12/15/18 (10 ng/mL, 100 ng/mL, 50 ng/mL). The influence 
of the treatment on the median fluorescence intensity of CD1d on monocytes was determined. 
Significance was calculated by paired t-test. 
4.1.7 Monocytes influence the expansion and activation of iNKT cells 
As monocytes were the most prominent cell type in the periphery expressing CD1d 
their impact on iNKT cell expansion and activation was addressed. We hypothesised 
that absence of CD1d expressing monocytes might lead to reduced expansion of 
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iNKT cells since cells able to present CD1d restricted glycolipid ligands to iNKT cells 
are decreased. Thus, PBMCs from 15 healthy individuals were stimulated with 
αGalCer either in the presence or absence of monocytes, followed by flow cytometric 
analysis. iNKT cell frequencies as well as CD38 expression as a marker for activated 
iNKT cell was determined. Indeed, a strong tendency towards a lower iNKT cell 
expansion capacity was observed in the monocyte depleted culture (p=0.0730, figure 
4.11 A). Furthermore, the analysis indicates that a depletion of monocytes has a 
major impact on the activation of iNKT cells since significantly reduced frequencies of 
CD38+ iNKT cells (p=0.0038) as well as a reduction in CD38 surface density 
(p=0.0203) on iNKT cells were detected (figure 4.11 B+C). These results proof that 
CD1d expressing cells are needed for proper iNKT cell expansion as well as iNKT 
cell activation. 
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Figure 4.11: Influence of monocytes on the expansion and activation of iNKT cells  
PBMCs from 15 healthy individuals were expanded over a period of 10 days with IL2 (25 IU/mL) and 
αGalCer (1 µg/mL) in the presence or absence of monocytes. Monocytes were depleted by adherence 
to plastic. iNKT cell frequencies (A) and frequency of CD38 expressing iNKT cells as well as CD38 
MFI on iNKT cells (B+C) was determined directly after thawing and after 10 days of culture. The 
median is shown and statistical significance was determined by Wilcoxon signed rank test *p≤ 0.05, 
**p≤ 0.01. 
4.1.8 CD1d is upregulated in HCV infected liver 
Previous reports demonstrated high NKT cell frequencies in the liver of mice (Eberl et 
al. 1999). Therefore, we tested if iNKT cell frequencies are similarly elevated in the 
human system. iNKT frequencies were determined in liver infiltrating lymphocytes 
and compared to the above stated iNKT cell frequencies in the periphery. In contrast 
to studies in mice, an enrichment of iNKT cells in the human liver could not be 
observed (figure 4.12 A+B). Moreover, studies in mice showed a proinflammatory 
role of CD1d restricted NKT cells contributing to hepatic inflammation and liver 
fibrosis (Ishikawa et al. 2011). Since HCV is a hepatotropic infection, upregulation of 
CD1d in the liver could contribute to iNKT cell activation. Therefore, the expression of 
CD1d was analysed in the liver. In cooperation with the clinic for Gastroenterology 
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and Hepatology at the University Hospital Essen an expression profile of CD1d from 
liver biopsies was generated to compare messenger RNA (mRNA) levels between 54 
HCV infected patients and 23 patients with HBV infection. The mRNA expression of 
CD1d was significantly higher in HCV infected individuals compared to HBV infected 
patients (p≤0.05, figure 4.12 C). As HCV infection in contrast to HBV infection is 
known to induce a strong type I IFN response in the liver, our observed effect of IFNα 
mediated upregulation of CD1d on monocytes in the periphery could therefore 
possibly account for the difference in CD1d mRNA level between HCV and HBV 
infected patients.  
 
 
 
Figure 4.12: iNKT frequencies and CD1d mRNA levels in the liver  
iNKT cell frequencies were analysed in four liver samples as CD1d dextramer+ CD19- lymphocytes 
(B). Frequencies in the liver were compared with initial determined iNKT cell frequencies in the 
periphery of HCV-RNA positive and HCV-RNA negative PWID (A). One-way ANOVA was used to 
analyse statistical significance. Furthermore, CD1d mRNA levels were compared between liver 
biopsies of 54 HCV and 23 HBV infected patients. Data of CD1d mRNA levels were kindly provided by 
the Clinic for Gastroenterology and Hepatology at the University Hospital Essen. The mean ± SEM is 
depicted. 
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4.2 NK cell in HCV infection 
While iNKT cells are still poorly covered by scientific reports in HCV infection there is 
growing evidence for the importance of NK cells for HCV infection outcome. Different 
genetic association studies revealed that genetically determined combinations of 
NK cell-receptors and their ligands are associated with differential outcome of HCV 
infection. NK cell function is regulated by a set of different inhibitory and activating 
receptors including killer-cell immunoglobulin-like receptors (KIRs). Khakoo et al. 
(2004) demonstrated that PWID homozygous for KIR2DL3 and its ligand HLA-C1 are 
significantly enriched in patients who spontaneously resolve HCV infection. 
Therefore, the aim was to analyse whether certain KIR/KIR-ligand combinations are 
associated with HCV infection outcome in our PWID cohort and if identified 
KIR/KIR-ligand combinations correlate with functional properties of NK cells. 
4.2.1 PWID cohort 
As previously described injection drug use is the most common risk factor for HCV 
infection in high income countries (Nelson et al. 2011). Consistent with these 
findings, we observed that with approximately 81% the majority of our PWID cohort 
(n=266) were HCV antibody positive (table 4.2). Of the analysed PWID, 57% had 
detectable HCV RNA consistent with ongoing viral infection. In turn, 24% were 
HCV-RNA negative with detectable HCV antibody titres, consistent with spontaneous 
immune control of HCV infection. Interestingly, the remaining 19% were HCV 
seronegative despite continuous high-risk behaviour. The high frequency of sharing 
injection materials among PWID suggests that at least parts of this group were also 
exposed to HCV infection. Accordingly, these exposed anti-HCV seronegative PWID 
were resistant to infection or achieved immune control during an early phase prior to 
seroconversion. The ratio between male and female patients included in this study 
did not significantly differ between the three subgroups. However, anti-HCV negative 
PWID were significantly younger than HCV-RNA positive patients (appendix figure 
6.2, p≤0.05). 
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Table 4.2: Patient characteristics of PWID included in the KIR study 
Germany North America  
complete cohort HCV-RNA positive 
HCV-RNA 
negative 
anti-HCV 
negative 
HCV-RNA 
positive 
HCV-RNA 
negative 
n 151 64 51 267 75 
mean age in years (range) 38 (18-61) 38 (20-53) 34 (18-49) 33 (18-73) 35 (19-59) 
male (%) 116 (76.8%) 56 (87.5%) 38 (74.5%) 168 (62.9%) 28 (37.3%) 
HCV genotype 1 (%) 84 (55.6%) n.d. n.d. 158 (59.2%) n.d. 
HCV genotype 3 (%) 64 (42.4%) n.d. n.d. 38 (14.2%) n.d. 
other HCV genotypes or 
unknown (%) 3 (2%) n.d. n.d. 71(26.6%) n.d. 
median viral load in 
IU/mL (range) 
852848 
(621-7 778 000) n.d. n.d. 
862456  
(200-40 500 000) n.d. 
anti-HIV positive (%) 5 (3.3%) 1 (1.5%)   31 (11.6%) 12 (16%) 
GT: genotype, IU: international units, n.d.: not determined 
 
4.2.2 KIR/KIR-ligand combinations associated with HCV infection outcome in a 
high-risk group of PWID 
A previous study in our group had the aim to identify if certain KIR/KIR-ligand 
constellations play a role in HCV infection outcome in a high-risk cohort of PWID. 
Therefore, 266 treatment naïve well characterised patients comprising 151 HCV-RNA 
positive PWID, 64 HCV-RNA negative PWID and 51 anti-HCV negative PWID were 
included in the genetic analysis (table 4.2). PWID were KIR and HLA class I typed at 
a 4-digit resolution level to allow discrimination between HLA-A and -B alleles 
encoding a Bw6, Bw4 80(I) or Bw4 80(T) motif. While all three motifs are seen on 
HLA-B alleles, HLA-A alleles only encode for Bw6 and Bw4 80(I).  
An univariate analysis testing all known KIR/KIR-ligand constellations for possible 
associations with infection outcome of HCV, revealed that the KIR/KIR-ligand 
constellation of KIR2DL1/HLA-C2 (p=0.014) as well as KIR3DL1/HLA-Bw4 80(T) 
(p=0.003) was significantly enriched in seropositive HCV-RNA negative PWID 
compared to HCV-RNA positive PWID (table 4.3). In contrast to Khakoo et al. (2004), 
no association between the constellation KIR2DL3/HLA-C1 and HCV infection 
outcome was observed. 
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Table 4.3: Genetic association between KIR/KIR-ligands and HCV infection status in 
PWID  
 
univariate 
analysis multivariate analysis 
gene HCV-RNA positive 
HCV-RNA 
negative 
anti-HCV 
negative p-value
a
 p-value
b 
 p-value
a
 
OR 95% CI 
KIR2DL1/HLA-C2 9.9% 20.3% 9.8% 0.014 1.000 n.s. - - 
KIR3DL1/HLA-
Bw4 80(T) 25.8% 46.9% 29.4% 0.003 0.714 0.007 2.90 
1.339
-
6.267 
n.s. not significant, a HCV-RNA pos vs. HCV-RNA neg, b HCV-RNA pos vs. anti-HCV neg 
OR: odds ratio; CI: confidence interval 
Through a multivariate logistic regression analysis, the association between the 
genetic constellation of KIR3DL1/HLA-Bw4 80(T) and spontaneous resolution of HCV 
was confirmed (p=0.007). In contrast, the association of KIR2DL1/HLA-C2 with 
infection outcome was not verified by multivariate logistic regression analysis. Table 
4.3 depicts all significant associations between KIR/KIR-ligand constellation and HCV 
infection status in a univariate and multivariate logistic regression analysis that were 
previously described in our group. Since no previous reports linking 
KIR3DL1/HLA-Bw4 80(T) to HCV infection outcome exist, a second genetic 
association study was performed in a separate North American PWID cohort. 
342 PWID including 267 HCV-RNA positive and 75 HCV-RNA negative individuals 
were analysed for associations between KIR/KIR-ligand constellation and infection 
outcome (table 4.2). The genetic data of the North American cohort were kindly 
provided by Georg M Lauer. As seen in the German cohort the genetic combination 
of KIR3DL1/HLA-Bw4 80(T) was significantly enriched in HCV-RNA negative 
individuals compared to HCV-RNA positive PWID (44.0% vs. 28.8%; p=0.017) and 
thereby verified an association between KIR3DL1/HLA-Bw4 80(T) and spontaneous 
clearance of hepatitis C. Figure 4.13 illustrates that PWID encoding the combination 
of KIR3DL1 and HLA-Bw4 80(T) were enriched in PWID that spontaneously control 
HCV infection. 
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Figure 4.13: Frequency of the genetic combination of KIR3DL1/HLA-Bw4 80(T) in two 
PWID cohorts from Germany and North America grouped by infection outcome 
The frequency of individuals with the KIR3DL1/Bw4 80(T) genotype in HCV-RNA positive PWID (dark 
blue) and HCV-RNA negative PWID (light blue) is shown in percent. P-values were calculated using 
Fisher’s exact test.  
In summary, our group could identify that the genetic combination of 
KIR3DL1/HLA-Bw4 80(T) was associated with spontaneous immune control of HCV 
infection in two separate cohorts. 
4.2.3 Bw4 copy number is associated with HCV infection outcome 
Since copy number of KIR-ligands were described to influence NK cell functionality 
(Kim et al. 2008) the PWID cohort described in table 4.2 was examined for possible 
association between HLA-Bw4 copy number and HCV infection status. PWID were 
grouped according to the HLA-Bw4 copy number into HCV-RNA positive PWID, 
HCV-RNA negative PWID and anti-HCV seronegative PWID either lacking a 
HLA-Bw4 allele, carrying one HLA-Bw4 allele or carrying two or more HLA-Bw4 
alleles (table 4.4).  
Table 4.4: Association between HLA-Bw4 copy number and HCV infection status in 
PWID 
  
HCV-RNA 
positive 
HCV-RNA 
negative 
anti-HCV 
negative p-value
a
 p-valueb 
n 151 (100%) 64 (100%) 51 (100%) n.s n.s 
no KIR3DL1 7 (4.6%) 4 (6.3%) 1 (2%) n.s n.s 
KIR3DL1 + 0 Bw4 45 (29.8%) 14 (21.9%) 13 (25.5%) n.s n.s 
KIR3DL1 + 1 Bw4 76 (50.3%) 27 (42.2%) 17 (33.3%) n.s n.s 
KIR3DL1 + ≥ 2 Bw4 23 (15.2%) 19 (29.7%) 20 (39.2%) 0.0299 0.0006 
n.s. not significant, a HCV-RNA pos vs. HCV-RNA neg, b HCV-RNA pos vs. anti-HCV neg 
 
PWID expressing multiple Bw4 copies were significantly enriched in HCV-RNA 
negative PWID (29.7%) compared to HCV-RNA positive PWID (15.2%, p=0.0299). 
This difference was even more pronounced when comparing anti-HCV negative 
PWID (39.2%; p=0.0006) to HCV-RNA positive PWID. Figure 4.14 visualises the 
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genetic association between multiple Bw4 copy numbers and infection outcome. 
Frequency of patients harbouring two or more Bw4 copies in HCV-RNA positive, 
HCV-RNA negative and anti-HCV negative PWID is displayed. 
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Figure 4.14: Frequency of PWID having ≥ 2 Bw4 motifs grouped by infection outcome 
The frequency of individuals having two or more Bw4 motifs in HCV-RNA positive PWID (dark blue), 
HCV-RNA negative PWID (light blue) and anti-HCV seronegatives (grey) are shown in percent. 
P-values were calculated by Fisher’s exact test. 
4.2.4 Frequency and function of KIR3DL1+ NK cells are independent of HCV 
infection status 
Since an association between the genetic constellation of KIR3DL1/HLA-Bw4 80(T) 
as well as Bw4 copy number and HCV infection outcome was observed by Christine 
Thöns, the influence of KIR3DL1+ NK cell was addressed further. Therefore, the aim 
of this project was to determine the functional consequences of this 
KIR3DL1/Bw4 80(T) genotype on the NK cells level in HCV infection. Moreover, the 
influence of the ligand for KIR3DL1, Bw4 was further investigated. For this reason, 
PBMCs from a representative subgroup of our PWID cohort was analysed through 
flow cytometry, including 30 HCV-RNA positive, 30 HCV-RNA negative and 
30 anti-HCV negative PWID. PWID were preselected by their expression of the 
KIR3DL1 gene. For phenotypic analysis, KIR3DL1 expressing NK cells were defined 
through CD16 and CD56 expression of live, single lymphocytes that lack the surface 
markers CD3, CD14 and CD19. Effector functions such as IFNγ and TNFα 
production as well as CD107a expression of KIR3DL1+ NK cells were determined. 
Therefore, PBMCs were stimulated with the HLA devoid target cell line K562 leading 
to the activation of NK cells through missing self-recognition. A representative gating 
strategy for NK cells and exemplary FACS plots from three individuals with different 
surface density of KIR3DL1 is shown in figure 4.15.  
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Figure 4.15 Representative gating strategy of the analysis of NK cell phenotype and 
function in PWID 
A representative gating strategy of the analysis of NK cell phenotype and function from 30 HCV-RNA 
positive, 30 HCV-RNA negative and 30 anti-HCV seronegative PWID. Cryopreserved PBMCs were 
thawed and NK cells were defined through CD16 and CD56 expression of CD3-/CD14-/CD19-, live, 
single lymphocytes. NK cells were further analysed for KIR3DL1 expression and function. IFNγ, TNFα 
and CD107a production was measured by intracellular cytokine staining after stimulation of PBMCs 
with K562 (10:1) for 5h. Flow cytometry results are shown from three different samples showing 
different KIR3DL1 expression on the cell surface of NK cells.  
Comparison of KIR3DL1 expression on NK cells between HCV-RNA positive, 
HCV-RNA negative and anti-HCV negative PWID revealed no differences. Neither 
frequency of KIR3DL1 (figure 4.16 A) nor density defined by KIR3DL1 MFI (data not 
shown) on NK cells were associated with infection outcome. Furthermore, no 
functional differences could be observed between groups regarding IFNγ (figure 
4.16 B) and TNFα production as well as CD107a expression of KIR3DL1+ NK cells.  
Results 
 
 72 
HCV-RNA posHCV-RNA neg anti-HCV neg
0
20
40
60
80
%
 
KI
R3
DL
1+
 
NK
 
ce
lls
HCV-RNA posHCV-RNA neg anti-HCV neg
0
5
10
15
20
25
%
 
IF
N γ
+
KI
R3
DL
1+
 
NK
 
ce
lls
null low high 
0
20
40
60 ***
*
%
 
KI
R3
DL
1+
 
NK
 
ce
lls
A B C
 
Figure 4.16: Phenotypic and functional analysis of NK cells from HCV-RNA positive, 
HCV-RNA negative and anti-HCV seronegative PWID 
(A) The frequencies of KIR3DL1 expressing NK cells in HCV-RNA positive, HCV-RNA negative and 
anti-HCV negative PWID are depicted for all 90 analysed individuals. (B) IFNγ producing KIR3DL1+ 
NK cells upon stimulation with K562 at an effector target ratio of 10:1 for 5h are shown. (C) The 
frequency of KIR3DL1+ NK cells is depicted for HCV-RNA positive and HCV-RNA negative PWID 
according to the KIR3DL1 subtype expression level (null, low, high) as determined by a multiplex PCR 
assay (4). P-values were calculated by Kruskal Wallis test (*p≤ 0.05 and ***p≤0.001) and the median 
is depicted in every graph. 
The KIR3DL1 gene locus is highly polymorphic with 79 described alleles to date. 
These alleles have been associated with different expression levels on the cell 
surface. While some alleles are linked to low or high density of KIR3DL1 expression 
on the cell surface, KIR3DL1*004 is not detectable on the cell surface due to 
intracellular retention. Therefore, a previous described multiplex PCR assay 
(Boudreau et al. 2014) with minor modifications was performed in cooperation with 
the Institute for Transplantation Diagnostics and Cell Therapeutics at the University 
Hospital Düsseldorf to characterise the KIR3DL1 gene in more detail. KIR3DL1 
alleles were determined in 60 PWID that were included in the flow cytometry 
analysis. According to the provided PCR results all samples were divided into three 
groups. PWID encoding solely non-expressed KIR3DL1 alleles were grouped as 
KIR3DL1 null, while PWID encoding one low-expressed KIR3DL1 gene and absence 
of a high-expressed allele were grouped as KIR3DL1 low. The KIR3DL1 low group 
therefore contained PWID homozygous for low-expressed alleles as well as PWID 
with low-expressed alleles combined with the activating receptor KIR3DS1 or 
non-expressed alleles. The third group consists of patients that harboured at least 
one high expressed allele and was termed KIR3DL1 high. The KIR3DL1 allele 
subgroups defined by PCR were significantly associated with KIR3DL1 expression 
on the cell surface (figure 4.16 C). Frequency of KIR3DL1+ NK cells as well as 
KIR3DL1 surface density (data not shown) was significantly higher in the KIR3DL1 
high group compared to the KIR3DL1 low group. These results are in line with 
Boudreau et al. (2016) showing that KIR3DL1 subtypes exhibit distinct expression 
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patterns on the NK cell surface. However, the KIR3DL1 frequency was not 
associated with HCV infection outcome.  
4.2.5 HLA-Bw4 copy number is associated with NK cell functionality in healthy 
individuals 
Since the genetic analysis revealed a significant association between Bw4 copy 
number and infection outcome, as PWID encoding two or more Bw4 motifs were 
enriched in the anti-HCV seronegative group, a possible functional impact of a Bw4 
copy number effect was addressed. Therefore, 90 PWID were grouped according to 
their number of Bw4 motifs rather than HCV infection status. A maximum of four Bw4 
motifs can be expressed in a single individual on HLA-A and HLA-B alleles but since 
three as well as four Bw4 motifs are rarely seen, PWID were divided into three 
groups (0 Bw4, 1 Bw4 and patients with two or more Bw4 motifs). Functionality of 
KIR3DL1+ NK cells was determined in response to stimulation with a HLA devoid 
target cell line K562 at an effector target ratio of 1:10. Differences in the ability to 
produce IFNγ and TNFα as well as in the degranulation potential was analysed. 
Even though a slight tendency towards increased functional responses of KIR3DL1+ 
NK cells could be observed with increasing Bw4 copy numbers, no significant 
differences between groups could be determined for any of the three analysed NK 
cell functions (figure 4.17 A-C). Since Kim et al. (2008) previously reported enhanced 
IFNγ responsiveness of KIR3DL1+ NK cells in healthy individuals with multiple Bw4 
copies and we could observe a trend in our PWID cohort as well, the aim was to 
validate our findings in a healthy cohort. Therefore, PBMCs from 120 healthy 
individuals were isolated and IFNγ, TNFα production and CD107a expression was 
analysed on KIR3DL1+ NK cells as described for the PWID cohort. In line with 
previous results we observed a significant stepwise increase in IFNγ production with 
an increasing number of Bw4 motifs (figure 4.17 D). Moreover, the degranulation 
ability of KIR3DL1+ NK cells was significantly increased in patients with one Bw4 
motif compared to patients with no Bw4 motif and even more pronounced in patients 
that harbour two or more Bw4 copies. In addition, TNFα production was significantly 
higher in healthy individuals with two or more Bw4 motifs than in individuals with no 
or one Bw4 motif. 
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Figure 4.17: Correlation of HLA-Bw4 copy number and NK cell functionality in PWID 
and healthy individuals 
PWID (A-C) and healthy individuals (D-F) were grouped according to the number of HLA-Bw4 alleles. 
Individuals lacking a Bw4 motif, with one Bw4 motif and individuals with two or more Bw4 motifs were 
grouped as indicated. The frequency of IFNγ producing (A+D), TNFα-producing (B+E) and CD107a 
(C+F) expressing KIR3DL1+ NK cells according to the number of Bw4 motifs are shown. Horizontal 
lines indicate the median. For statistical analysis Kruskal Wallis test or One-way ANOVA (*p≤ 0.05 and 
***p≤0.001) were performed. 
4.2.6 HLA-Bw4 80(T) is associated with an increased functional ability of NK 
cells in PWID 
The genetic association studies revealed that the combination of HLA-Bw4 80(T) and 
KIR3DL1 is enriched in HCV-RNA negative PWID. Since this was the first report 
suggesting a protective effect of HLA-Bw4 80(T) in HCV infection, hereafter the 
influence of this genetic constellation on NK cell function was examined. To exclude 
effects possibly mediated by HLA-Bw4 copy number as stated in table 4.4 only PWID 
carrying a single HLA-Bw4 motif were analysed. Therefore, PWID with either one 
Bw4 80(T) or one Bw4 80(I) motif were compared and individuals lacking Bw4 were 
included as a control group. Interestingly, KIR3DL1+ NK cells of PWID expressing a 
Bw4 80(T) motif produced significantly higher amounts of IFNγ (p≤0.05) and TNFα 
(p≤0.01) and showed an enhanced degranulation ability (CD107a p≤0.05) compared 
to patients that harbour a Bw4 80(I) motif (figure 4.18 A-C). In addition, PWID 
encoding Bw4 80(T) expressed significantly more TNFα (p≤0.05) and CD107a 
(p≤0.05) than patients lacking a Bw4 motif. Furthermore, to address if this is a 
general or an HCV mediated effect, healthy individuals were grouped accordingly. 
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However, the increased functionality of KIR3DL1+ NK cells in the context of 
HLA-Bw4 80(T) in PWID was not observed in healthy individuals (figure 4.18 D-F). 
No difference between individuals encoding a Bw4 80(I) motif or a Bw4 80(T) motif 
regarding IFNγ, TNFα and CD107a expression was detected.  
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Figure 4.18: Functional analysis of KIR3DL1+ NK cells from PWID and healthy 
individuals in the presence of the KIR3DL1 ligand HLA-Bw4 80(T) and 80(I) 
PWID and healthy individuals were grouped according to their KIR3DL1-ligand status. PWID (A-C) 
and healthy individuals (D-F) carrying either no Bw4 or a single HLA-Bw4 80(T) or HLA-Bw4 80(I) 
motif were grouped as indicated. All individuals with multiple HLA-Bw4 alleles were removed from the 
analysis. The frequencies of IFNγ producing (A+D), TNFα producing (B+E) and CD107a expressing 
(C+F) KIR3DL1+ NK cells according to the KIR3DL1-ligand status are shown. Horizontal lines indicate 
the median. For statistical analysis Kruskal Wallis test or One-way ANOVA (*p≤ 0.05 and **p≤ 0.01) 
were performed.  
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4.3 DNA methylation of the IFNG locus  
This study described that Bw4 copy number is associated with enhanced NK cell 
functionality. To determine possible underlying mechanisms leading to improved 
IFNγ production of KIR3DL1+ NK cells in individuals encoding multiple Bw4 motifs 
epigenetic alterations were analysed. Therefore, we aimed to investigate if Bw6+ 
individuals showed an aberrant methylation pattern at the IFNG locus in comparison 
to individuals with two Bw4 motifs. Since epigenetic modifications of regulatory 
elements upstream or downstream of IFNG as well as methylation of the IFNG 
promoter can alter IFNG transcription (Melvin et al. 1995, Schoenborn et al. 2007), 
the DNA methylation pattern of the IFNG promoter as well as the upstream CNS1 
region was investigated. CNS1 is located 4.2 kb upstream of the IFNG gene and 
displays a transcription factor binding site for NFAT and Tbet, thus is an enhancer for 
IFNG transcription (Lee et al. 2004). 
4.3.1 DNA methylation analysis of the IFNG locus of naïve CD4+ T cells, TH1 
cells and NK cells 
It has been reported that different cell types are associated with distinct methylation 
patterns of the IFNG locus (Dong et al. 2013). As a first step, we tested if the 
described methylation patterns could be reproduced in our study. Therefore, we 
determined the DNA methylation pattern of six CpG sites in the CNS1 region and five 
CpGs in the IFNG promoter of naïve CD4+ T cells, TH1 cells and NK cells in a 
healthy individual. Figure 4.19 displays a representative gating strategy used to sort 
naïve CD4+ T cells and TH1 cells.  
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Figure 4.19: Representative gating strategy of FACS sorted naïve CD4+ T cells and 
TH1 cells 
Freshly thawed PBMCs were FACS sorted for naïve CD4+ T cells and TH1 cells. Therefore, single 
lymphocytes expressing CD3+ and CD4+ cell surface antigens were further divided into CCR7+ 
CD45RO- CD45RA+ naïve CD4+ T cells as well as CCR7- CD45RO+ CD45RA- TH1 cells. 
While all analysed CpG sites were completely methylated in naïve CD4 T cells, TH1 
cells showed a partial demethylation in the CNS region as well as at the IFNG 
promoter. NK cells displayed a demethylated IFNG promoter whereas the upstream 
element regulating IFNG transcription appeared to be highly methylated as described 
by Luetke-Eversloh et al. (2014). Hence, previous findings were reproduced and this 
method was utilised for further NK cell methylation analysis (figure 4.20). 
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Figure 4.20: DNA methylation pattern of the IFNG locus from CD4+ T cells, TH1 cells 
and NK cells  
The percentage of DNA methylation was determined via NGS for five CpG sites in the IFNG promoter 
(A) and six CpG sites in the CNS1 region upstream of the IFNG promoter. Depicted is the pattern of 
FACS sorted naïve CD4 T cells (white), TH1 cells (black) and NK cells (grey) from one healthy 
individual. Furthermore, the distance of each CpG to the IFNG transcriptional start site (TSS) is 
indicated. 
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4.3.2 HLA-Bw4 copy number has no impact on CNS1 methylation of NK cells 
Since the detected results were in line with previous data it was further investigated if 
DNA methylation at the IFNG locus accounts for the observed difference in 
functionality of KIR3DL1+ NK cells between Bw4+ and Bw6+ individuals. We 
hypothesised that individuals encoding multiple Bw4 motifs might show 
demethylation of the CNS1 region resulting in higher transcription, leading to 
enhanced IFNγ production capability. Based on the observed complete 
demethylation of the IFNG promoter in NK cells the following analysis focused on the 
methylation pattern of the CNS1 region. To exclude described differences in the 
methylation status between different NK cell developmental stages only CD56dim 
NK cells were included (Luetke-Eversloh et al. 2014). KIR3DL1- and KIR3DL1+ NK 
cells were sorted from ten healthy individuals including five individuals with two Bw4 
motifs and five lacking a Bw4 motif. The gating strategy and representative dot plots 
are shown in figure 4.21. 
 
 
Figure 4.21: Representative gating strategy of FACS sorted KIR3DL1- and KIR3DL1+ 
NK cells  
PBMCs from 10 healthy individuals were FACS sorted for KIR3DL1- and KIR3DL1+ CD56dim NK cells. 
Cryopreserved PBMCs were thawed and NK cells were defined through CD16 and CD56 expression 
of CD3-/CD14-/CD19-, live, single lymphocytes. 
The level of methylation was analysed for each CpG site in the CNS1 region. 
However, comparison between individuals expressing two Bw4 motifs or lacking a 
Bw4 motif revealed no significant differences, neither for KIR3DL1- nor KIR3DL1+ NK 
cells (figure 4.22 A+B). Moreover, the mean methylation of all investigated CpG sites 
was similar between KIR3DL1- and KIR3DL1+ NK cells irrespective of the number of 
Bw4 motifs (figure 4.22 C+D). This suggests that the number of Bw4 motifs is not 
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associated with an aberrant DNA methylation pattern of the IFNG locus in KIR3DL1+ 
NK cells. While most samples showed a high level of methylation in the CNS1 region, 
three samples were hypomethylated at the analysed six CpG sites (figure 4.22 D 
indicated in blue). 
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Figure 4.22: CNS1 methylation pattern of KIR3DL1neg and KIR3DL1pos NK cells grouped 
by number of Bw4 motifs 
KIR3DL1- and KIR3DL1+ CD56dim NK cells were sorted from five individuals without a Bw4 motif and 
five with two Bw4 copies. DNA methylation is depicted in percent for each of the six analysed CpG 
sites comparing 0 Bw4 with two Bw4 copies (A+B) and the mean with SEM is shown. The mean 
methylation of all CpG sites for every individual is depicted for KIR3DL1- (C) and for KIR3DL1+ (D) NK 
cells. For statistical analysis, unpaired t-test was performed.  
4.3.3 CMV seropositivity and NKG2C expression are associated with 
demethylation of the CNS1 region of NK cells 
It has been reported that the CMV status can influence the methylation pattern of NK 
cells (Luetke-Eversloh et al. 2014). Therefore, it was addressed if CMV seropositivity 
has an influence on the methylation pattern of KIR3DL1- and KIR3DL1+ NK cells and 
thus accounts for the outliers seen in figure 4.22. Healthy individuals were grouped 
according to their CMV IgG status into CMV+ and CMV- individuals. CMV+ individuals 
showed a significantly lower mean methylation in comparison to CMV- individuals on 
KIR3DL1- (p=0.0362) as well as KIR3DL1+ (p=0.0483) NK cells (figure 4.23 B). DNA 
demethylation in CMV+ individuals was independent of KIR3DL1 expression on NK 
cells and could also be observed at each analysed CpG site individually (figure 
4.23 A). 
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Figure 4.23: CNS1 methylation pattern of KIR3DL1neg and KIR3DL1pos NK cells grouped 
by CMV status 
The DNA methylation data from KIR3DL1- and KIR3DL1+ NK cells of 10 healthy individuals was 
grouped according to the CMV status. The methylation of the CNS1 region is depicted for each of the 
six analysed CpG sites (A). Furthermore, the mean methylation of the six measured CpG sites was 
calculated for each individual (B). P-values were calculated by unpaired t-test and the median is 
shown. 
To further address the impact of the CMV status on DNA demethylation of the CNS1 
region, PBMCs were analysed by flow cytometry. As CMV seropositivity has been 
repeatedly linked to the expansion of NKG2C+ NK cells and decreased DNA 
methylation of the IFNG locus has been described in CMV+ individuals with an 
expansion of a NKG2Chigh NK cell population, PBMCs were analysed for their 
NKG2C expression on NK cells (Luetke-Eversloh et al. 2014). In our study, a 
tendency towards an expansion of NKG2C+ NK cells could be observed in CMV+ 
individuals (figure 4.24 C). While three out of five examined CMV+ individuals showed 
an NKG2C expansion, two individuals displayed normal frequencies of NKG2C+ NK 
cells. The CNS1 region of CMV+ individuals without an expansion was highly 
methylated in KIR3DL1- and KIR3DL1+ NK cells (figure 4.24 A+D) as seen in CMV- 
individuals. In contrast, hypomethylation of CpG sites in the CNS1 region occurred in 
CMV+ individuals with an expanded NKG2C population (figure 4.24 B+E). 
Interestingly, the mean methylation of all analysed CpGs significantly correlated with 
the expression of NKG2C on NK cells (figure 4.24 F, p≤0.0001 R2=0.8966). 
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Figure 4.24: Demethylation of the CNS1 region in CMV+ individuals with an NKG2C 
expansion 
PBMCs from ten healthy individuals were analysed for their expansion of NKG2C+ NK cells. Cells 
were gated for single, viable lymphocytes and after exclusion of B cells, T cells and monocytes 
through CD3, CD19 and CD14, NK cells were defined by the expression of the cell surface antigens 
CD16 and CD56. A and B show exemplary flow cytometry plots from two CMV+ individuals either 
without (A) or with an expansion of the NKG2C population (B). Moreover, the corresponding 
methylation pattern of the CNS1 region for both individuals is displayed in D and E. The percentage of 
NKG2C+ NK cells from all CMV- and CMV+ individuals is depicted in C. Unpaired t-test was calculated 
to determine significance between groups. The frequency of NKG2C+ NK cells was correlated with the 
mean methylation of the six investigated CpG sites in the CNS1 region and a linear regression 
analysis was performed. 
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5 Discussion 
The importance of studying HCV infection is highlighted by the fact that the 2016 
Lasker award went to Rice, Bartenschlager and Sofia for their contributions in the 
field of HCV infection research. Rice and Bartenschlager developed a replication 
system that enabled high throughput screening of novel HCV drugs (Lohmann et al. 
1999, Lindenbach et al. 2005) and Sofia was awarded for the discovery of Sofosbuvir 
a highly efficient NS5B nucleotide polymerase inhibitor (Sofia et al. 2010). 
Nevertheless, the underlying mechanisms that either confer protection prior to 
seroconversion or lead to spontaneous resolution of HCV infection are not fully 
defined. Therefore, the influence of NK cells and iNKT cells on spontaneous 
resolution, protection from HCV infection or their role in chronic HCV infection were 
further addressed in this thesis. 
5.1 iNKT cells in HCV infection 
CD1d restricted iNKT cells, one subset of NKT cells, have been repeatedly reported 
to play a role in various viral infections (De Santo et al. 2008, Fernandez et al. 2014, 
Li et al. 2016, Ahmad et al. 2017). However, the involvement of iNKT cells in HCV 
infection remains poorly understood and their contribution to early immune responses 
as well as to liver injury in humans is not well defined. Therefore, the aim of this study 
was to comparatively analyse the phenotype and function of iNKT cells in HCV 
infected PWID with different infection outcome in detail. The role of iNKT cells in HCV 
infection was determined in a high-risk cohort of anti-HCV positive PWID. The cohort 
was grouped into PWID with detectable HCV-RNA (HCV-RNA positive) and anti-HCV 
seropositive individuals without detectable RNA (HCV-RNA negative). The 
comparison of the phenotype of iNKT cells from HCV-RNA positive and HCV-RNA 
negative PWID suggested iNKT cells to be activated in chronic HCV infection as they 
showed significantly increased expression of the activation marker CD38. Expression 
of various exhaustion and differentiation markers as well as NK cell receptors 
however, did not correlate with HCV infection outcome. Moreover, iNKT cell 
frequencies as well as their functionality were similar between PWID groups. 
However, iNKT cells from HCV-RNA positive PWID showed a trend towards an 
increased proliferation potential as well as an enhanced IFNγ production capacity. In 
vitro expansion of iNKT cells resulted in a significant upregulation of CD38 
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independent of HCV infection outcome. Interestingly, cytokines associated with NK 
cell activation significantly activated iNKT cells as measured by an increase of CD38 
expression. Notably, the frequency of iNKT cells in the liver was not enriched 
compared to frequencies in the peripheral blood, however, we were unable to test 
liver samples from HCV-infected individuals, as nowadays liver biopsies to determine 
the stage of liver fibrosis in HCV infected individuals are replaced by non-invasive 
approaches (reviewed in Castera 2012). It is well described, that IFN levels and 
consequently ISG expression levels are elevated in the liver of patients with chronic 
infection (Helbig et al. 2005, Sarasin-Filipowicz et al. 2008). We therefore tested, if 
treatment of peripheral iNKT cells with IFNα or IFNλ resulted in iNKT cell activation 
and thus an upregulation of CD38. Although such a direct effect on peripheral iNKT 
cells was not observed, an increase of CD1d expression was noted on monocytes, 
which is the cell type with the highest CD1d expression in the periphery. It would be 
important to analyse the impact of IFN treatment on CD1d expression levels on liver 
resident cells and more importantly to directly address if CD1d expression levels are 
elevated in the liver compartment in the context of HCV infection. In a cooperation 
project, the latter aspect was addressed and expression profiles from liver biopsies of 
HCV and HBV infected livers were compared. In line with an increased expression of 
CD1d in the context of chronic HCV infection in the liver, CD1d transcript levels were 
significantly higher in the HCV-infected liver compared to the HBV-infected liver. 
Although not conclusive, this could point towards a role of type I or type III interferons 
in intrahepatic CD1d regulation, because it has been described that ISGs are 
strongly upregulated in the liver during hepatitis C but not hepatitis B (Su et al. 2002, 
Wieland et al. 2004).  
 
iNKT cells have been extensively studied in mice models and associated with a role 
in several viral infections such as MCMV, HBV and HSV. iNKT cell activation resulted 
in reduced (van Dommelen et al. 2003) or inhibited (Kakimi et al. 2000) viral 
replication of MCMV and HBV, mediated by the induction of IFNγ, suggesting that in 
addition to NK cells NKT cells can mediate early viral clearance by either directly 
killing the virus infected cells or indirectly activating other immune mechanisms. 
Furthermore, the absence of iNKT cells was associated with impaired clearance of 
HSV (Grubor-Bauk et al. 2003). In addition, there are multiple indications in hepatitis 
mouse models for the importance of iNKT cells in liver immunology. Moreover, 
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mouse models could provide explanations for the importance of iNKT cells in the 
clearance or the progression of HCV infection. Previous studies proposed that 
activated iNKT cells can mediate hepatocyte damage (Osman et al. 2000) even in 
the absence of NK cells (Nakagawa et al. 2001). In addition, it has been reported that 
iNKT cell activation contributes to the development of liver fibrosis (Ishikawa et al. 
2011). Furthermore, IFNγ produced by activated iNKT cells enhanced NK cell 
cytotoxicity as well as potentiated their IFNγ capacity and increased CD8+ T cell 
responses (Carnaud et al. 1999, Nakagawa et al. 2001). Collectively, the existing 
mouse data suggests that iNKT cell activation in acute HCV infection might be 
beneficial for clearance, as they activate NK as well as T cells which are important 
mediators for early immune control of HCV infection. Whereas, activated iNKT cells 
might be disadvantageous in chronic infection as they have the ability to promote 
liver fibrosis. Based on data generated in various mouse models we hypothesised 
that potentially iNKT cells play a role in HCV infection outcome. However, there might 
be some limitations in the transferability into the human system. Although some 
similarities between CD1d restricted iNKT cells from mice and humans have been 
described, there are major differences as well. Especially reported iNKT cell 
frequencies in several tissues differ vastly between these species. Whereas high 
frequencies of CD1d restricted iNKT cells have been described in livers of mice 
(approximately 30% of IHL), invariant Vα24+ iNKT cells were rare in the human liver 
(0.03-0.34% of IHL) (Matsuda et al. 2000, Exley et al. 2002). Our report proposed 
even lower iNKT cell frequencies in the human liver (mean: 0.03% of IHL). 
Furthermore, in accordance with our study, iNKT cell frequencies in the peripheral 
blood of humans were reported to be highly variable compared to mice and span a 
100-fold range in healthy individuals (Lee et al. 2002). Therefore, suggesting that 
mice studies might not adequately reflect the importance of iNKT cells in human HCV 
infection. Even though hepatitis mouse models have provided evidence for the role of 
iNKT cells in liver inflammation (Ishikawa et al. 2011) and the recently developed 
HCV mouse model (Billerbeck et al. 2017) offers the opportunity to study iNKT as 
well as non-invariant NKT cells in acute and chronic infection, these models cannot 
replace human cohort studies. 
 
In HCV infection, no alterations in iNKT cell numbers have been reported upon 
treatment with PEGylated IFNα and ribavirin. Moreover, iNKT cell frequencies were 
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neither associated with HCV genotype nor with SVR to IFNα based treatment (van 
der Vliet et al. 2005). Thus, this indicates that iNKT cell frequencies were not 
influenced by HCV therapy and moreover did not predict treatment response. Here, 
however we aimed to elucidate the role of iNKT cells on HCV infection outcome 
rather than treatment outcome. Therefore, the underlying study solely focused on 
iNKT cell analysis in treatment naïve HCV infected patients. Our study described no 
differences in iNKT cell frequencies in HCV-RNA positive and HCV-RNA negative 
PWID, thus our results were in accordance with studies from Inoue et al. (2006) and 
van der Vliet et al. (2005) that reported comparable Vα24+ Vß11+ iNKT cells 
frequencies in the periphery. However, Lucas et al. (2003) provided conflicting 
results, as they described decreased frequencies of Vα24+ Vß11+ iNKT cells in HCV-
RNA positive individuals compared to HCV-RNA negative individuals with resolved 
HCV infection. Since no anti-HCV negative PWID were included in our iNKT cell 
study, we were not able to confirm reported elevated iNKT cell frequencies in 
exposed uninfected individuals (Werner et al. 2013). The explanation for the reported 
differences in iNKT cell frequencies between cohorts is likely to be multifactorial. 
However, differences in definition of the iNKT cell population through varying 
methodology could be excluded as the underlying cause. All included studies fulfilled 
the criteria of a clearly defined iNKT cell population, since staining was performed for 
the Vα as well as the Vβ chain of the invariant TCR and not solely through the 
expression of the cell surface markers CD56 and CD3. Although the iNKT cell 
definition in our study differed, as iNKT cell flow cytometric analysis was based on 
the ability of iNKT cells to recognise αGalCer loaded CD1d dextramers, we provided 
evidence that the definition of iNKT cells through the TCR chains Vα24 and Vß11 
was congruent with the dextramer analysis. Thus, investigated iNKT cell populations 
were comparable based on the methodology used for their definition. In addition, 
various characteristics such as gender and age have been described to affect iNKT 
cell numbers. Sandberg et al. (2003) provided evidence that the female sex was 
associated with elevated Vα24+ iNKT cell frequencies. Moreover, an inverse 
correlation between iNKT cell frequencies and age has been proposed in healthy 
individuals (Mansour et al. 2015). Although our association analysis was limited in 
regard of gender evaluation, since the proportion of male PWID was significantly 
higher than female PWID in our cohort, a weak association between iNKT cell 
frequencies and age in HCV infected individuals was observed in our study as well. 
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In HCV infection, the female sex that has been linked to increased iNKT cell 
frequencies, has a higher likelihood for viral clearance compared with males (Bakr et 
al. 2006), thus gender distribution in HCV cohorts is generally different between the 
HCV-RNA positive group and the HCV-RNA negative group. Variations in gender 
distribution might partially explain discrepant results between cohorts. In our iNKT 
cell study the mean age in years as well as the gender distribution of PWID was 
comparable between HCV-RNA positive and HCV-RNA negative individuals. 
However, other studies might not be well controlled for age and gender and could 
account for the observed differences. 
 
Interestingly, iNKT cells of HCV-RNA positive PWID showed significantly higher 
expression of the activation marker CD38 than HCV-RNA negative PWID. Although 
iNKT cells have not been associated with an activated phenotype in the periphery 
before, Lucas et al. (2003) reported that liver Vα24+ Vß11+ iNKT cells of HCV 
infected individuals compared to peripheral iNKT cells displayed an elevated 
expression of CD69, a marker for recent activation. Moreover, liver infiltrating NKT 
cells from chronically HCV infected individuals, defined as CD56+CD3+ lymphocytes, 
showed a trend towards increased CD69 expression compared to HCV negative 
patients (Boisvert et al. 2003). In addition, activation of mucosal associated invariant 
T (MAIT) cells, another population of semi-invariant T cells which displays several 
similarities with NKT cells (reviewed in Treiner et al. 2006) has been reported in 
chronic HCV infection (van Wilgenburg et al. 2016). Taken together these data 
support our findings that iNKT cells are activated during chronic infection. However, 
longitudinal studies are needed to determine if this activation state is induced by HCV 
infection or if elevated frequencies of CD38+ iNKT cells promote persistence of HCV 
infection. Despite the activated phenotype of iNKT cells from chronically HCV 
infected individuals, none of the other analysed markers were associated with 
infection outcome. Although functional impairment of iNKT cells has been linked to 
enhanced PD1 expression in HIV infected individuals (Moll et al. 2009) and 
exhaustion of HCV specific CD8+ T cells in chronic infection were commonly 
characterised by an increased PD1 expression (reviewed in Timm et al. 2015), PD1 
expression levels on iNKT cells were neither associated with HCV infection outcome 
nor reduced functional capacity.  
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While the enhanced ex vivo activation, seen in chronically infected individuals was 
not linked to the extent of iNKT cell activation after in vitro expansion, expansion 
upon αGalCer stimulation was in general associated with a significant upregulation of 
CD38 on the cell surface. Our reported phenotype of iNKT cells after proliferation 
was expected and in line with a study by Kitamura et al. (2000) who described an 
upregulation of the early activation marker CD69 on iNKT cells upon αGalCer 
stimulation. Therefore, we propose that the expansion of iNKT cells in HCV infected 
individuals is associated with tremendous activation of iNKT cells.  
As αGalCer is an exogenous antigen derived from a marine sponge, iNKT cell 
activation in HCV infection is mediated by other mechanisms. Critical factors that 
regulate activation and effector functions of iNKT cells are the type of 
antigen-presenting cell, the availability of the presented antigen and the cytokine 
environment. Possibly, the cytokine milieu in chronic HCV infection influences iNKT 
cells and might activate them which could explain the observed CD38 upregulation. 
To provide insight into the underlying mechanisms the influence of various cytokines 
previously described to be associated with HCV infection or NK cell activation was 
analysed in this study. Our study demonstrated that IFNα treatment indirectly and a 
combination of IL12, -15 and -18 directly activated iNKT cells. IFNα based therapy of 
chronically HCV infected individuals was described to not alter MAIT cell frequencies 
but to enhance CD38 expression on MAIT cells (Spaan et al. 2016). In contrast, no 
direct effect of IFNα treatment on the frequency of CD38+ iNKT cells was observed in 
our study. However, van Wilgenburg et al. (2016) described that the activation of 
MAIT cells by IFNα was dose dependent. MAIT cell activation was only induced with 
particularly high IFNα concentrations that far exceeded the concentration used in our 
study. This might explain the absence of a direct effect of IFNα treatment on CD38 
expression on iNKT cells in our analysis. In line with our report suggesting a direct 
effect of the combination of IL12, -15 and -18, the early activation marker CD69 was 
significantly upregulated on MAIT cells upon IL12 and IL18 stimulation (Spaan et al. 
2016). The activation of MAIT cells was dose dependent and the combination of IL12 
and IL15 was sufficient to induce a high activation state (van Wilgenburg et al. 2016). 
Since IL18 alone had no impact on CD38 expression, we as well propose that a 
combination of IL12 and IL15 is sufficient to activate iNKT cells. Elevated IL12 serum 
levels have been described in HCV infection and IFNγ priming induced a significant 
increase of IL12 in chronically HCV infected individuals especially in patients with 
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severe liver inflammation (Quiroga et al. 1998). In addition, serum IL15 was also 
significantly elevated in chronic HCV infection, compared to healthy controls and 
increased with disease progression to HCC (Kakumu et al. 1997). Collectively, the 
existing data support our idea that IL12 and IL15 probably influence iNKT cell 
activation in the natural course of HCV infection and might explain the activated 
phenotype of iNKT cells in chronically HCV infected individuals. 
iNKT cells are activated either by direct or indirect mechanisms. The direct 
mechanisms via a strong TCR signal would include the specific recognition of a viral 
or virus-induced antigen. However, no HCV derived glycolipid that can activate either 
iNKT or non-invariant NKT cells via CD1d presentation has been identified so far. 
Indirect mechanisms by virus induced cytokines combined with a weak TCR signal 
mediated by an endogenous glycolipid are more likely to induce iNKT cell activation 
in the HCV infection setting. Even though iNKT cells in HCV infection probably 
depend only on a weak TCR signal, antigen presentation by CD1d is still crucial for 
iNKT cell activation. It has been demonstrated that viruses can manipulate CD1d 
expression to escape recognition by CD1d restricted iNKT cells, thus leading to 
reduced iNKT cell activation. HCMV, HSV and HIV developed mechanisms to 
downregulate CD1d surface expression through inhibition of CD1d transcription, 
increasing the internalisation of CD1d, intracellular retention of CD1d molecules and 
active prevention of the reappearance of CD1d on the cell surface after endocytosis 
(Chen et al. 2006, Yuan et al. 2006, Raftery et al. 2008, Han et al. 2013). Our study 
however reported no differences in CD1d expression on monocytes as well as B cells 
between HCV-RNA positive and HCV-RNA negative PWID in the periphery, 
indicating that in HCV infection CD1d expression is not altered on peripheral cells. 
Interestingly, CD1d mRNA levels in the liver were significantly higher in HCV infected 
patients compared to HBV infected patients. In contrast to CMV, HSV and HIV that 
downregulate CD1d expression, CD1d expression seems to be upregulated in HCV 
infected livers and therefore might explain the activated phenotype of iNKT cells in 
chronically infected PWID, as upregulation of the ligand CD1d in chronic HCV 
infection can subsequently lead to iNKT cell activation. Upregulation of CD1d might 
not only mediate iNKT activation but could contribute to non-invariant NKT cell 
activation as well, since this subset is also CD1d restricted. IFNα treatment of CD1d 
expressing monocytes significantly enhanced CD1d surface expression and might 
explain elevated CD1d mRNA levels in the liver from HCV infected individuals. Taken 
Discussion 
 
 89 
together these data suggest that continuous exposure to IFNs in chronically HCV 
infected individuals might result in iNKT cell activation. In addition, another 
mechanism that might account for the activation of iNKT cells in the HCV infection 
setting besides the upregulation of the ligand CD1d or the upregulation of cytokines 
could be the induction of the expression of CD1d restricted endogenous lipid 
antigens as seen in HBV infection (Zeissig et al. 2012). However, such mechanisms 
have not been reported for HCV infection so far. 
 
This study provides evidence for the activation of iNKT cells in chronic HCV infection 
and proposes two possible mechanisms that might mediate this activation. However, 
the functional impact of this activation has been inconclusive and needs to be further 
addressed in future studies. Interestingly, in comparison to the previously described 
low proliferation potential of Vα24+ Vß11+ iNKT cells in HIV infection (Moll et al. 
2009), our study demonstrated that iNKT cells in HCV infection rapidly proliferate 
after activation with αGalCer. In addition, even though not statistically significant a 
trend towards an increased proliferation capacity of iNKT cells of HCV-RNA positive 
individuals compared to HCV-RNA negative individuals was observed. Thus, the 
increased expansion of iNKT cells in chronic infection might indicate that the 
pre-activated state results in a reduced proliferation threshold. Furthermore, 
functional analysis of iNKT cells from HCV-RNA positive and HCV-RNA negative 
PWID, performed ex vivo as well as after in vitro expansion, revealed no association 
between the functional capacity of iNKT cells to produce IL2, IFNγ or their 
degranulation ability and infection outcome. However, a tendency towards increased 
IFNγ production was observed in chronically HCV infected individuals compared to 
patients that spontaneously resolve the infection. Although iNKT cells in the liver 
were reported to be mainly TH1 restricted, CD4+, CD4- and DN iNKT cell subsets in 
the periphery each harbour distinct effector functions (Exley et al. 2002, Gumperz et 
al. 2002). As discussed earlier in this study iNKT cell frequencies were low in the 
periphery and moreover material from HCV infected PWID is limited. Therefore, 
sufficient numbers of iNKT cells to further subdivide them into TH1 and TH2 iNKT cell 
subsets could not be acquired. Hence, our analysis could not exclude the possibility 
that IFNγ production by TH1 iNKT cells in the periphery might significantly differ 
according to HCV infection outcome. Furthermore, differences in effector functions 
might have been overlooked as an artificial stimulation with PMA and Ionomycin was 
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used to induce iNKT cell activation. Thus, a more physiological stimulation, for 
instance with cytokines, might reflect the situation in HCV infection more accurately. 
Despite this, our study provided evidence that iNKT cells in the periphery are efficient 
IFNγ producers. 
 
Although collectively the results indicate that chronic inflammation as observed in 
chronic HCV infection leads to activation of iNKT cells, our data are based on 
analysis of iNKT cells from the peripheral blood. It would be important to study iNKT 
cells at the site of infection, which is on the one hand in general technically 
challenging since only a few mononuclear cells can be isolated from liver biopsies 
and on the other hand, is nowadays highly limited by the number of biopsies 
available from HCV infected patients, since non-invasive strategies are preferred to 
determine the stage of liver fibrosis (Castera 2012). Moreover, acquisition of liver 
material through biopsies from patients with resolved infection is ethically challenging 
as there is generally no medical indication for such an invasive procedure. Currently, 
isolation of IHL from liver perfusions provides the opportunity to study, for instance 
iNKT cells at the site of HCV infection.  
Notably, in line with Karadimitris et al. (2001) the frequency of iNKT cells in the liver 
was low and comparable to frequencies in the peripheral blood. However, 
contradicting data exists as significant enrichment of Vα24+ Vβ 11+ iNKT cells in the 
liver compartment compared to the periphery, has been reported in healthy 
individuals (Ward et al. 2004). One has to keep in mind that our approach to use IHL, 
obtained by liver perfusion, has limitations since material was obtained from patients 
undergoing liver resections with various underling diseases. Therefore, the 
comparison between iNKT cells in both compartments provided by Ward et al. (2004) 
might reflect the situation in healthy individuals more accurately as they analysed 
liver perfusate from transplanted healthy livers. However, we were unable to test liver 
samples from HCV-infected individuals in this study, thus could not address 
differences in iNKT cell frequencies and comment on a previously described trend 
towards ongoing reduction of Vα24+ iNKT cell frequencies during HCV disease 
progression as well as depletion of Vα24+ iNKT in patients with end-stage HCV 
cirrhosis (Deignan et al. 2002). Although we could not address this in the underlying 
study, a comparison of iNKT between both compartments could give further insights 
into the role of iNKT cells during HCV infection and might provide evidence for the 
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functional impact of the activated state observed in chronically HCV infected PWID. 
In addition, the described effect of IFNα on CD1d expression points towards a role of 
IFNs in hepatic CD1d regulation. However, with the analysis of monocytes from the 
periphery an artificial system was used that might not adequately reflect the situation 
in the liver compartment. Thus, to conclusively determine IFN mediated upregulation 
of CD1d, IHL as well as CD1d expressing hepatocytes have to be analysed. 
Although, in our study neither liver enzymes nor viral load of HCV-RNA positive 
individuals correlated with iNKT cells frequencies in the periphery, which is in 
accordance with previously reported MAIT cell data (Spaan et al. 2016), iNKT cells in 
the HCV infected liver might still be associated with hepatocyte damage. In addition 
to studying HCV infected liver samples, the use of a HCV cell culture replicon system 
might provide further insights into the possibly antiviral properties of human iNKT 
cells. Efficient suppression of HCV replication in a genotype 2a HCV cell culture 
replicon system by IFNγ production of activated MAIT, has recently been described 
(van Wilgenburg et al. 2016). Even though iNKT cells display a much smaller 
proportion of intrahepatic lymphocytes compared to MAIT cells, they have the ability 
to rapidly expand upon activation, thus might play a critical role in HCV infection.  
 
 
 
Figure 5.1: Graphical summary: activated iNKT cells in chronic HCV infection 
iNKT cells are activated in HCV-RNA positive PWID. Two possible mechanisms have been postulated 
in this study that result in the direct or indirect activation of iNKT cells in HCV infection. Cytokines as 
IL12 and IL15 directly activate iNKT cells whereas IFNα leads to an indirect activation through the 
upregulation of CD1d, the ligand for iNKT cells. Activated iNKT cells of HCV RNA positive PWID might 
for instance contribute to hepatocyte damage during chronic HCV infection. Even though we are 
lacking human data this effect of activated iNKT cells has been described in mice. However, to 
conclusively link activated iNKT cells to HCV pathology further research is needed. 
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Collectively, our data provides evidence that iNKT cells from HCV-RNA positive 
PWID are activated in chronic HCV infection. In addition, two possible mechanisms 
have been proposed that result in the activation of iNKT cells in HCV infection. IFNα 
mediated upregulation of the iNKT cell ligand CD1d and the direct effect of IL12 
and -15 on CD38 expression indicate that CD1d expressing cells and the cytokine 
environment modulate iNKT cell activation in HCV infection. In conclusion, additional 
studies are needed to elucidate the role of iNKT cells in the context of HCV infection 
further and to characterise the impact of the activation status on the functionality in 
more detail. 
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5.2 NK cells in HCV infection 
This study was based on the recent finding of our group, that a distinct KIR/KIR 
ligand constellations was associated with HCV infection outcome in a high-risk cohort 
of PWID. HCV-treatment naïve patients were grouped according to their antibody 
serostatus and viral RNA levels into anti-HCV seropositive PWID with detectable 
HCV RNA, anti-HCV seropositive PWID without detectable HCV RNA and anti-HCV 
seronegative PWID. The genetic combination of KIR3DL1 and a HLA class I allele 
encoding a Bw4 80(T) motif was significantly enriched in HCV infected patients that 
spontaneously control the infection. This effect was not observed in the anti-HCV 
seronegative group. The association of KIR3DL1/HLA-Bw4 80(T) and spontaneous 
clearance of HCV infection was confirmed in a second independent cohort of PWID 
from North America. This indicates that NK cells in the context of KIR3DL1 combined 
with the ligand HLA-Bw4 80(T) are beneficial for the outcome of acute HCV infection 
mediating resolution of the virus but do not confer protection prior to seroconversion. 
Therefore, the influence of this genetic constellation on NK cell function was 
addressed and confirmed a superior functionality of KIR3DL1+ NK cells from 
Bw4 80(T) positive patients compared to Bw4 80(I) positive patients. Moreover, a 
second distinct predisposition associated with infection outcome was identified in the 
genetic correlation study. KIR3DL1 in combination with multiple copies of the ligand 
HLA-Bw4 (≥ two Bw4 motifs) was significantly increased in individuals with an 
anti-HCV seronegative state. Therefore, this genetic constellation mediated a 
protective effect upon HCV exposure which results in resolution prior to 
seroconversion. In addition, functional analysis confirmed an enhanced cytokine 
secretion as well as cytotoxic potential of NK cells in individuals with multiple Bw4 
copies. Hence this study proposes two distinct genetic predispositions that result in 
either protection from HCV acquisition prior to seroconversion or driving spontaneous 
resolution of HCV infection. Interestingly, both genetic associations were associated 
with enhanced NK cell functionality. 
 
Here, we examined the human NK cell subset expressing KIR3DL1, the only known 
KIR specific for HLA-Bw4 alleles. KIR3DL1 frequencies on NK cells were similar 
between HCV-RNA positive, HCV-RNA negative and anti-HCV negative PWID in our 
cohort. In line with this study Alter et al. (2011) reported similar KIR3DL1 frequencies 
in HCV-RNA positive and HCV-RNA negative individuals. Moreover, in contrast to 
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previously described decreased proportions of KIR3DL1 expressing NK cells in HCV 
infected patients the observed expression of KIR3DL1 on NK cells from healthy 
individuals and chronically HCV infected individuals was comparable in our analysis 
(median frequency of KIR3DL1+ NK cells 14.5% vs. 15.1%). Differences might be 
due to the low number of included individuals in the study of Oliviero et al. (2009) 
while our flow cytometric analysis included 90 PWID and 120 healthy individuals. 
Therefore, we propose that the frequency of KIR3DL1 expressing NK cells is not 
associated with HCV infection outcome in PWID. 
However, KIR expression on T cells might influence HCV infection outcome. The 
frequency of KIR3DL1 expressing T cells from healthy individuals were low 
compared to NK cells. The frequencies of KIR3DL1+ CD8+ T cells ranged from 0.02% 
to 7.83% whereas KIR3DL1 was mostly undetectable on CD4+ T cells (mean: 0.15%, 
appendix figure 6.3). In line with our results low levels of KIR (KIR2DL1/S1/L2/S2/L3) 
expression on CD8+ T cells have been described in the periphery as well as in the 
liver from HCV infected individuals. Even though KIR expression on HCV-specific 
CD8+ T cells in the liver was low, Bonorino et al. (2007) proposed that expressed 
KIRs are able to efficiently impair their virus specific reactivity. KIR expressing 
CD8+ T cells in HCV infection were terminally differentiated and displayed a reduced 
replicative potential. Although KIR3DL1 expression on CD8+ T cells was not further 
investigated in this study, existing data suggests that KIR expression on T cells might 
be disadvantageous for the adaptive immune response against HCV infection. 
 
Several studies associated different KIR/KIR ligand constellations with disease 
severity or outcome in various virus infections such as HIV or HCV (Martin et al. 
2002, Khakoo et al. 2004). Moreover, reduction of CMV reactivation after stem cell 
transplantation was correlated with the presence of multiple activating KIRs in the 
donor (Cook et al. 2006). In HCV infection, the genetic constellation of the inhibitory 
NK cell receptor KIR2DL3 in combination with homozygosity of the ligand HLA-C1 
was reproducibly associated with infection outcome. Khakoo et al. (2004) were the 
first who identified a direct influence of KIR2DL3 and HLA-C1 on spontaneous 
resolution of HCV infection, which was confirmed in a PWID cohort of Puerto Rican 
ethnicity (Romero et al. 2008). Furthermore, the same group could extend the 
association of this genetic predisposition to protection from HCV infection prior to 
seroconversion (Zúñiga et al. 2009). In addition, Knapp et al. (2010) confirmed the 
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association with HCV resistance in seronegative PWID and further correlated 
homozygosity for KIR2DL3 in combination with HLA-C1 allotypes with an enhanced 
likelihood to achieve SVR upon IFNα-based therapy. In contrast, no correlation of this 
KIR/KIR ligand constellation with HCV infection outcome was detected in our genetic 
association study. However, a previous study of our group could show increased 
KIR2DL3 expression on NK cells of seronegative PWID and PWID with resolved 
infection compared to HCV-RNA positive PWID (Thöns et al. 2014). The discrepancy 
between results from genetic association studies might be explained by factors that 
influence HCV infection outcome such as viral genotype, gender and the IL28B 
genotype, since these factors are not always well controlled (Grebely et al. 2014). 
Moreover, HCV resolution is not solely mediated by NK cell responses but CTLs, 
especially virus specific CD8+ T cells with a broad response efficiently clear the 
infection (Cooper et al. 1999). CD8+ T cell responses in HCV infection are partially 
genetically determined. Immunogenetic studies reproducibly associated HLA-B*27 
and HLA-B*57 with spontaneous immune control of HCV infection (McKiernan et al. 
2004, Kim et al. 2011, Fitzmaurice et al. 2015). In addition, our group confirmed the 
protective effect of HLA-B*27 for PWID exposed to genotype 1 as well as genotype 3 
(data unpublished). Moreover, the occurrence of the HLA-B*27:05 allele that 
comprises a Bw4 80(T) motif was associated with infection outcome in our PWID 
cohort. To exclude that the genetic correlation of KIR3DL1/HLA-Bw4 80(T) and 
spontaneous clearance of HCV infection in our PWID cohort was exclusively driven 
by HLA-B*27, all B*27 positive patients were excluded. The analysis showed that the 
protective effect of the KIR3DL1/HLA-Bw4 80(T) genotype was not solely mediated 
by HLA-B*27 since the frequency of this constellation was still higher in HCV-RNA 
negative PWID (37.5%) compared to HCV-RNA positive PWID (22.9%) however, this 
association was borderline significant (p=0.05). Although studies provided evidence 
that adaptive as well as innate immune events independently contribute to the 
outcome of HCV infection (Khakoo et al. 2004, McKiernan et al. 2004, Thomas et al. 
2009), collectively our results suggest an additive effect of HLA-B*27 and 
KIR3DL1/HLA-Bw4 80(T) on HCV infection outcome. 
 
The beneficial effect of the KIR3DL1/HLA-Bw4 80(T) genotype on spontaneous 
clearance of HCV infection could be demonstrated in two independent HCV cohorts. 
However, no association was observed in a third cohort from the UK. In addition to 
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the above stated factors, that could influence the observed variances between 
genetic association studies, the most probable explanation for the variance between 
the UK and our cohort are differences in distribution of HLA-B alleles between 
cohorts. Differences in HLA-B allele frequency as observed for HLA-B*13, *38, *44 
and *57, might affect the contribution of CTLs to HCV resolution and therefore 
account for observed difference in the genetic association study.  
Interestingly, we observed that in the context of HLA-Bw4 80(T) NK cell functionality 
was enhanced compared to HLA-Bw4 80(I) allele carriers in PWID, whereas this 
phenomenon was not observed in healthy individuals. The HLA-Bw4 subtype that 
harbours an isoleucine (I) at amino acid position 80 exhibits a stronger affinity to 
KIR3DL1 compared to threonine (T) at this position (Cella et al. 1994) and therefore 
should be better armed to efficiently produce cytokines upon MHC downregulation. 
This phenomenon was observed by Boudreau et al. (2016) in healthy donors, since 
KIR3DL1+ NK cells with a HLA-Bw4 80(I) background exhibited a better functionality 
compared to HLA-Bw4 80(T) positive individuals against HLA-negative targets cells. 
In contrast, to these results we observed no functional benefit of HLA-Bw4 80(I) in 
healthy individuals. Furthermore, the reason for our observed superior functionality of 
KIR3DL1+ NK from HLA-Bw4 80(T) positive PWID remains unclear. Previous data 
might provide an explanation for the reported superior functionality of KIR3DL1+ NK 
cells in the context of a weaker affinity ligand as HLA-Bw4 80(T) in HCV infection. 
KIR2DL3 in combination with HLA-C1 has been reproducibly correlated with HCV 
infection outcome however, expression of an inhibitory KIR with HCV infection 
outcome was surprising at first. KIR2DL3 inhibits NK cells and NK cell activation is 
crucial for killing of virus infected hepatocytes either directly or by mediating the 
activation of the adaptive immune system (Golden-Mason et al. 2010, Pelletier et al. 
2010). The described binding affinity of KIR2DL3 to HLA C1 was lower than for 
KIR2DL2 (Winter et al. 1998), thus HLA-C1 mediated inhibition of NK cells is lower in 
KIR2DL3 homozygous individuals. In HCV infection it was suggested that a weaker 
inhibitory control of NK cells might be beneficial as NK cells are more easily activated 
and are therefore able to contribute to resolution during acute infection or even 
mediate early immune control prior to seroconversion (Khakoo et al. 2004). This 
reduced threshold to activate NK cells could explain our observed increased cytokine 
production as well as degranulation ability in the low affinity ligand HLA-Bw4 80(T) 
carriers. 
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NK cells gain their functional competence during NK cell development in a process 
called NK cell education and NK cell education might provide an explanation for our 
observed superior NK cell functionality in the presence of multiple HLA-Bw4 alleles. 
Inhibitory receptor expression is essential to obtain functional cells that respond 
efficiently to a lack of self-MHC on the target cell (Kim et al. 2005). The number of 
inhibitory receptors as well as the presence of the ligand have a major impact on the 
functionality of NK cells (Sim et al. 2016). While homozygosity for the ligand for 
KIR2DL3 and KIR2DL1 expressing NK cells (C1/C1 or C2/C2) did not confer better 
education compared to heterozygosity of the ligand, KIR3DL1+ NK cell function is 
dependent on the number of Bw4 motifs. The presence of two Bw4 copies was 
associated with a trend towards increased functionality of KIR3DL1+ NK cells, thus 
multiple Bw4 copies resulted in enhanced education of KIR3DL1+ NK cells (Sim et al. 
2016). Comparable results were obtained in a study by Kim et al. (2008) 
demonstrating that KIR3DL1+ NK cells from healthy individuals with the 
HLA-Bw4/Bw4 genotype had a higher ability to produce IFNγ compared to Bw4 
heterozygous individuals and individuals lacking a Bw4 motif (Kim et al. 2008). Our 
results of healthy individuals were in line with these studies and confirmed a positive 
correlation between functionality of KIR3DL1+ NK cells and Bw4 copy number. In 
addition, we could extend the observed superior functionality of NK cells in the 
presence of multiple Bw4 copies to increased TNFα production as well as enhanced 
degranulation ability. Furthermore, Boudreau et al. (2016) described that besides 
Bw4 copy number, functionality of KIR3DL1 NK cells was affected by the binding 
strength of KIR3DL1 to its ligand Bw4 as well as the receptor and ligand density on 
the cell surface. We observed congruent results for KIR3DL1 receptor density 
analysis whereas ligand density was not addressed in our study. Even though the 
differences were not statistically significant a tendency towards increased 
functionality of KIR3DL1+ NK cells with multiple Bw4 copy numbers was observed in 
the PWID cohort as well. 
 
Our study was the first to report that KIR3DL1 in combination with HLA-Bw4 was 
associated with resolution of HCV infection and being the only study so far that 
demonstrated a beneficial effect of HLA-Bw4 80(T) for viral clearance. In line with our 
results, Ruiz-Extremera et al. (2017) recently described an influence of KIR3DL1 as 
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well as HLA-Bw4 on the natural course of HCV infection in a study analysing the 
Mother-to-child transmission of HCV. The study indicated, that homozygosity for 
KIR3DL1 and the presence of multiple HLA-Bw4 alleles in the mother were two 
independent predictors for clearance of HCV infection in the child. However, no 
correlation of the combination of both with infection outcome or transmission rate was 
described. In addition, the combination of KIR3DL1 and HLA-Bw4 alleles has 
recently been described to influence treatment outcome. Nozawa et al. (2013) and 
Umemura et al. (2014) demonstrated that the KIR3DL1/HLA-Bw4 genotype was an 
independent predictor for SVR in a genotype 1b infected cohort from Japan after 
combination therapy with either PEGylated IFNα and ribavirin or after treatment with 
a triple therapy of telaprevir, PEGylated IFNα and ribavirin.  
Furthermore, KIR3DL1 and Bw4 as well as the combination of both have been 
associated with beneficial effects in other diseases. In cancer, the genetic 
constellation of KIR3DL1 and HLA-Bw4 has been linked to the protection from diffuse 
large B-cell lymphoma and significant better overall survival in metastatic colorectal 
cancer patients (Karabon et al. 2011, De Re et al. 2014, Vejbaesya et al. 2014). 
Patients with neuroblastoma or Non-Hodgkin's Lymphoma harbouring the 
KIR3DL1/HLA-Bw4 genotype showed improved clinical outcome, especially 
individuals carrying the Bw4 80(T) motif. They reported that for monoclonal antibody 
based immunotherapy success, a weaker NK cell inhibition mediated by 
HLA-Bw4 80(T) was beneficial (Erbe et al. 2017), thus proposing the same 
mechanism for advantageous outcome as our HCV study. Moreover, the low-affinity 
ligand HLA-Bw4 80(T) has been associated with reduced relapse rates in acute 
myeloid leukaemia (AML) patients and multiple copies of HLA-Bw4 80(T) further 
decreased the incidence of AML relapses (Marra et al. 2015).  
Furthermore, the HLA-Bw4 motif was correlated with a significant advantage in HIV 
infection outcome, as homozygosity for HLA-Bw4 was associated with suppression of 
HIV viremia, delayed HIV progression and thus delayed acquired immunodeficiency 
syndrome (AIDS) pathogenesis (Flores-Villanueva et al. 2001). Interestingly, the 
intracellularly retained KIR3DL1*004 in the presence of HLA-Bw4 was protective in 
HIV infection and influenced AIDS progression as well as plasma HIV RNA level 
(Martin et al. 2007). In contrast to our study, in HIV infection KIR3DL1 combined with 
HLA-Bw4 80(I) rather than HLA-Bw4 80(T) has been correlated with a significantly 
slower progression from HIV infection to AIDS (Martin et al. 2007) which indicates 
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that the impact of different combinations of KIR3DL1 alleles and their ligands varies 
between HIV and HCV infection. Numerous studies linked the Bw4 80(I) motif 
harbouring HLA-B*57 allele to favourable HIV outcome. The genetic combination of 
KIR3DL1, especially high expressing alleles, and HLA-B*57 were associated with a 
reduced risk of HIV infection in exposed uninfected individuals and slower disease 
progression (Martin et al. 2007, Boulet et al. 2008). In addition, NK cells from 
individuals with this protective genotype showed enhanced functionality (Boulet et al. 
2010). Since the observed increased functionality of KIR3DL1+ NK cell in the context 
of Bw4 80(T) was only seen in the PWID cohort, further analysis of possible effects of 
protective alleles in HCV infection like HLA-B*27 adding to NK cell functionality was 
limited in our study. Out of the 90 analysed PWIDs only four expressed KIR3DL1 and 
carried a HLA-B*27 allele including two individuals with multiple Bw4 copies, thus not 
allowing a valid and reliable analysis of the impact of HLA-B*27 on NK cell function.  
 
 
 
Figure 5.2: Graphical summary: association of KIR3DL1/HLA-Bw4 with HCV infection 
outcome and NK cell functionality in PWID 
Upon HCV exposure, the majority of PWID develop chronic HCV infection. A second subgroup is able 
to clear HCV infection prior to seroconversion, thus remain HCV seronegative whereas a third group 
spontaneously resolves HCV infection after seroconversion. PWID with multiple Bw4 alleles are more 
likely to clear HCV infection before seroconversion compared to PWID with one or no Bw4 allele. In 
addition, increasing HLA-Bw4 copy numbers were correlated with a stepwise increase of functionality 
of KIR3DL1+ NK cells in healthy individuals. Better NK cell functionality is probably mediated by 
enhanced education in the presence of multiple Bw4 copies. KIR3DL1 in combination with 
HLA-Bw4 80(T) was associated with spontaneous resolution of HCV infection after seroconversion 
and KIR3DL1+ NK cells from HLA-Bw4 80(T)-positive PWID showed superior functionality compared 
to HLA-Bw4 80(I) positive PWID. Presumably a low activation threshold of NK cells in the presence of 
the low affinity ligand HLA-Bw4 80(T) results in enhanced functionality. 
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In summary, these data indicate that KIR3DL1 in the presence of HLA-Bw4 80(T) 
promotes spontaneous resolution of HCV during acute infection in a high-risk group 
of PWID, whereas this genetic combination however, does not mediate protection 
from HCV infection. In addition, multiple Bw4 copies were associated with HCV 
clearance prior to seroconversion, thus proposing a mechanism that mediates 
protection from HCV infection. Both genetic constellations were associated with 
superior NK cell functionality. Whereas enhanced KIR3DL1+ NK cell functionality in 
the context of multiple Bw4 copies is probably mediated by better NK cell education, 
the HLA-Bw4 80(T) effect in HCV infected individuals is most likely due to a lowered 
threshold to activate NK cells in the context of the low affinity ligand. Taken together 
this suggest that a superior NK cell functionality plays a critical role for HCV infection 
outcome in PWID. 
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5.3 DNA methylation of the IFNG locus 
Our study showed that increased IFNγ production by KIR3DL1+ NK cells in the 
context of multiple HLA-Bw4 copies was not epigenetically imprinted in the IFNG 
locus. DNA methylation of the CNS1 region in KIR3DL1- and KIR3DL1+ NK cells was 
independent of the Bw4 copy number. Interestingly, DNA methylation within the IFNG 
locus was significantly reduced in CMV+ individuals. Moreover, hypomethylation of 
the CNS1 region was correlated with the NKG2C expression on NK cells.  
Previous studies reported a closed conformation and a highly methylated CNS1 
region as well as IFNG promoter in naïve T cells, whereas the CNS1 region in 
TH1 cells was hypomethylated (Dong et al. 2013, Luetke-Eversloh et al. 2014). 
Moreover, the IFNG promoter was broadly demethylated in resting NK cells and 
methylation patterns were independent of NK cell activation (Wiencke et al. 2016). In 
accordance with these studies we observed similar methylation patterns of the IFNG 
locus comprising the CNS1 region as well as the IFNG promoter, for naïve 
CD4+ T cells, TH1 cells and NK cells. Furthermore, it has been described that the 
occurrence of hypomethylation of an upstream region regulating the transcription of 
IFNγ as part of the IFNG locus was associated with NK cell activation (Luetke-
Eversloh et al. 2014). Moreover, demethylation of the CNS1 region confered an 
increased IFNγ competence of NK cells (Luetke-Eversloh et al. 2014). However, our 
observed superior IFNγ production of KIR3DL1+ NK cells could not be associated to 
hypomethylation occurring within the analysed CNS1 region. Even though 
investigated epigenetic modifications did not provide an explanation for superior IFNγ 
functionality of NK cells from multiple HLA-Bw4 motif carriers, other epigenetic 
modification might be responsible for the observed differences in functionality 
between individuals lacking a Bw4 motif in comparison to Bw4+ individuals. In 
addition to an increased IFNγ production, KIR3DL1+ NK cells from individuals with 
multiple HLA-Bw4 motifs exhibited an enhanced ability to produce TNFα. DNA 
methylation might be the underlying mechanism mediating this functional difference, 
since previous reports described that the methylation pattern of the TNFA promoter 
correlated with gene transcription and demethylation of the TNFA promoter was 
described in activated NK cells (Wiencke et al. 2016). 
 
In HCMV infection NKG2Chigh NK cells show characteristics of adaptive immune 
cells, since they are clonally expanded after reactivation, highly functional and 
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long-lived. As these NK cells display features usually associated with adaptive 
memory cells they are termed memory NK cells (Sun et al. 2009). The expansion of 
this NKG2Chigh memory NK cell population in HCMV infected individuals was 
associated with demethylation of the CNS1 region. Moreover, the open configuration 
and accessibility of CNS1 correlated with enhanced IFNγ competence (Luetke-
Eversloh et al. 2014). Our study demonstrated an association between the occurring 
hypomethylation of the CNS1 region and the CMV seropositivity of investigated 
individuals. In addition, we provided evidence that the epigenetic remodelling at this 
site within the IFNG locus was attributed to memory NK cells since we observed an 
inverse correlation between the DNA methylation and the frequency of 
NKG2C+ NK cells. Therefore, our study confirmed the previously reported association 
between NKG2C expression of CMV+ individuals and hypomethylation of the CpG 
sites within the CNS1 region. Collectively the existing data suggest that memory 
features of NK cells are epigenetically regulated. 
In summary, our data confirms that NK cell memory features, which are attributed to 
NKG2C expressing NK cells in CMV positive individuals, are epigenetically imprinted 
within the CNS1 region of the IFNG locus, whereas the significantly enhanced IFNγ 
capacity of KIR3DL1+ NK in the context of multiple HLA-Bw4 motifs is not 
epigenetically regulated by DNA methylation. 
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5.4 Future directions 
5.4.1 iNKT cells in HCV infection 
The impact of the activated iNKT cell status in HCV-RNA positive PWID on their 
functionality is not fully understood. It is reported that iNKT cell activation leads to an 
upregulation of FasL (Nakagawa et al. 2001), indicating that iNKT cells might directly 
induce liver injury through the Fas-FasL signalling pathway. This effector 
mechanisms could differ between individuals with different infection outcome, thus 
might provide functional explanations for the observed activated phenotype of iNKT 
cells in HCV infection. Therefore, further analysis of iNKT cell functions are 
necessary to understand the impact of iNKT cells in HCV infection outcome in depth. 
In addition, the role of iNKT cells in the activation of innate as well as adaptive 
immune cells should be further addressed in the context of HCV infection. The 
absence of NKT cells in HBV infection reduced HBV specific T cell responses 
(Zeissig et al. 2012). In addition, IFNγ produced by activated iNKT cells in mice 
increased CD8+ T cell responses in a hepatic tumour mouse model (Nakagawa et al. 
2001) which leads to the assumption that iNKT cell activation induced by αGalCer 
might positively affect CD8+ T cell responses in HCV infection. Furthermore, direct 
antiviral effects of iNKT cells could be determined in cell culture based replicon 
systems. Recently, a mouse model of an HCV-related hepacivirus, that displays 
similarities with HCV infections in humans, was established (Billerbeck et al. 2017). 
Therefore, this new mouse model represents a suitable method to elaborately study 
the role of iNKT and non-invariant NKT cells in acute and chronic HCV infection.  
5.4.2 NK cells in HCV infection 
Here, we reported that the combination of KIR3DL1 and HLA-Bw4 80(T) was 
associated with spontaneous immune control of HCV infection in a high-risk cohort of 
PWID. Moreover, HLA-B*27 was reproducibly linked to spontaneous resolution of 
HCV infection and escape mutations within the presented epitope were associated 
with viral persistence. Interestingly, KIR3DL1 is not only able to bind to the Bw4 motif 
from HLA-A and HLA-B molecules but also makes contact to the presented peptide 
(reviewed in Parham et al. 2012, and O'Connor et al. 2013). Thus, it might be of 
interest to determine if viral peptide variants presented by a HLA-B*27 allele that 
harbours a Bw4 80(T) motif like HLA-B*27:05 modulate NK cell responses. 
Moreover, future analysis could determine if mutations within the presented viral 
epitope which confer T cell escape can also escape NK cell recognition. 
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6 Appendix 
 
HCV-RNA positive HCV-RNA negative
0
20
40
60
80 0.6664
%
CD
38
+
 
CD
1d
 
de
x
tr
am
er
-
 
ce
lls
 
Figure 6.1: Expression of CD38 on CD1d dextramer negative lymphocytes 
CD38 expression was analysed on CD1d dextramer negative lymphocytes from 13 HCV-RNA positive 
and 13 HCV-RNA negative individuals. The frequency of CD38+ non iNKT cells is depicted and an 
unpaired t-test was used to determine significance. The mean ± SEM is shown.  
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Figure 6.2: Age distribution within the PWID cohort 
The age in years is depicted for every individual PWID that was included in the genetic KIR/KIR ligand 
association study. The median age of HCV-RNA positive (n=151), HCV-RNA negative (n=64) and 
anti-HCV negative (n=51) PWID is indicated. Significance was calculated by one-way ANOVA 
(p≤0.05). 
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Figure 6.3: Frequency of KIR3DL1 expressing T cells  
The frequency of KIR3DL1+ T cells was determined in PBMCs from 15 healthy individuals. 
KIR3DL1+ T cells were defined as CD3+ single, viable lymphocytes and were compared to KIR3DL1 
expressing NK cells. CD3+ T cells were further subdivided into CD4+ and CD8+ cells. Significance was 
calculated by the use of the Wilcoxon signed rank test (****p≤0.0001) and the mean ± SEM is 
depicted. 
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7 Summary 
Worldwide 71 million people are chronically infected with HCV and each year 
approximately 400 000 people die from HCV associated liver diseases. The most 
important risk factor in western industrialised countries to acquire HCV infection is 
intravenous drug use. For this reason, we utilised a cohort of people who inject drugs 
(PWID) to comparatively analyse PWID developing chronic infection (HCV-RNA 
positive), spontaneously resolving HCV infection (HCV-RNA negative) and PWID 
remaining anti HCV seronegative (anti-HCV negative), to provide novel insights into 
the contribution of innate and adaptive immune mechanisms to HCV infection 
outcome. 
The role of Natural Killer T (NKT) cells, which share characteristics of innate and 
adaptive immune cells, for the outcome of HCV infection is poorly defined. Invariant 
NKT (iNKT) cells, a subset of NKT cells, recognise glycolipid antigens such as 
α galactosylceramide (αGalCer) presented by the non-classical MHC molecule 
CD1d. Decreased iNKT cell frequencies have been reported in chronically HCV 
infected patients, however, contradicting reports exist. In this study iNKT cell 
frequencies did not differ between HCV-RNA positive (n=28) and HCV-RNA negative 
(n=33) PWID. Interestingly, phenotypic analysis of iNKT cells of chronically infected 
PWID showed significantly higher expression of the activation marker CD38, 
however, this was not associated with apparent differences in 
PMA/ionomycin-stimulated effector functions. In addition, treatment with a 
combination of IL12, -15 and -18, which is described to activate NK cells, led to a 
significant increase in CD38+ iNKT cells. Since IFN stimulated genes are induced in 
patients with chronic infection the influence of IFNs on iNKT cell activation was 
addressed as well. Although no direct effect of IFNα on iNKT cell activation was 
observed, CD1d was upregulated on peripheral monocytes, the cell type with the 
highest expression of CD1d in the periphery. However, CD1d levels on monocytes, 
did not differ between PWID with chronic and resolved HCV infection. Nevertheless, 
presence of monocytes promoted iNKT cell expansion and activation, as depletion of 
monocytes significantly reduced the frequency of CD38+ iNKT cells. Furthermore, 
CD1d transcript levels were significantly higher in HCV-infected liver compared to 
HBV-infected liver. Collectively the data demonstrate that iNKT cells are activated in 
chronically HCV infected PWID, possibly via type I interferon-induced upregulation of 
CD1d on monocytes or other liver resident cells or via direct activation by 
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pro-inflammatory cytokines. However, the functional consequences of increased 
activation of iNKT cells are not fully defined. 
While iNKT cells are still poorly covered by scientific reports in HCV infection there is 
growing evidence for the importance of NK cells for HCV infection outcome. Genetic 
association studies revealed that specific genetically determined combinations of NK 
cell-receptors and their ligands are associated with differential outcome of HCV 
infection. NK cell function is regulated by a set of inhibitory and activating receptors 
including killer-cell immunoglobulin-like receptors (KIRs). A previous study in our lab 
identified that KIR3DL1/HLA-Bw4 80(T) was associated with spontaneous clearance 
of HCV infection in our PWID cohort (n=266) which was validated in a second PWID 
cohort from North America (n=342). For this reason, this study focused on the 
functional characterisation of NK cells according to the identified KIR/KIR-ligand 
genotype. Besides PWID, healthy individuals (n=120) were included in the analysis 
as well. KIR3DL1+ NK cells from HLA-Bw4 80(T) positive PWID showed superior 
functionality compared to HLA-Bw4 80(I) positive PWID. However, this differential 
impact was not observed in healthy donors. Moreover, the frequency of individuals 
with multiple HLA-Bw4 alleles was significantly higher in HCV-RNA negative as well 
as anti-HCV negative PWID compared to HCV-RNA positive PWID and HLA-Bw4 
copy number strongly correlated with the functionality of KIR3DL1+ NK cells in 
healthy individuals. HLA-Bw4 80(T) and multiple HLA-Bw4 copies in combination with 
KIR3DL1 are associated with protection against chronic HCV in PWID by distinct 
mechanisms. Better education of KIR3DL1+ NK cells in the presence of multiple 
HLA-Bw4 copies is beneficial prior to seroconversion whereas HLA-Bw4 80(T) may 
be beneficial during acute hepatitis C. To determine possible underlying mechanisms 
leading to the superior functionality of KIR3DL1+ NK cells, the DNA methylation 
pattern of the IFNG locus was analysed, since demethylation of the IFNG locus is 
generally associated with increased IFNG transcription. Unfortunately, the 
significantly enhanced IFNγ capacity of KIR3DL1+ NK cells from multiple HLA-Bw4 
motif carriers was not epigenetically regulated by DNA methylation. However, our 
data could confirm that NK cell memory features, attributed to NKG2C expressing NK 
cells in CMV positive individuals, are epigenetically imprinted within the IFNG locus. 
In summary, these studies contribute novel evidence for the importance of NK cells 
and iNKT cells for HCV infection outcome and describe possible underlying 
mechanisms. However, further research is needed to elucidate for instance, the role 
of HCV peptides presented by HLA alleles harbouring a Bw4 motif on the function of 
KIR3DL1+ NK cells or the exact mechanism leading to the activated state of iNKT 
cells during chronic HCV infection. 
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8 Zusammenfassung 
Nach Schätzung der WHO sind zurzeit 71 Millionen Menschen weltweit chronisch mit 
dem Hepatis C Virus (HCV) infiziert und jährlich sterben etwa 400.000 Menschen an 
den Folgen einer HCV induzierten Leberkrankungen. In westlichen Industrieländern 
stellt der intravenöse Drogenkonsum hierbei den höchsten Risikofaktor dar, sich mit 
HCV zu infizieren. Um neue Erkenntnisse über die Rolle des natürlichen und 
angeboren Immunsystems in der HCV Infektion zu gewinnen, wurde einer Kohorte 
von intravenös Drogen gebrauchenden Menschen („people who inject drugs“ PWID) 
analysiert. Hierbei wurden PWID mit chronischer HCV-Infektion (HCV-RNA positiv), 
ausgeheilter HCV-Infektion (HCV-RNA negativ) und HCV seronegative PWID 
(anti-HCV negativ) miteinander verglichen. 
Welche Rolle Natürliche Killer T (NKT) Zellen, die sowohl Eigenschaften von innaten 
als auch adaptiven Immunzellen aufweisen, bei dem Verlauf einer HCV Infektion 
spielen ist nicht klar definiert. Invariante NKT (iNKT) Zellen stellen eine Subgruppe 
der NKT Zellen dar und erkennen Glycolipid Antigene wie z.B. α galactosylceramid 
(αGalCer), die durch das nicht-klassische MHC Molekül CD1d präsentiert werden. 
Die Untersuchung der iNKT Zellfrequenzen zeigte keine Unterschiede zwischen 
HCV-RNA positiven (n=28) und HCV-RNA negativen (n=33) PWID. 
Interessanterweise ergab die phänotypische Analyse, dass sich iNKT Zellen von 
chronisch HCV infizierten PWID durch eine signifikant erhöhte Expression des 
Aktivierungsmarkers CD38 auszeichnen. Allerdings konnten keine funktionellen 
Unterschiede mit diesem aktivierten Phänotyp assoziiert werden. Zusätzlich wurde 
die Auswirkung von Interferonen auf iNKT Zellen in dieser Studie adressiert. 
Während kein direkter Effekt von IFNα oder IFNλ festgestellt werden konnte, führte 
eine Kombination von NK Zell aktivierenden Zytokinen (IL12, IL15 und IL18) zu einer 
signifikanten Erhöhung der CD38+ iNKT Zellen. Auch wenn gezeigt werden konnte, 
dass der Ligand von iNKT Zellen durch IFNα Stimulation hochreguliert wird, konnte 
kein Unterschied in der CD1d Expression auf peripheren Monozyten, welche in der 
Peripherie den Zelltyp mit der höchsten CD1d Expression darstellen, zwischen 
HCV-RNA positiven und HCV-RNA negativen PWID festgestellt werden. Dennoch 
nehmen Monozyten eine wichtige Rolle in der Expansion und Aktivierung von iNKT 
Zellen ein, da eine Depletierung selbiger eine signifikant verminderte Frequenz von 
CD38+ iNKT Zellen zur Folge hat. Des Weiteren ergaben Leberanalysen, dass 
HCV-infizierte Lebern im Vergleich zu HBV-infizierten Lebern eine signifikant erhöhte 
CD1d Transkription aufweisen. Zusammengefasst weisen unsere Daten darauf hin, 
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dass iNKT Zellen in der chronischen HCV Infektion aktiviert sind. Sowohl eine Typ I 
Interferon induzierte Hochregulation von CD1d auf Monozyten oder anderen Zellen in 
der Leber als auch das proinflammatorische Zytokine Milieu sind potentiell für die 
Modulation des Aktivierungsstatus von iNKT Zellen in der HCV Infektion 
verantwortlich.  
Während es kaum wissenschaftliche Berichte gibt, die sich mit iNKT Zellen im 
Kontext der HCV Infektion auseinandersetzen, steigt die Zahl an Belegen, die NK 
Zellen eine wichtige Bedeutung für die Prävention und Kontrolle einer HCV Infektion 
zusprechen. Verschiedene Assoziationsstudien konnten bereits zeigen, dass 
genetisch determinierten Kombinationen von NK Zell Rezeptoren und ihren Liganden 
mit der HCV Verlaufsprognose assoziiert sind. Die NK Zell Funktion wird durch 
aktivierende und inhibierende Rezeptoren einschließlich der 
Killerzell-Immunglobulin-ähnlichen Rezeptoren (KIR) reguliert. In einer 
vorangegangenen Studie wurde mit Hilfe einer multivariaten logistischen 
Regressionsanalyse KIR3DL1/HLA-Bw4 80(T) mit der spontanen Ausheilung einer 
HCV Infektion in unserer PWID Kohorte (n=266) assoziiert. Diese Assoziation konnte 
in einer zweiten anti-HCV positiven PWID Kohorte (n=342) aus Nordamerika validiert 
werden. Auf Grund dessen wurden in der vorliegenden Studie NK Zellen anhand 
ihres KIR/KIR-Liganden Genotyps funktionell charakterisiert. Neben PWID wurden 
auch gesunde Proben (n=120) in der Analyse inkludiert. Es konnte gezeigt werden, 
dass KIR3DL1+ NK Zellen von HLA-Bw4 80(T) positiven PWID verglichen mit 
HLA-Bw4 80(I) positiven PWID eine signifikant erhöhte NK Zell Funktionalität 
aufweisen. Hingegen konnte kein funktioneller Einfluss dieses Genotyps in gesunden 
Individuen beobachtet werden. Darüber hinaus wurde gezeigt, dass multiple 
HLA-Bw4 Allele, deren Frequenz signifikant in HCV-RNA negativen und anti-HCV 
negativen PWID im Vergleich zu HCV-RNA positiven PWID erhöht ist, auch mit einer 
starken NK Zell Funktionalität einhergehen. Zusammenfassend können sowohl 
HLA-Bw4 80(T) als auch multiple Kopien von HLA-Bw4 in Kombination mit KIR3DL1 
mit der Protektion gegen eine chronische Hepatitis C assoziiert werden. Diese wird 
über verschiedene Mechanismen vermittelt: während eine bessere NK Zell 
Lizensierung durch die Anwesenheit von multiplen HLA-Bw4 Kopien vor der 
Serokonversion vorteilhaft ist, könnte HLA-Bw4 80(T) während eine akuten HCV 
Infektion von Vorteil sein. Epigenetische Veränderung könnten eine mögliche 
Erklärung für die erhöhte IFNγ Produktion von KIR3DL1+ NK Zellen im Kontext von 
multiplen HLA-Bw4 Allelen bieten. Hierfür wurde die DNA Demethylierung des IFNG 
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Lokus, welche generell mit einer erhöhten Transkription assoziiert ist, analysiert. Es 
konnte jedoch kein Zusammenhang zwischen dem Methylierungsstatus und der 
Anzahl an HLA-Bw4 Kopien hergestellt werden. Hingegen konnten vorausgegangene 
Studien bestätigt werden, die besagen, dass Memory-Eigenschaften von NKG2C 
exprimierenden NK Zellen in CMV positiven Individuen epigenetisch reguliert sind.  
Abschließend lässt sich feststellen, dass die hier präsentierten Studien neue 
Beweise für die Bedeutsamkeit von NK und iNKT Zellen für den HCV 
Infektionsverlauf liefern und Hinweise auf mögliche zugrundeliegende Mechanismen 
geben. Dennoch sind weitere Arbeiten notwendig die z.B. klären ob HCV Peptide, die 
durch Bw4 Motiv tragende HLA Allele präsentiert werden, einen Einfluss auf die 
Funktion von KIR3DL1+ NK Zellen haben oder welche Mechanismen genau während 
der chronischen Infektion zu einer Aktivierung von iNKT Zellen führen. 
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